


11/839,520

d que stat l10
L9 STR



VAR G1=10/12/14/17/28/31
VAR G2=OH/38/40/11/36
VAR G3=OH/38/40/11/36
VAR G10=10/12/35
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 1
CONNECT IS E2 RC AT 4
CONNECT IS E2 RC AT 5
CONNECT IS E2 RC AT 14
CONNECT IS E2 RC AT 17
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 41
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 6
NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE
L10 0 SEA FILE=REGISTRY SSS SAM L9

0.6% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 7056340 TO 7125500
PROJECTED ANSWERS: 0 TO 0

11/839,520

=> d que l1

L1 5 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS

=> d que l2

L2 1 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON US2007-839520/APPS

=> d que l4

L1 5 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS

L3 TRANSFER PLU=ON L1 1- RN : 82 TERMS

L4 82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L3


=> d que stat l15

L1 5 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS

L3 TRANSFER PLU=ON L1 1- RN : 82 TERMS

L4 82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L3

L5 STR



VAR G1=10/12/14/17/28/31

VAR G2=OH/38/40/11/36

VAR G3=OH/38/40/11/36

VAR G10=10/12/35

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 41

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE

L15 28 SEA FILE=REGISTRY SUB=L4 SSS FUL L5

100.0% PROCESSED 42 ITERATIONS


28 ANSWERS

SEARCH TIME: 00.00.01

=> d que l18

11/839,520

L1 5 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
 L3 TRANSFER PLU=ON L1 1- RN : 82 TERMS
 L4 82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L3
 L5 STR



VAR G1=10/12/14/17/28/31
 VAR G2=OH/38/40/11/36
 VAR G3=OH/38/40/11/36
 VAR G10=10/12/35
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 41
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE

L15 28 SEA FILE=REGISTRY SUB=L4 SSS FUL L5
 L16 270 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (1007839-71-5/CRN OR
 1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
 1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
 1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
 1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
 1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
 1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
 21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
 8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
 79122-68-2/CRN OR 88-46-0/CRN)
 L18 293 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L15 OR L16

=> d his 115-118

(FILE 'REGISTRY' ENTERED AT 15:28:55 ON 24 SEP 2009)

L15 28 S L5 SSS FUL SUB=L4
 SAVE TEMP L15 PAG520PSET1/A
 SELECT L15 1- RN
 L16 270 S E13-E40/CRN
 L17 2 S (21799-87-1 OR 88-46-0)/RN
 L18 293 S L15 OR L16

11/839,520

=> d que nos 118

```
L1      5 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L3      TRANSFER  PLU=ON  L1 1- RN :      82 TERMS
L4      82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L3
L5      STR
L15     28 SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L16    270 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (1007839-71-5/CRN OR
1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
79122-68-2/CRN OR 88-46-0/CRN)
L18    293 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L15 OR L16
```

=> d his 119-121

(FILE 'REGISTRY' ENTERED AT 15:28:55 ON 24 SEP 2009)
SAVE TEMP L18 PAG520CROSS/A

FILE 'STNGUIDE' ENTERED AT 15:38:22 ON 24 SEP 2009

FILE 'WPIX' ENTERED AT 15:39:29 ON 24 SEP 2009

```
L19      1 S L5 SAM
L20      0 S L9 SAM
          SELECT L2 1- DCR
L21     34 S E41-E145/AN.S
          SAVE TEMP L21 PAG520WPIANS/A
```

FILE 'STNGUIDE' ENTERED AT 15:46:16 ON 24 SEP 2009

=> d que 121

```
L21     34 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (1595296-K/AN.S OR
1595296-M/AN.S OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K
/AN.S OR 1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR
9091-U/AN.S OR DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/A
N.S OR DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S
OR DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S
OR DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR
DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR
DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR
DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR
DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR
DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/A
N.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR
DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/
AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR
12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.
S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR
1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K
/AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR
1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M
/AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR
1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K
/AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR
1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M
```

11/839,520

/AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR
1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/
AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR
528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR
86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR
91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S
OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S
)

=> d his ful

(FILE 'HOME' ENTERED AT 13:36:43 ON 24 SEP 2009)

FILE 'STNGUIDE' ENTERED AT 13:36:46 ON 24 SEP 2009

FILE 'ZCAPLUS' ENTERED AT 13:37:07 ON 24 SEP 2009
E US2007-839520/APPS

L1 FILE 'HCAPLUS' ENTERED AT 13:37:18 ON 24 SEP 2009
5 SEA SPE=ON ABB=ON PLU=ON US2007-839520/APPS
SAVE TEMP L1 PAG520HCAAPP/A
D SCAN

FILE 'STNGUIDE' ENTERED AT 13:37:50 ON 24 SEP 2009

L2 FILE 'WPIX' ENTERED AT 13:51:40 ON 24 SEP 2009
1 SEA SPE=ON ABB=ON PLU=ON US2007-839520/APPS
D IALL CODE

FILE 'STNGUIDE' ENTERED AT 13:53:16 ON 24 SEP 2009

FILE 'HCAPLUS' ENTERED AT 13:54:58 ON 24 SEP 2009

FILE 'WPIX' ENTERED AT 13:55:12 ON 24 SEP 2009
SAVE TEMP L2 PAG520WPIAPP/A

FILE 'STNGUIDE' ENTERED AT 13:55:26 ON 24 SEP 2009

FILE 'REGISTRY' ENTERED AT 13:55:36 ON 24 SEP 2009

L3 FILE 'HCAPLUS' ENTERED AT 13:55:40 ON 24 SEP 2009
TRA PLU=ON L1 1- RN : 82 TERMS

L4 FILE 'REGISTRY' ENTERED AT 13:55:40 ON 24 SEP 2009
82 SEA SPE=ON ABB=ON PLU=ON L3
SAVE TEMP L4 PAG520REGAPP/A

FILE 'STNGUIDE' ENTERED AT 14:01:34 ON 24 SEP 2009

FILE 'STNGUIDE' ENTERED AT 15:08:06 ON 24 SEP 2009
D SAVED

L5 FILE 'LREGISTRY' ENTERED AT 15:08:46 ON 24 SEP 2009
STR

L6 FILE 'REGISTRY' ENTERED AT 15:17:06 ON 24 SEP 2009
0 SEA SSS SAM L5

FILE 'LREGISTRY' ENTERED AT 15:17:28 ON 24 SEP 2009

11/839,520

L7 STR L5

L8 FILE 'REGISTRY' ENTERED AT 15:18:40 ON 24 SEP 2009
1 SEA SSS SAM L7
D SCAN

L9 FILE 'LREGISTRY' ENTERED AT 15:19:08 ON 24 SEP 2009
STR L7

L10 FILE 'REGISTRY' ENTERED AT 15:19:25 ON 24 SEP 2009
0 SEA SSS SAM L9

FILE 'STNGUIDE' ENTERED AT 15:20:24 ON 24 SEP 2009

L11 FILE 'REGISTRY' ENTERED AT 15:21:28 ON 24 SEP 2009
1 SEA SUB=L4 SSS SAM L5
D SCAN

L12 FILE 'REGISTRY' ENTERED AT 15:21:58 ON 24 SEP 2009
SAVE TEMP L9 PAG520PSTR/Q
57 SEA SPE=ON ABB=ON PLU=ON L4 AND C6/ES
D SCAN

FILE 'STNGUIDE' ENTERED AT 15:23:09 ON 24 SEP 2009

L13 FILE 'HCAPLUS' ENTERED AT 15:23:47 ON 24 SEP 2009
86511 SEA SPE=ON ABB=ON PLU=ON L12

FILE 'STNGUIDE' ENTERED AT 15:23:52 ON 24 SEP 2009
D QUE STAT L11

FILE 'STNGUIDE' ENTERED AT 15:24:12 ON 24 SEP 2009
D QUE STAT L10

L14 FILE 'REGISTRY' ENTERED AT 15:28:55 ON 24 SEP 2009
1 SEA SUB=L4 SSS SAM L5
D SCAN

L15 28 SEA SUB=L4 SSS FUL L5
SAVE TEMP L15 PAG520PSET1/A
D SCAN
SELECT L15 1- RN

L16 270 SEA SPE=ON ABB=ON PLU=ON (1007839-71-5/CRN OR 1007839-72-6/C
RN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR 1007839-91-9/CRN
OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR 1007839-96-4/CRN OR
1007840-16-5/CRN OR 1007840-17-6/CRN OR 1007840-18-7/CRN OR
1007840-19-8/CRN OR 1007840-20-1/CRN OR 1007840-21-2/CRN OR
1007840-22-3/CRN OR 1007840-23-4/CRN OR 1007840-24-5/CRN OR
1007849-27-5/CRN OR 159252-66-1/CRN OR 21799-87-1/CRN OR
51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-8/CRN OR 60630-38-
8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR 79122-68-2/CRN OR
88-46-0/CRN)

L17 2 SEA SPE=ON ABB=ON PLU=ON (21799-87-1 OR 88-46-0)/RN
D SCAN

L18 293 SEA SPE=ON ABB=ON PLU=ON L15 OR L16
SAVE TEMP L18 PAG520CROSS/A

FILE 'STNGUIDE' ENTERED AT 15:38:22 ON 24 SEP 2009
D SAVED

FILE 'WPIX' ENTERED AT 15:39:29 ON 24 SEP 2009

```

L19      1 SEA SSS SAM L5
L20      0 SEA SSS SAM L9
          SELECT L2 1- DCR
L21      34 SEA SPE=ON  ABB=ON  PLU=ON  (1595296-K/AN.S OR 1595296-M/AN.S
          OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K/AN.S OR
          1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR 9091-U/AN.S OR
          DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/AN.S OR
          DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S OR
          DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S OR
          DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR
          DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR
          DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR
          DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR
          DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR
          DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/A
          N.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR
          DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/
          AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR
          12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.
          S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR
          1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K
          /AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR
          1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M
          /AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR
          1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K
          /AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR
          1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M
          /AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR
          1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/
          AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR
          528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR
          86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR
          91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S
          OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S
          )
          D TRI 1-34
          SAVE TEMP L21 PAG520WPIANS/A

```

FILE 'STNGUIDE' ENTERED AT 15:46:16 ON 24 SEP 2009

```

D SAVED
D QUE L1
D QUE L2
D QUE L4
D QUE STAT L15
D QUE L18
D QUE NOS L18
D QUE L21

```

FILE HOME

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 18, 2009 (20090918/UP).

FILE ZCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

11/839,520

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2009 VOL 151 ISS 13
FILE LAST UPDATED: 23 Sep 2009 (20090923/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2009 VOL 151 ISS 13
FILE LAST UPDATED: 23 Sep 2009 (20090923/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

FILE WPIX

FILE LAST UPDATED: 18 SEP 2009 <20090918/UP>
 MOST RECENT UPDATE: 200960 <200960/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
 >>> Now containing more than 1.4 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
 and FI-Terms have been updated with reclassifications to
 mid-June 2009.
 No update date (UP) has been created for the reclassified
 documents, but they can be identified by
 specific update codes (see HELP CLA for details)<<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:

http://www.stn-international.com/stn_guide.html

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdate>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/DWPIAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2009 HIGHEST RN 1186189-89-8
 DICTIONARY FILE UPDATES: 23 SEP 2009 HIGHEST RN 1186189-89-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

FILE LREGISTRY


LREGISTRY IS A STATIC LEARNING FILE

CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

11/839,520

=> => d que stat l10

```
L6 ( 5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L7 SEL PLU=ON L6 1- RN : 82 TERMS
L8 ( 82)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L7
L9 STR
```



```
VAR G1=10/12/14/17/28/31
VAR G2=OH/38/40/11/36
VAR G3=OH/38/40/11/36
VAR G10=10/12/35
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 41
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 41
```

```
STEREO ATTRIBUTES: NONE
L10 28 SEA FILE=REGISTRY SUB=L8 SSS FUL L9
```

```
100.0% PROCESSED 42 ITERATIONS 28 ANSWERS
SEARCH TIME: 00.00.01
```

=> d que nos l17

```
L11 ( 5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L12 SEL PLU=ON L11 1- RN : 82 TERMS
L13 ( 82)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L12
L14 STR
L15 ( 28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
L16 ( 270)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (1007839-71-5/CRN OR
1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
```

11/839,520

79122-68-2/CRN OR 88-46-0/CRN)
L17 293 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L15 OR L16

=> d que nos 118
L11 (5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L12 SEL PLU=ON L11 1- RN : 82 TERMS
L13 (82)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L12
L14 STR
L15 (28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
L16 (270)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (1007839-71-5/CRN OR
1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
79122-68-2/CRN OR 88-46-0/CRN)
L17 293 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L15 OR L16
L18 129 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L17 NOT PMS/CI

=> d que nos 171
L11 (5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L12 SEL PLU=ON L11 1- RN : 82 TERMS
L13 (82)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L12
L14 STR
L15 (28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
L16 (270)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (1007839-71-5/CRN OR
1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
79122-68-2/CRN OR 88-46-0/CRN)
L17 293 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L15 OR L16
L18 129 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L17 NOT PMS/CI
L21 QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
L22 QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
L23 QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
L24 QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
L25 QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
L30 QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
U, AUTH
L31 QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
L32 QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
L33 QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
L34 QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH
L35 QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU,AUTH
L36 QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU,AUTH

11/839,520

```


L37      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38      QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42      QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44      QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46      QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50      QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51      QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
      PA
L53      QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54      QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L55      QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56      QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L57      QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L58      QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L59      780 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L18
L60      11 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 (L)((L53 OR L54
      OR L55 OR L56))
L61      10 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L58
L62      6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L57
L63      QUE  SPE=ON  ABB=ON  PLU=ON  "DERMATOLOGICAL AGENTS"+PFT,
      OLD,NEW/CT
L64      3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L63
L65      1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L64 AND (L55 OR L56)
L66      7 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND (L55 OR L56)
L67      20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L60 OR L61 OR L62)
      OR (L64 OR L65 OR L66)
L68      20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L67 AND (L53 OR L54
      OR L55 OR L56)
L69      20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L67 OR L68)
L70      14 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L69 AND (L21 OR L22
      OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
      OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
      OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
      OR L50 OR L51)
L71      6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L69 NOT L70

```

```

=> d que stat 1114
L9      STR

```



VAR G1=10/12/14/17/28/31

VAR G2=OH/38/40/11/36

VAR G3=OH/38/40/11/36

VAR G10=10/12/35

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 41

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE

L19 34 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (1595296-K/AN.S OR 1595296-M/AN.S OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K/AN.S OR 1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR 9091-U/AN.S OR DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/AN.S OR DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S OR DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S OR DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/AN.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR 12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR 1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K/AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR 1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M/AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR 1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K/AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR 1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M/AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR 1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR 528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR

86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR
 91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S
 OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S
)

L106 1009 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (R00180/SDCN OR R03057/SDCN OR R10974/SDCN OR R18653/SDCN OR R18808/SDCN OR RACANB/SDCN OR RACRCN/SDCN OR RACRCO/SDCN OR RACRCQ/SDCN OR RACRCY/SDCN OR RACRCZ/SDCN OR RACRDB/SDCN OR RACRDC/SDCN OR RACRDE/SDCN OR RACRDF/SDCN OR RACRDG/SDCN OR RACRDH/SDCN OR RACRDN/SDCN OR RACRDO/SDCN OR RACRDQ/SDCN OR RACRDR/SDCN OR RACRDS/SDCN OR RACRDV/SDCN OR RACRD0/SDCN OR RADRS8/SDCN OR RAF0PZ/SDCN OR RA0DJE/SDCN OR RA0HDM/SDCN OR RA00C8/SDCN OR RA00GT/SDCN OR RA00H3/SDCN OR RA00TQ/SDCN OR RA0120/SDCN OR RA0120/SDCN OR RA02SP/SDCN OR RA040B/SDCN OR RA088T/SDCN OR RA1HNP/SDCN OR RA1YR6/SDCN OR RA6EV7/SDCN OR R00076/SDCN OR R00122/SDCN OR R00137/SDCN OR R00291/SDCN OR R00689/SDCN OR R01330/SDCN OR R01987/SDCN OR R02044/SDCN OR R02049/SDCN OR R02069/SDCN OR R03442/SDCN OR R04259/SDCN OR R06973/SDCN OR R09011/SDCN OR R10769/SDCN OR R11063/SDCN OR R12996/SDCN OR R20748/SDCN OR R21749/SDCN OR R23692/SDCN OR RAAJSH/SDCN OR RAALE1/SDCN OR RAAMCC/SDCN OR RAAMCD/SDCN OR RAAMCE/SDCN OR RAAMCF/SDCN OR RAAMCG/SDCN OR RAAMCI/SDCN OR RAAMCK/SDCN OR RAAMCN/SDCN OR RAAMCO/SDCN OR RAAMCP/SDCN OR RAAMCQ/SDCN OR RAAMCR/SDCN OR RAAMCS/SDCN OR RAAMCT/SDCN OR RAAMCW/SDCN OR RAAMCX/SDCN OR RAAMCY/SDCN OR RAAMCZ/SDCN OR RAAMDF/SDCN OR RAAMDG/SDCN OR RAAMDJ/SDCN OR RAAMD L/SDCN OR RAAMDM/SDCN OR RAAMDN/SDCN OR RAAMDO/SDCN OR RAAMDP/SDCN OR RAAMDR/SDCN OR RAAMDS/SDCN OR RAAMDT/SDCN OR RAAMDU/SDCN OR RAAMD0/SDCN OR RAAMD1/SDCN OR RAAMD2/SDCN OR RAAMD6/SDCN OR RAAM1I/SDCN OR RAAM1J/SDCN OR RAAM1K/SDCN OR RAAM1L/SDCN OR RAAM1M/SDCN OR RAAM1N/SDCN OR RAAM1O/SDCN OR RAAM1P/SDCN OR RAAM1Q/SDCN OR RAAM1R/SDCN OR RAAM1S/SDCN OR RAAM1T/SDCN OR RAAM1U/SDCN OR RAAM1V/SDCN OR RAAM1W/SDCN OR RAAM1X/SDCN OR RAAM1Y/SDCN OR RAAM1Z/SDCN OR RAAM2A/SDCN OR RAAM2B/SDCN OR RAAM2C/

L107 418 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RA02SP/SDCN OR R18653/SDCN OR R01614/SDCN OR R04292/SDCN OR R13080/SDCN OR R23692/SDCN OR RA0DWB/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA01SC/SDCN OR RA02JW/SDCN OR RA040B/SDCN OR RA1C7N/SDCN OR RA28R6/SDCN OR RA5D1M/SDCN OR R00095/SDCN OR R00298/SDCN OR R03361/SDCN OR R04116/SDCN OR R04227/SDCN OR R04654/SDCN OR R09668/SDCN OR RA0K9J/SDCN OR RA00C8/SDCN OR RA01E9/SDCN OR RA1HNP/SDCN OR RA43CA/SDCN OR RA74YB/SDCN OR RA74YC/SDCN OR RA74YE/SDCN OR RA74YZ/SDCN OR RA74Y7/SDCN OR RA74Y8/SDCN OR RA74ZA/SDCN OR RA74ZI/SDCN OR RA74ZY/SDCN OR RA74ZZ/SDCN OR RA74Z0/SDCN OR RA74Z1/SDCN OR RA74Z2/SDCN OR RA74Z3/SDCN OR RA74Z4/SDCN OR RA74Z5/SDCN OR RA74Z7/SDCN OR RA74Z8/SDCN OR RA74Z9/SDCN OR RA750A/SDCN OR RA750B/SDCN OR RA7500/SDCN OR RA7501/SDCN OR RA7502/SDCN OR RA7503/SDCN OR RA7505/SDCN OR RA7506/SDCN OR RA7507/SDCN OR RA7508/SDCN OR R00271/SDCN OR R00991/SDCN OR RA0CGV/SDCN OR RA0C4V/SDCN OR RA0HNY/SDCN OR RA0IKS/SDCN OR RA0KH3/SDCN OR RA0LMH/SDCN OR RA0MTA/SDCN OR RA0WLX/SDCN OR RA006H/SDCN OR RA01BE/SDCN OR RA01Q7/SDCN OR RA01SX/SDCN OR RA015V/SDCN OR RA02DZ/SDCN OR RA021Q/SDCN OR RA027G/SDCN OR RA027I/SDCN OR RA027J/SDCN OR RA03SR/SDCN OR RA03YX/SDCN OR RA03YY/SDCN OR RA05GM/SDCN OR RA05JM/SDCN OR RA05WC/SDCN OR RA07GX/SDCN OR RA1HN1/SDCN OR RA1QEQ/SDCN OR RA1QXS/SDCN OR RA1YFH/SDCN OR RA13IL/SDCN OR RA13XQ/SDCN OR RA152R/SDCN OR RA18TQ/SDCN OR RA2VNT/SDCN OR RA20DZ/SDCN OR RA3ITX/SDCN OR RA3SGW/SDCN OR RA41J1/SDCN OR RA44DH/SDCN OR RA6SD5/SDCN OR RA6VEH/SDCN OR RA6VEI/SDCN OR RA6VEJ/SDCN OR RA6VEK/SDCN OR

11/839,520

RA6VEL/SDCN OR RA6VEM/SDCN OR RA6VEN/SDCN OR RA6VEO/SDCN OR
RA6VEP/SDCN OR RA6VER/SDCN OR RA6VES/SDCN OR RA6VET/SDCN OR
RA6VEU/SDCN OR RA6VEV/SDCN OR RA6VEW/SDCN OR RA6VEX/SDCN OR
RA6VEY/SDCN OR RA6VEZ/SDCN OR RA6VFA/SDCN OR RA6VFB/SDCN OR
RA6VFC/SDCN OR RA6VFD/SDCN OR RA6VFE/SDCN OR RA6VFF/SDCN OR
RA6VFG/SDCN OR RA6VFH/SDCN OR RA6VFI/SDCN OR RA6VFJ/SDCN OR
RA6VFK/SDCN OR RA6VFL


L108 324 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RA00C8/SDCN OR RA0ETL/SD
CN OR RA0ETQ/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA0K9J/SDCN
OR RA0YL4/SDCN OR RA00GT/SDCN OR RA02JW/SDCN OR RA02SP/SDCN OR
RA04OB/SDCN OR RA1HNP/SDCN OR RA28R6/SDCN OR RA43CA/SDCN OR
R00477/SDCN OR R00669/SDCN OR R01119/SDCN OR R03562/SDCN OR
R04115/SDCN OR R04292/SDCN OR R09668/SDCN OR R13080/SDCN OR
R18653/SDCN OR R23692/SDCN OR RA00H1/SDCN OR RA00NS/SDCN OR
RA01SC/SDCN OR RA012P/SDCN OR RA043B/SDCN OR RA043C/SDCN OR
RA043E/SDCN OR RA043F/SDCN OR RA043G/SDCN OR RA043H/SDCN OR
RA043I/SDCN OR RA043J/SDCN OR RA043K/SDCN OR RA043L/SDCN OR
RA043M/SDCN OR RA043N/SDCN OR RA043O/SDCN OR RA043P/SDCN OR
RA1C7N/SDCN OR RA1ILG/SDCN OR RA1ILH/SDCN OR RA1ILU/SDCN OR
RA1ILW/SDCN OR RA1ILX/SDCN OR RA1ILY/SDCN OR RA1ILZ/SDCN OR
RA1IMB/SDCN OR RA1IMK/SDCN OR RA1IMO/SDCN OR RA1IM0/SDCN OR
RA1IM2/SDCN OR RA1IM4/SDCN OR RA1IM9/SDCN OR RA1INB/SDCN OR
RA1IND/SDCN OR RA1IN0/SDCN OR RA1IN2/SDCN OR RA1IN5/SDCN OR
RA1IN6/SDCN OR RA1IN7/SDCN OR RA100A/SDCN OR RA100C/SDCN OR
RA100D/SDCN OR RA100F/SDCN OR RA1000/SDCN OR RA1002/SDCN OR
RA1003/SDCN OR RA1004/SDCN OR RA1005/SDCN OR RA1006/SDCN OR
RA1007/SDCN OR RA1008/SDCN OR RA1009/SDCN OR RA1WSI/SDCN OR
RA1WSJ/SDCN OR RA1WSQ/SDCN OR RA1WTY/SDCN OR RA17JY/SDCN OR
RA17KF/SDCN OR RA17KG/SDCN OR RA17K3/SDCN OR RA195G/SDCN OR
RA195H/SDCN OR RA195I/SDCN OR RA195J/SDCN OR RA195K/SDCN OR
RA195L/SDCN OR RA195M/SDCN OR RA195N/SDCN OR RA195O/SDCN OR
RA2FSP/SDCN OR RA250K/SDCN OR RA250R/SDCN OR RA250S/SDCN OR
RA250T/SDCN OR RA250V/SDCN OR RA250W/SDCN OR RA250X/SDCN OR
RA250Y/SDCN OR RA2510/SDCN OR RA2511/SDCN OR RA2512/SDCN OR
RA2513/SDCN OR RA2514/SDCN OR RA2515/SDCN OR RA2516/SDCN OR
RA2517/SDCN OR RA2518/SDCN OR RA2519/SDCN OR RA33DB/SDCN OR
RA33DC/SDCN OR RA33DD/SDCN OR RA33DO/SDCN OR RA33DP/SDCN OR
RA33DW/SDCN OR RA33D7/SDCN OR RA33D8/SDCN OR RA33EN/SDCN OR
RA33ER/SDCN OR RA33ES/SDCN OR RA33E1/S
L109 1658 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (L106 OR L107 OR L108)
L112 1685 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L109 OR L19
L114 22 SEA FILE=WPIX SUB=L112 SSS FUL L9

100.0% PROCESSED 436 ITERATIONS
SEARCH TIME: 00.00.08

22 ANSWERS

=> d que 1123

L9 STR



VAR G1=10/12/14/17/28/31

VAR G2=OH/38/40/11/36

VAR G3=OH/38/40/11/36

VAR G10=10/12/35

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 41

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE

L19 34 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (1595296-K/AN.S OR 1595296-M/AN.S OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K/AN.S OR 1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR 9091-U/AN.S OR DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/AN.S OR DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S OR DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S OR DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/AN.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR 12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR 1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K/AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR 1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M/AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR 1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K/AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR 1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M/AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR 1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR 528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR

86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR
 91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S
 OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S
)

L21	QUE	SPE=ON	ABB=ON	PLU=ON	CUEVAS SANCHEZ, P?/AU,AUTH		
L22	QUE	SPE=ON	ABB=ON	PLU=ON	CUEVASSANCHEZ, P?/AU,AUTH		
L23	QUE	SPE=ON	ABB=ON	PLU=ON	CUEVAS, P?/AU,AUTH		
L24	QUE	SPE=ON	ABB=ON	PLU=ON	SANCHEZ, P?/AU,AUTH		
L25	QUE	SPE=ON	ABB=ON	PLU=ON	GIMENEZ GALLEGO, G?/AU,AUTH		
L26	QUE	SPE=ON	ABB=ON	PLU=ON	GIMENEZGALLEGO, G?/AU,AUTH		
L27	QUE	SPE=ON	ABB=ON	PLU=ON	GIMENEZ, G?/AU,AUTH		
L28	QUE	SPE=ON	ABB=ON	PLU=ON	GALLEGO, G?/AU,AUTH		
L29	QUE	SPE=ON	ABB=ON	PLU=ON	MORGAN, I?/AU,AUTH		
L30	QUE	SPE=ON	ABB=ON	PLU=ON	SAENZ DE TEJADA MORGAN, I?/A U, AUTH		
L31	QUE	SPE=ON	ABB=ON	PLU=ON	SAENZDETEJADA, I?/AU,AUTH		
L32	QUE	SPE=ON	ABB=ON	PLU=ON	SAENZ, I?/AU,AUTH		
L33	QUE	SPE=ON	ABB=ON	PLU=ON	DETEJADA, I?/AU,AUTH		
L34	QUE	SPE=ON	ABB=ON	PLU=ON	DE TEJADA, I?/AU,AUTH		
L35	QUE	SPE=ON	ABB=ON	PLU=ON	ANGULO FRUTOS, J?/AU,AUTH		
L36	QUE	SPE=ON	ABB=ON	PLU=ON	ANGULOFRUTOS, J?/AU,AUTH		
L37	QUE	SPE=ON	ABB=ON	PLU=ON	ANGULO, J?/AU,AUTH		
L38	QUE	SPE=ON	ABB=ON	PLU=ON	FRUTOS, J?/AU,AUTH		
L39	QUE	SPE=ON	ABB=ON	PLU=ON	VALVERDE LOPEZ, S?/AU,AUTH		
L40	QUE	SPE=ON	ABB=ON	PLU=ON	VALVERDELOPEZ, S?/AU,AUTH		
L41	QUE	SPE=ON	ABB=ON	PLU=ON	VALVERDE, S?/AU,AUTH		
L42	QUE	SPE=ON	ABB=ON	PLU=ON	LOPEZ, S?/AU,AUTH		
L43	QUE	SPE=ON	ABB=ON	PLU=ON	ROMERO GARRIDO, A?/AU,AUTH		
L44	QUE	SPE=ON	ABB=ON	PLU=ON	ROMEROGARRIDO, A?/AU,AUTH		
L45	QUE	SPE=ON	ABB=ON	PLU=ON	ROMERO, A?/AU,AUTH		
L46	QUE	SPE=ON	ABB=ON	PLU=ON	GARRIDO, A?/AU,AUTH		
L47	QUE	SPE=ON	ABB=ON	PLU=ON	LOZANO PUERTO, R?/AU,AUTH		
L48	QUE	SPE=ON	ABB=ON	PLU=ON	LOZANOPUERTO, R?/AU,AUTH		
L49	QUE	SPE=ON	ABB=ON	PLU=ON	LOZANO, R?/AU,AUTH		
L50	QUE	SPE=ON	ABB=ON	PLU=ON	PUERTO, R?/AU,AUTH		
L51	QUE	SPE=ON	ABB=ON	PLU=ON	(ACTION(1W)MEDICINE#)/CS, SO, PA		
L53	QUE	SPE=ON	ABB=ON	PLU=ON	SKIN		
L54	QUE	SPE=ON	ABB=ON	PLU=ON	?DERM?		
L55	QUE	SPE=ON	ABB=ON	PLU=ON	?PSORIA?		
L56	QUE	SPE=ON	ABB=ON	PLU=ON	ANTIPSORIA?		
L58	QUE	SPE=ON	ABB=ON	PLU=ON	A61P0017-06/IPC		
L74	QUE	SPE=ON	ABB=ON	PLU=ON	(B14-N17C OR C14-N17C OR B12 -A07 OR C12-A07)/MC		
L106	1009	SEA	FILE=WPIX	SPE=ON	ABB=ON	PLU=ON	(R00180/SDCN OR R03057/SD CN OR R10974/SDCN OR R18653/SDCN OR R18808/SDCN OR RACANB/SDCN OR RACRCN/SDCN OR RACRCO/SDCN OR RACRCQ/SDCN OR RACRCY/SDCN OR RACRCZ/SDCN OR RACRDB/SDCN OR RACRDC/SDCN OR RACRDE/SDCN OR RACRDF/SDCN OR RACRDG/SDCN OR RACRDH/SDCN OR RACRDN/SDCN OR RACRDO/SDCN OR RACRDQ/SDCN OR RACRDR/SDCN OR RACRDS/SDCN OR RACRDV/SDCN OR RACRD0/SDCN OR RADRS8/SDCN OR RAF0PZ/SDCN OR RA0DJE/SDCN OR RA0HDM/SDCN OR RA00C8/SDCN OR RA00GT/SDCN OR RA00H3/SDCN OR RA00TQ/SDCN OR RA0120/SDCN OR RA0120/SDCN OR RA02SP/SDCN OR RA04OB/SDCN OR RA088T/SDCN OR RA1HNP/SDCN OR RA1YR6/SDCN OR RA6EV7/SDCN OR R00076/SDCN OR R00122/SDCN OR R00137/SDCN OR R00291/SDCN OR R00689/SDCN OR R01330/SDCN OR R01987/SDCN OR R02044/SDCN OR R02049/SDCN OR R02069/SDCN OR R03442/SDCN OR R04259/SDCN OR R06973/SDCN OR R09011/SDCN OR R10769/SDCN OR R11063/SDCN OR R12996/SDCN OR R20748/SDCN OR R21749/SDCN OR R23692/SDCN OR RAAJSH/SDCN OR RAALE1/SDCN OR

RAAMCC/SDCN OR RAAMCD/SDCN OR RAAMCE/SDCN OR RAAMCF/SDCN OR
 RAAMCG/SDCN OR RAAMCI/SDCN OR RAAMCK/SDCN OR RAAMCN/SDCN OR
 RAAMCO/SDCN OR RAAMCP/SDCN OR RAAMCQ/SDCN OR RAAMCR/SDCN OR
 RAAMCS/SDCN OR RAAMCT/SDCN OR RAAMCW/SDCN OR RAAMCX/SDCN OR
 RAAMCY/SDCN OR RAAMCZ/SDCN OR RAAMDF/SDCN OR RAAMDG/SDCN OR
 RAAMDJ/SDCN OR RAAMD L/SDCN OR RAAMDM/SDCN OR RAAMDN/SDCN OR
 RAAMDO/SDCN OR RAAMDP/SDCN OR RAAMDR/SDCN OR RAAMDS/SDCN OR
 RAAMDT/SDCN OR RAAMDU/SDCN OR RAAMD0/SDCN OR RAAMD1/SDCN OR
 RAAMD2/SDCN OR RAAMD6/SDCN OR RAAM1I/SDCN OR RAAM1J/SDCN OR
 RAAM1K/SDCN OR RAAM1L/SDCN OR RAAM1M/SDCN OR RAAM1N/SDCN OR
 RAAM1O/SDCN OR RAAM1P/SDCN OR RAAM1Q/SDCN OR RAAM1R/SDCN OR
 RAAM1S/SDCN OR RAAM1T/SDCN OR RAAM1U/SDCN OR RAAM1V/SDCN OR
 RAAM1W/SDCN OR RAAM1X/SDCN OR RAAM1Y/SDCN OR RAAM1Z/SDCN OR
 RAAM2A/SDCN OR RAAM2B/SDCN OR RAAM2C/

L107

418 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RA02SP/SDCN OR R18653/SD
 CN OR R01614/SDCN OR R04292/SDCN OR R13080/SDCN OR R23692/SDCN
 OR RA0DWB/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA01SC/SDCN OR
 RA02JW/SDCN OR RA04OB/SDCN OR RA1C7N/SDCN OR RA28R6/SDCN OR
 RA5D1M/SDCN OR R00095/SDCN OR R00298/SDCN OR R03361/SDCN OR
 R04116/SDCN OR R04227/SDCN OR R04654/SDCN OR R09668/SDCN OR
 RA0K9J/SDCN OR RA00C8/SDCN OR RA01E9/SDCN OR RA1HNP/SDCN OR
 RA43CA/SDCN OR RA74YB/SDCN OR RA74YC/SDCN OR RA74YE/SDCN OR
 RA74YZ/SDCN OR RA74Y7/SDCN OR RA74Y8/SDCN OR RA74ZA/SDCN OR
 RA74ZI/SDCN OR RA74ZY/SDCN OR RA74ZZ/SDCN OR RA74Z0/SDCN OR
 RA74Z1/SDCN OR RA74Z2/SDCN OR RA74Z3/SDCN OR RA74Z4/SDCN OR
 RA74Z5/SDCN OR RA74Z7/SDCN OR RA74Z8/SDCN OR RA74Z9/SDCN OR
 RA750A/SDCN OR RA750B/SDCN OR RA7500/SDCN OR RA7501/SDCN OR
 RA7502/SDCN OR RA7503/SDCN OR RA7505/SDCN OR RA7506/SDCN OR
 RA7507/SDCN OR RA7508/SDCN OR R00271/SDCN OR R00991/SDCN OR
 RA0CGV/SDCN OR RA0C4V/SDCN OR RA0HNY/SDCN OR RA0IKS/SDCN OR
 RA0KH3/SDCN OR RA0LMH/SDCN OR RA0MTA/SDCN OR RA0WLX/SDCN OR
 RA006H/SDCN OR RA01BE/SDCN OR RA01Q7/SDCN OR RA01SX/SDCN OR
 RA015V/SDCN OR RA02DZ/SDCN OR RA021Q/SDCN OR RA027G/SDCN OR
 RA027I/SDCN OR RA027J/SDCN OR RA03SR/SDCN OR RA03YX/SDCN OR
 RA03YY/SDCN OR RA05GM/SDCN OR RA05JM/SDCN OR RA05WC/SDCN OR
 RA07GX/SDCN OR RA1HN1/SDCN OR RA1QEQ/SDCN OR RA1Q SX/SDCN OR
 RA1YFH/SDCN OR RA13IL/SDCN OR RA13XQ/SDCN OR RA152R/SDCN OR
 RA18TQ/SDCN OR RA2VNT/SDCN OR RA20DZ/SDCN OR RA3ITX/SDCN OR
 RA3SGW/SDCN OR RA41J1/SDCN OR RA44DH/SDCN OR RA6SD5/SDCN OR
 RA6VEH/SDCN OR RA6VEI/SDCN OR RA6VEJ/SDCN OR RA6VEK/SDCN OR
 RA6VEL/SDCN OR RA6VEM/SDCN OR RA6VEN/SDCN OR RA6VEO/SDCN OR
 RA6VEP/SDCN OR RA6VER/SDCN OR RA6VES/SDCN OR RA6VET/SDCN OR
 RA6VEU/SDCN OR RA6VEV/SDCN OR RA6VEW/SDCN OR RA6VEX/SDCN OR
 RA6VEY/SDCN OR RA6VEZ/SDCN OR RA6VFA/SDCN OR RA6VFB/SDCN OR
 RA6VFC/SDCN OR RA6VFD/SDCN OR RA6VFE/SDCN OR RA6VFF/SDCN OR
 RA6VFG/SDCN OR RA6VFH/SDCN OR RA6VFI/SDCN OR RA6VFJ/SDCN OR
 RA6VFK/SDCN OR RA6VFL


L108

324 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RA00C8/SDCN OR RA0ETL/SD
 CN OR RA0ETQ/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA0K9J/SDCN
 OR RA0YL4/SDCN OR RA00GT/SDCN OR RA02JW/SDCN OR RA02SP/SDCN OR
 RA04OB/SDCN OR RA1HNP/SDCN OR RA28R6/SDCN OR RA43CA/SDCN OR
 R00477/SDCN OR R00669/SDCN OR R01119/SDCN OR R03562/SDCN OR
 R04115/SDCN OR R04292/SDCN OR R09668/SDCN OR R13080/SDCN OR
 R18653/SDCN OR R23692/SDCN OR RA00H1/SDCN OR RA00NS/SDCN OR
 RA01SC/SDCN OR RA012P/SDCN OR RA043B/SDCN OR RA043C/SDCN OR
 RA043E/SDCN OR RA043F/SDCN OR RA043G/SDCN OR RA043H/SDCN OR
 RA043I/SDCN OR RA043J/SDCN OR RA043K/SDCN OR RA043L/SDCN OR
 RA043M/SDCN OR RA043N/SDCN OR RA043O/SDCN OR RA043P/SDCN OR
 RA1C7N/SDCN OR RA1ILG/SDCN OR RA1ILH/SDCN OR RA1ILU/SDCN OR
 RA1ILW/SDCN OR RA1ILX/SDCN OR RA1ILY/SDCN OR RA1ILZ/SDCN OR

RA1IMB/SDCN OR RA1IMK/SDCN OR RA1IMO/SDCN OR RA1IM0/SDCN OR
 RA1IM2/SDCN OR RA1IM4/SDCN OR RA1IM9/SDCN OR RA1INB/SDCN OR
 RA1IND/SDCN OR RA1IN0/SDCN OR RA1IN2/SDCN OR RA1IN5/SDCN OR
 RA1IN6/SDCN OR RA1IN7/SDCN OR RA100A/SDCN OR RA100C/SDCN OR
 RA100D/SDCN OR RA100F/SDCN OR RA1000/SDCN OR RA1002/SDCN OR
 RA1003/SDCN OR RA1004/SDCN OR RA1005/SDCN OR RA1006/SDCN OR
 RA1007/SDCN OR RA1008/SDCN OR RA1009/SDCN OR RA1WSI/SDCN OR
 RA1WSJ/SDCN OR RA1WSQ/SDCN OR RA1WTY/SDCN OR RA17JY/SDCN OR
 RA17KF/SDCN OR RA17KG/SDCN OR RA17K3/SDCN OR RA195G/SDCN OR
 RA195H/SDCN OR RA195I/SDCN OR RA195J/SDCN OR RA195K/SDCN OR
 RA195L/SDCN OR RA195M/SDCN OR RA195N/SDCN OR RA195O/SDCN OR
 RA2FSP/SDCN OR RA250K/SDCN OR RA250R/SDCN OR RA250S/SDCN OR
 RA250T/SDCN OR RA250V/SDCN OR RA250W/SDCN OR RA250X/SDCN OR
 RA250Y/SDCN OR RA2510/SDCN OR RA2511/SDCN OR RA2512/SDCN OR
 RA2513/SDCN OR RA2514/SDCN OR RA2515/SDCN OR RA2516/SDCN OR
 RA2517/SDCN OR RA2518/SDCN OR RA2519/SDCN OR RA33DB/SDCN OR
 RA33DC/SDCN OR RA33DD/SDCN OR RA33DO/SDCN OR RA33DP/SDCN OR
 RA33DW/SDCN OR RA33D7/SDCN OR RA33D8/SDCN OR RA33EN/SDCN OR
 RA33ER/SDCN OR RA33ES/SDCN OR RA33E1/S
 L109 1658 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (L106 OR L107 OR L108)
 L112 1685 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L109 OR L19
 L114 22 SEA FILE=WPIX SUB=L112 SSS FUL L9
 L118 16 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RASW2T/DCN OR RASW2U/DCN
 OR RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW3A/DCN OR
 RASW3B/DCN OR RASW3C/DCN OR RASW3D/DCN OR RASW3E/DCN OR
 RASW3F/DCN OR RASW3G/DCN OR RASW3H/DCN OR RASW39/DCN OR
 RAUHHC/DCN OR RAUHHD/DCN OR RAUHHE/DCN OR RAUHHF/DCN OR
 RAUHHG/DCN OR RAUH HH/DCN OR RAUHH9/DCN OR RA2Y7A/DCN) OR
 L114/DCR
 L119 6 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L118 AND (L58 OR L74 OR
 (L55 OR L56))
 L120 14 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L118 AND (L53 OR L54 OR
 L55 OR L56)
 L121 14 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (L119 OR L120)
 L122 13 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L121 AND (L21 OR L22 OR
 L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
 L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR
 L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR
 L50 OR L51)
 L123 1 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L121 NOT L122

=> d que stat l130
 L126 STR

11/839,520



VAR G1=10/12/14/17/28/31

VAR G2=OH/38/40/11/36

VAR G3=OH/38/40/11/36

VAR G10=10/12

VAR G11=AK/43

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 14

CONNECT IS E2 RC AT 17

CONNECT IS E2 RC AT 33

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 41

GGCAT IS UNS AT 43

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE

L128 SCR 1812 OR 1758

L130 1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)

100.0% PROCESSED 547534 ITERATIONS

1799 ANSWERS

SEARCH TIME: 00.00.08

=> d que nos l131

L126 STR

L128 SCR 1812 OR 1758


L130 1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)

L131 1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI

=> d que stat l143

L141 STR

11/839,520



```

REP G1=(0-6) CH2
VAR G2=OH/84/51/62/70/77
VAR G3=OH/84/51/62/70/77
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 86
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 54


```
STEREO ATTRIBUTES: NONE
L143          173 SEA FILE=REGISTRY SSS FUL L141
```

```
100.0% PROCESSED 140832 ITERATIONS
SEARCH TIME: 00.00.03
```

173 ANSWERS

```
=> d que stat l148
L141          STR
```

11/839,520



```

REP G1=(0-6) CH2
VAR G2=OH/84/51/62/70/77
VAR G3=OH/84/51/62/70/77
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 86
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 54

```

```

STEREO ATTRIBUTES: NONE
L143          173 SEA FILE=REGISTRY SSS FUL L141
L146          STR

```



```

REP G1=(0-6) CH2
VAR G2=OH/84/51/62/70/77
VAR G3=OH/84/51/62/70/77

```

11/839,520

NODE ATTRIBUTES:
CONNECT IS E1 RC AT 86
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 42 52 63 71 2
NUMBER OF NODES IS 54

STEREO ATTRIBUTES: NONE
L148 160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146

100.0% PROCESSED 160 ITERATIONS 160 ANSWERS
SEARCH TIME: 00.00.01

=> d que nos l150
L126 STR
L128 SCR 1812 OR 1758
L130 1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131 1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI
L141 STR
L143 173 SEA FILE=REGISTRY SSS FUL L141
L144 170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
L145 146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES
L146 STR
L148 160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149 133 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L145 AND L148
L150 1427 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L131 OR L149

=> d que nos l179
L3 (5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L4 SEL PLU=ON L3 1- RN : 82 TERMS
L5 82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L4
L126 STR
L128 SCR 1812 OR 1758
L130 1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131 1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI
L141 STR
L143 173 SEA FILE=REGISTRY SSS FUL L141
L144 170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
L145 146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES
L146 STR
L148 160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149 133 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L145 AND L148
L150 1427 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L131 OR L149
L179 28 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L5 AND L150

=> d que nos l166
L11 (5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L12 SEL PLU=ON L11 1- RN : 82 TERMS
L13 (82)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L12
L14 STR
L15 (28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
L16 (270)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (1007839-71-5/CRN OR
1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR

1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
79122-68-2/CRN OR 88-46-0/CRN)

L17 293 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L15 OR L16
L18 129 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L17 NOT PMS/CI
L21 QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
L22 QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
L23 QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
L24 QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
L25 QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
L30 QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
U, AUTH
L31 QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
L32 QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
L33 QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
L34 QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH
L35 QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU,AUTH
L36 QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU,AUTH
L37 QUE SPE=ON ABB=ON PLU=ON ANGULO, J?/AU,AUTH
L38 QUE SPE=ON ABB=ON PLU=ON FRUTOS, J?/AU,AUTH
L39 QUE SPE=ON ABB=ON PLU=ON VALVERDE LOPEZ, S?/AU,AUTH
L40 QUE SPE=ON ABB=ON PLU=ON VALVERDELOPEZ, S?/AU,AUTH
L41 QUE SPE=ON ABB=ON PLU=ON VALVERDE, S?/AU,AUTH
L42 QUE SPE=ON ABB=ON PLU=ON LOPEZ, S?/AU,AUTH
L43 QUE SPE=ON ABB=ON PLU=ON ROMERO GARRIDO, A?/AU,AUTH
L44 QUE SPE=ON ABB=ON PLU=ON ROMEROGARRIDO, A?/AU,AUTH
L45 QUE SPE=ON ABB=ON PLU=ON ROMERO, A?/AU,AUTH
L46 QUE SPE=ON ABB=ON PLU=ON GARRIDO, A?/AU,AUTH
L47 QUE SPE=ON ABB=ON PLU=ON LOZANO PUERTO, R?/AU,AUTH
L48 QUE SPE=ON ABB=ON PLU=ON LOZANOPUERTO, R?/AU,AUTH
L49 QUE SPE=ON ABB=ON PLU=ON LOZANO, R?/AU,AUTH
L50 QUE SPE=ON ABB=ON PLU=ON PUERTO, R?/AU,AUTH
L51 QUE SPE=ON ABB=ON PLU=ON (ACTION(1W)MEDICINE#)/CS, SO,
PA
L53 QUE SPE=ON ABB=ON PLU=ON SKIN
L54 QUE SPE=ON ABB=ON PLU=ON ?DERM?
L55 QUE SPE=ON ABB=ON PLU=ON ?PSORIA?
L56 QUE SPE=ON ABB=ON PLU=ON ANTIPSORIA?
L57 QUE SPE=ON ABB=ON PLU=ON PSORIASIS+PFT, OLD, NEW, NT/CT
L58 QUE SPE=ON ABB=ON PLU=ON A61P0017-06/IPC
L59 780 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L18
L63 QUE SPE=ON ABB=ON PLU=ON "DERMATOLOGICAL AGENTS"+PFT,
OLD, NEW/CT
L64 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L59 AND L63
L126 STR
L128 SCR 1812 OR 1758
L130 1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131 1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI
L141 STR
L143 173 SEA FILE=REGISTRY SSS FUL L141
L144 170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
L145 146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES

L146 STR
 L148 160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
 L149 133 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L145 AND L148
 L150 1427 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L131 OR L149
 L151 1760 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L150
 L152 11 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L151 AND L58
 L153 8 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L151 AND L57
 L154 9 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L151 AND (L55 OR L56)

 L155 14 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L152 OR L153 OR
 L154)
 L156 QUE SPE=ON ABB=ON PLU=ON "SKIN, DISEASE"+PFT,OLD,NEW,
 NT/CT
 L157 95 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L151 AND (L156 OR L64
 OR (L53 OR L54 OR L55 OR L56 OR L57))
 L158 316 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L151 (L) (THU OR PKT
 OR PAC OR DMA OR BAC) /RL
 L159 63 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L157 AND L158
 L160 QUE SPE=ON ABB=ON PLU=ON DISEAS? OR DISORDER? OR SYND
 ROM? OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB
 ? OR DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)
 L161 18 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L159 AND ((L53 OR
 L54) (3A) L160)
 L162 27 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L155 OR L161
 L163 27 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L162 AND ((L53 OR L54
 OR L55 OR L56 OR L57 OR L58) OR L64)
 L164 27 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L162 OR L163)
 L165 14 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L164 AND (L21 OR L22
 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
 OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
 OR L50 OR L51)
 L166 13 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L164 NOT L165

=> d his 1214

(FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:20:08 ON 25 SEP 2009)

L214 2 S L212 NOT L213

=> d que nos 1214

L21 QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
 L22 QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
 L23 QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
 L24 QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
 L25 QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
 L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
 L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
 L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
 L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
 L30 QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
 U, AUTH
 L31 QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
 L32 QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
 L33 QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
 L34 QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH
 L35 QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU,AUTH
 L36 QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU,AUTH
 L37 QUE SPE=ON ABB=ON PLU=ON ANGULO, J?/AU,AUTH
 L38 QUE SPE=ON ABB=ON PLU=ON FRUTOS, J?/AU,AUTH

11/839,520

```

L39      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42      QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44      QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46      QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50      QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51      QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS, SO,
PA
L55      QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56      QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L126     STR
L128     SCR 1812 OR 1758
L130     1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131     1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141     STR
L143     173 SEA FILE=REGISTRY SSS FUL L141
L144     170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145     146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146     STR
L148     160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149     133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150     1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L186     QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS
L204     QUE  SPE=ON  ABB=ON  PLU=ON  WILLAN (1A) LEPRO
L205     QUE  SPE=ON  ABB=ON  PLU=ON  PARAPSORIA?
L210     333 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L150 AND (USPATFULL
OR USPAT2 OR USPATOLD)/LC
L211     409 SEA L210
L212     5 SEA L211 AND (L55/CLM OR L56/CLM OR L186/CLM OR L204/CLM OR
L205/CLM)
L213     3 SEA L212 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
L46 OR L47 OR L48 OR L49 OR L50 OR L51)
L214     2 SEA L212 NOT L213


```

```

=> d que stat 1169
L126     STR

```

11/839,520



VAR G1=10/12/14/17/28/31

VAR G2=OH/38/40/11/36

VAR G3=OH/38/40/11/36

VAR G10=10/12

VAR G11=AK/43

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 14

CONNECT IS E2 RC AT 17

CONNECT IS E2 RC AT 33

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 41

GGCAT IS UNS AT 43

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE

L128 SCR 1812 OR 1758

L169 82 SEA FILE=WPIX SSS FUL (L128 AND L126)


100.0% PROCESSED 25989 ITERATIONS (3 INCOMPLETE)

82 ANSWERS

SEARCH TIME: 00.00.43

=> d que stat 1171

L141 STR



REP G1=(0-6) CH2
 VAR G2=OH/84/51/62/70/77
 VAR G3=OH/84/51/62/70/77
 NODE ATTRIBUTES:
 CONNECT IS E1 RC AT 86
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 54

STEREO ATTRIBUTES: NONE
 L171 15 SEA FILE=WPIX SSS FUL L141

100.0% PROCESSED 6752 ITERATIONS 15 ANSWERS
 SEARCH TIME: 00.00.10

=> d que nos 1172
 L126 STR
 L128 SCR 1812 OR 1758
 L141 STR
 L169 82 SEA FILE=WPIX SSS FUL (L128 AND L126)
 L171 15 SEA FILE=WPIX SSS FUL L141
 L172 97 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L169 OR L171

=> d que nos 1178
 L21 QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
 L22 QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
 L23 QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
 L24 QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
 L25 QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
 L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
 L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
 L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
 L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH

L30 QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
 U, AUTH
 L31 QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU, AUTH
 L32 QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU, AUTH
 L33 QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU, AUTH
 L34 QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU, AUTH
 L35 QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU, AUTH
 L36 QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU, AUTH
 L37 QUE SPE=ON ABB=ON PLU=ON ANGULO, J?/AU, AUTH
 L38 QUE SPE=ON ABB=ON PLU=ON FRUTOS, J?/AU, AUTH
 L39 QUE SPE=ON ABB=ON PLU=ON VALVERDE LOPEZ, S?/AU, AUTH
 L40 QUE SPE=ON ABB=ON PLU=ON VALVERDELOPEZ, S?/AU, AUTH
 L41 QUE SPE=ON ABB=ON PLU=ON VALVERDE, S?/AU, AUTH
 L42 QUE SPE=ON ABB=ON PLU=ON LOPEZ, S?/AU, AUTH
 L43 QUE SPE=ON ABB=ON PLU=ON ROMERO GARRIDO, A?/AU, AUTH
 L44 QUE SPE=ON ABB=ON PLU=ON ROMEROGARRIDO, A?/AU, AUTH
 L45 QUE SPE=ON ABB=ON PLU=ON ROMERO, A?/AU, AUTH
 L46 QUE SPE=ON ABB=ON PLU=ON GARRIDO, A?/AU, AUTH
 L47 QUE SPE=ON ABB=ON PLU=ON LOZANO PUERTO, R?/AU, AUTH
 L48 QUE SPE=ON ABB=ON PLU=ON LOZANOPUERTO, R?/AU, AUTH
 L49 QUE SPE=ON ABB=ON PLU=ON LOZANO, R?/AU, AUTH
 L50 QUE SPE=ON ABB=ON PLU=ON PUERTO, R?/AU, AUTH
 L51 QUE SPE=ON ABB=ON PLU=ON (ACTION(1W)MEDICINE#)/CS, SO,
 PA
 L53 QUE SPE=ON ABB=ON PLU=ON SKIN
 L54 QUE SPE=ON ABB=ON PLU=ON ?DERM?
 L55 QUE SPE=ON ABB=ON PLU=ON ?PSORIA?
 L56 QUE SPE=ON ABB=ON PLU=ON ANTIPSORIA?
 L58 QUE SPE=ON ABB=ON PLU=ON A61P0017-06/IPC
 L74 QUE SPE=ON ABB=ON PLU=ON (B14-N17C OR C14-N17C OR B12
 -A07 OR C12-A07)/MC
 L126 STR
 L128 SCR 1812 OR 1758
 L141 STR
 L160 QUE SPE=ON ABB=ON PLU=ON DISEAS? OR DISORDER? OR SYND
 ROM? OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB
 ? OR DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)
 L169 82 SEA FILE=WPIX SSS FUL (L128 AND L126)
 L171 15 SEA FILE=WPIX SSS FUL L141
 L172 97 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L169 OR L171
 L173 122 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RABCOA/DCN OR RABCO3/DCN
 OR RABCO8/DCN OR RABCO9/DCN OR RABNDP/DCN OR RABNDQ/DCN OR
 RAGHZJ/DCN OR RAGHZM/DCN OR RAHO0Q/DCN OR RAI7ME/DCN OR
 RAKQX2/DCN OR RALH0H/DCN OR RAL3SN/DCN OR RAL3SO/DCN OR
 RAL3SP/DCN OR RAL3SQ/DCN OR RAL3SR/DCN OR RAL3ST/DCN OR
 RANFVN/DCN OR RAN401/DCN OR RAN403/DCN OR RAPVAI/DCN OR
 RAPVAJ/DCN OR RAPVAK/DCN OR RAQW9I/DCN OR RAQW9P/DCN OR
 RAQW9R/DCN OR RAR1ZL/DCN OR RASW2T/DCN OR RASW2U/DCN OR
 RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW2Y/DCN OR
 RASW2Z/DCN OR RASW3A/DCN OR RASW3B/DCN OR RASW3C/DCN OR
 RASW3D/DCN OR RASW3E/DCN OR RASW3F/DCN OR RASW3G/DCN OR
 RASW3H/DCN OR RASW30/DCN OR RASW38/DCN OR RASW39/DCN OR
 RASW4A/DCN OR RASW50/DCN OR RASXL7/DCN OR RAUHHHC/DCN OR
 RAUHHH/DCN OR RAUHH9/DCN OR RAUHSQ/DCN OR RAUVSR/DCN OR
 RAWFMV/DCN OR RAWUPX/DCN OR RAW47P/DCN OR RAW47Q/DCN OR
 RAW47R/DCN OR RAW47S/DCN OR RAW47T/DCN OR RAW47U/DCN OR
 RAXSIA/DCN OR RA0MNZ/DCN OR RA0020/DCN OR RA007X/DCN OR
 RA0083/DCN OR RA2NB0/DCN OR RA2Y7A/DCN OR RA3MBV/DCN OR
 RA4GNI/DCN OR RA4GOC/DCN OR RA4GOL/DCN OR RA4KMT/DCN OR

11/839,520

RA4KMZ/DCN OR RA4KN3/DCN OR RA4KN4/DCN OR RA4NBT/DCN OR
RA4NBW/DCN OR RA6Q5K/DCN OR RA63TX/DCN OR RA660M/DCN OR
RA8AOM/DCN OR RA9JSH/DCN OR RA9JSI/DCN OR RA9XSQ/DCN OR
RB0D0S/DCN OR RB0D0T/DCN OR RB0D0U/DCN OR RB0D0V/DCN OR
R11693/DCN OR R11694/DCN OR R20556/DCN OR R21482/DCN) OR
L172/DCR

L174 10 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L173 AND (L58 OR L74 OR
(L55 OR L56))
L175 7 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L174 AND (L21 OR L22 OR
L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR
L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR
L50 OR L51)
L176 3 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L174 NOT L175
L177 3 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L176 AND ((L53 OR L54 OR
L55 OR L56) OR L160)
L178 3 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (L176 OR L177)

=> d que nos 1190

L3 (5) SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L4 SEL PLU=ON L3 1- RN : 82 TERMS
L5 82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L4
L21 QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
L22 QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
L23 QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
L24 QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
L25 QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
L30 QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
U, AUTH
L31 QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
L32 QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
L33 QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
L34 QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH
L35 QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU,AUTH
L36 QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU,AUTH
L37 QUE SPE=ON ABB=ON PLU=ON ANGULO, J?/AU,AUTH
L38 QUE SPE=ON ABB=ON PLU=ON FRUTOS, J?/AU,AUTH
L39 QUE SPE=ON ABB=ON PLU=ON VALVERDE LOPEZ, S?/AU,AUTH
L40 QUE SPE=ON ABB=ON PLU=ON VALVERDELOPEZ, S?/AU,AUTH
L41 QUE SPE=ON ABB=ON PLU=ON VALVERDE, S?/AU,AUTH
L42 QUE SPE=ON ABB=ON PLU=ON LOPEZ, S?/AU,AUTH
L43 QUE SPE=ON ABB=ON PLU=ON ROMERO GARRIDO, A?/AU,AUTH
L44 QUE SPE=ON ABB=ON PLU=ON ROMEROGARRIDO, A?/AU,AUTH
L45 QUE SPE=ON ABB=ON PLU=ON ROMERO, A?/AU,AUTH
L46 QUE SPE=ON ABB=ON PLU=ON GARRIDO, A?/AU,AUTH
L47 QUE SPE=ON ABB=ON PLU=ON LOZANO PUERTO, R?/AU,AUTH
L48 QUE SPE=ON ABB=ON PLU=ON LOZANOPUERTO, R?/AU,AUTH
L49 QUE SPE=ON ABB=ON PLU=ON LOZANO, R?/AU,AUTH
L50 QUE SPE=ON ABB=ON PLU=ON PUERTO, R?/AU,AUTH
L51 QUE SPE=ON ABB=ON PLU=ON (ACTION(1W)MEDICINE#)/CS, SO,
PA
L55 QUE SPE=ON ABB=ON PLU=ON ?PSORIA?
L56 QUE SPE=ON ABB=ON PLU=ON ANTIPSORIA?
L126 STR
L128 SCR 1812 OR 1758

```

L130      1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131      1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141      STR
L143      173 SEA FILE=REGISTRY SSS FUL L141
L144      170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145      146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146      STR
L148      160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149      133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150      1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L179      28 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L5 AND L150
L180      7 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L150 AND MEDLINE/LC
L181      392 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L180
L182      SEL  PLU=ON  L179 1- NAME :      13 TERMS
L183      17 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L182
L184      399 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L181 OR L183
L185      QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L186      QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOLYSIS
L187      QUE  SPE=ON  ABB=ON  PLU=ON  "SKIN DISEASES, PAPULOSQUAMO
      US"+PFT,OLD,NEW,NT/CT
L188      1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L184 AND ((L55 OR
      L56) OR L185 OR (L186 OR L187))
L189      1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L188 AND (L21 OR L22
      OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
      OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
      OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
      OR L50 OR L51)
L190      0 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L188 NOT L189

```

=> d que nos 1199

```

L3  (      5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L4      SEL  PLU=ON  L3 1- RN :      82 TERMS
L5      82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L4
L21      QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22      QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23      QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24      QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25      QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26      QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27      QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28      QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29      QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
      U, AUTH
L31      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33      QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34      QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38      QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42      QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44      QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH

```

11/839,520

L46 QUE SPE=ON ABB=ON PLU=ON GARRIDO, A?/AU,AUTH
L47 QUE SPE=ON ABB=ON PLU=ON LOZANO PUERTO, R?/AU,AUTH
L48 QUE SPE=ON ABB=ON PLU=ON LOZANOPUERTO, R?/AU,AUTH
L49 QUE SPE=ON ABB=ON PLU=ON LOZANO, R?/AU,AUTH
L50 QUE SPE=ON ABB=ON PLU=ON PUERTO, R?/AU,AUTH
L51 QUE SPE=ON ABB=ON PLU=ON (ACTION(1W)MEDICINE#)/CS, SO,
PA
L55 QUE SPE=ON ABB=ON PLU=ON ?PSORIA?
L56 QUE SPE=ON ABB=ON PLU=ON ANTIPSORIA?
L126 STR
L128 SCR 1812 OR 1758
L130 1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131 1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI
L141 STR
L143 173 SEA FILE=REGISTRY SSS FUL L141
L144 170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
L145 146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES
L146 STR
L148 160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149 133 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L145 AND L148
L150 1427 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L131 OR L149
L179 28 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L5 AND L150
L182 SEL PLU=ON L179 1- NAME : 13 TERMS
L186 QUE SPE=ON ABB=ON PLU=ON EPIDERMOPOIESIS
L191 4 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L150 AND EMBASE/LC
L192 794 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L191
L193 69 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L182
L194 838 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON (L192 OR L193)
L195 QUE SPE=ON ABB=ON PLU=ON PSORIASIS+PFT,OLD,NEW,NT/CT
L196 QUE SPE=ON ABB=ON PLU=ON "ERYTHEMATOSQUAMOUS SKIN DIS
EASE"+PFT,OLD,NEW,NT/CT
L197 2 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L194 AND ((L55 OR L56)
OR L186 OR (L195 OR L196))
L198 1 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L197 AND (L21 OR L22
OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
OR L50 OR L51)
L199 1 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L197 NOT L198

=> d his 1209

(FILE 'BIOSIS, BIOTECHNO, CABA, DRUGU, VETU' ENTERED AT 11:16:26 ON 25
SEP 2009)

L209 2 S L207 NOT L208

=> d que nos 1209

L3 (5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L4 SEL PLU=ON L3 1- RN : 82 TERMS
L5 82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L4
L21 QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
L22 QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
L23 QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
L24 QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
L25 QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH

11/839,520

```

L30      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
        U,AUTH
L31      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33      QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34      QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38      QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42      QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44      QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46      QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50      QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51      QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
        PA
L53      QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54      QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L126     STR
L128     SCR 1812 OR 1758
L130     1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131     1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI
L141     STR
L143     173 SEA FILE=REGISTRY SSS FUL L141
L144     170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
L145     146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES
L146     STR
L148     160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149     133 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L145 AND L148
L150     1427 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L131 OR L149
L160     QUE  SPE=ON  ABB=ON  PLU=ON  DISEAS? OR DISORDER? OR SYND
        ROM? OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB
        ? OR DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)
L179     28 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L5 AND L150
L182     SEL  PLU=ON  L179 1- NAME :      13 TERMS
L200     11 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L150 AND (BIOSIS OR
        BIOTECHNO OR CABA OR DRUGU OR VETU)/LC
L201     437 SEA L200
L202     45 SEA L182
L203     469 SEA (L201 OR L202)
L207     2 SEA L203 AND ((L53 OR L54) (5A) L160)
L208     0 SEA L207 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
        L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
        L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
        L46 OR L47 OR L48 OR L49 OR L50 OR L51)
L209     2 SEA L207 NOT L208

```

=> d his 1218

(FILE 'HCAPLUS, WPIX, PASCAL, JAPIO, MEDLINE, BIOSIS, EMBASE, CABA,
CEABA-VTB, LIFESCI, KOSMET, BIOENG, BIOTECHNO, BIOTECHDS, DRUGU, DRUGB,

11/839,520

VETU, VETB, SCISEARCH, CONFSCI, DISSABS, RDISCLOSURE' ENTERED AT 11:29:03
ON 25 SEP 2009)

L218 1 S L216 NOT L217

FILE 'STNGUIDE' ENTERED AT 11:33:45 ON 25 SEP 2009

FILE 'REGISTRY' ENTERED AT 11:33:54 ON 25 SEP 2009

FILE 'STNGUIDE' ENTERED AT 11:34:02 ON 25 SEP 2009

=> d que nos l218

L3 (5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L4 SEL PLU=ON L3 1- RN : 82 TERMS
L5 82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L4
L21 QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
L22 QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
L23 QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
L24 QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
L25 QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
L30 QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
U,AUTH
L31 QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
L32 QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
L33 QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
L34 QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH
L35 QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU,AUTH
L36 QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU,AUTH
L37 QUE SPE=ON ABB=ON PLU=ON ANGULO, J?/AU,AUTH
L38 QUE SPE=ON ABB=ON PLU=ON FRUTOS, J?/AU,AUTH
L39 QUE SPE=ON ABB=ON PLU=ON VALVERDE LOPEZ, S?/AU,AUTH
L40 QUE SPE=ON ABB=ON PLU=ON VALVERDELOPEZ, S?/AU,AUTH
L41 QUE SPE=ON ABB=ON PLU=ON VALVERDE, S?/AU,AUTH
L42 QUE SPE=ON ABB=ON PLU=ON LOPEZ, S?/AU,AUTH
L43 QUE SPE=ON ABB=ON PLU=ON ROMERO GARRIDO, A?/AU,AUTH
L44 QUE SPE=ON ABB=ON PLU=ON ROMEROGARRIDO, A?/AU,AUTH
L45 QUE SPE=ON ABB=ON PLU=ON ROMERO, A?/AU,AUTH
L46 QUE SPE=ON ABB=ON PLU=ON GARRIDO, A?/AU,AUTH
L47 QUE SPE=ON ABB=ON PLU=ON LOZANO PUERTO, R?/AU,AUTH
L48 QUE SPE=ON ABB=ON PLU=ON LOZANOPUERTO, R?/AU,AUTH
L49 QUE SPE=ON ABB=ON PLU=ON LOZANO, R?/AU,AUTH
L50 QUE SPE=ON ABB=ON PLU=ON PUERTO, R?/AU,AUTH
L51 QUE SPE=ON ABB=ON PLU=ON (ACTION(1W)MEDICINE#)/CS, SO,
PA
L55 QUE SPE=ON ABB=ON PLU=ON ?PSORIA?
L56 QUE SPE=ON ABB=ON PLU=ON ANTIPSORIA?
L58 QUE SPE=ON ABB=ON PLU=ON A61P0017-06/IPC
L126 STR
L128 SCR 1812 OR 1758
L130 1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131 1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI
L141 STR
L143 173 SEA FILE=REGISTRY SSS FUL L141
L144 170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
L145 146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES
L146 STR
L148 160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146

11/839,520

```
L149      133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150      1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L179      28  SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L5 AND L150
L182      SEL  PLU=ON  L179 1- NAME :      13 TERMS
L186      QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS
L204      QUE  SPE=ON  ABB=ON  PLU=ON  WILLAN (1A) LEpra
L205      QUE  SPE=ON  ABB=ON  PLU=ON  PARAPSORIA?
L215      425 SEA L182
L216      13 SEA L215 AND ((L55 OR L56) OR L186 OR (L204 OR L205) OR L58)
L217      12 SEA L216 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
          L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
          L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
          L46 OR L47 OR L48 OR L49 OR L50 OR L51)
L218      1 SEA L216 NOT L217
```

=> dup rem 171 1123 1166 1214 1178 1190 1199 1209 1218

L190 HAS NO ANSWERS

DUPLICATE IS NOT AVAILABLE IN 'KOSMET, RDISCLOSURE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

FILE 'HCAPLUS' ENTERED AT 11:40:01 ON 25 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 11:40:01 ON 25 SEP 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 11:40:01 ON 25 SEP 2009

CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:40:01 ON 25 SEP 2009

Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:40:01 ON 25 SEP 2009

Copyright (c) 2009 The Thomson Corporation

FILE 'DRUGU' ENTERED AT 11:40:01 ON 25 SEP 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

PROCESSING COMPLETED FOR L71

PROCESSING COMPLETED FOR L123

PROCESSING COMPLETED FOR L166

PROCESSING COMPLETED FOR L214

PROCESSING COMPLETED FOR L178

PROCESSING COMPLETED FOR L190

PROCESSING COMPLETED FOR L199

PROCESSING COMPLETED FOR L209

PROCESSING COMPLETED FOR L218

L219 21 DUP REM L71 L123 L166 L214 L178 L190 L199 L209 L218 (8 DUPLICATES
REMOVED)

ANSWERS '1-15' FROM FILE HCAPLUS

ANSWERS '16-17' FROM FILE WPIX

ANSWERS '18-19' FROM FILE USPATFULL

ANSWER '20' FROM FILE EMBASE

ANSWER '21' FROM FILE DRUGU

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 11:40:18 ON 25 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

11/839,520

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 18, 2009 (20090918/UP).

=> d ibib ed abs hitind hitstr 1-15

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' -
CONTINUE? (Y)/N:y

L219 ANSWER 1 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2007:1163610 HCAPLUS Full-text

DOCUMENT NUMBER: 148:69764

TITLE: Clinical study of calcium dobesilate in treatment of
diabetic skin ulcer

AUTHOR(S): Liu, Qiliang; Hu, Jie; Zhang, Dengke; Fang, Degang

CORPORATE SOURCE: 163 Hospital of People's Liberation Army, Changsha,
410003, Peop. Rep. China

SOURCE: Yixue Linchuang Yanjiu (2007), 24(1), 59-60, 64

CODEN: YLYIAB; ISSN: 1671-7171

PUBLISHER: Yixue Linchuang Yanjiu Zazhishe

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

ED Entered STN: 16 Oct 2007

AB The objective was to evaluate the efficacy and safety of calcium dobesilate in
the treatment of diabetic skin ulcer. Seventy-six cases of diabetic skin
ulcer patients were randomly assigned to calcium dobesilate group or control
group, 38 cases received oral calcium dobesilate, 38 cases received oral
vitamin C. The whole observation lasted 8 wk. The efficacy of the calcium
dobesilate group was much better than that of the control group, the total
therapeutic effective rate was 94.74% in the calcium dobesilate group and
52.63% in the control group (P<0.01). NO adverse effect of liver and kidney
function was found. Calcium dobesilate is effective and safe in the treatment
of diabetic skin ulcer.

CC 1-10 (Pharmacology)

ST diabetes mellitus complication skin ulcer sulfonic acid

IT Diabetes mellitus

Human

Kidney

Liver

Skin, disease

(clin. study of calcium dobesilate in treatment of diabetic
skin ulcer)

IT Sulfonic acids, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(clin. study of calcium dobesilate in treatment of diabetic
skin ulcer)

IT 50-81-7, Vitamin C, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(clin. study of calcium dobesilate in treatment of diabetic
skin ulcer)

IT 20123-80-2, Calcium dobesilate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)


(clin. study of calcium dobesilate in treatment of diabetic
skin ulcer)

IT 20123-80-2, Calcium dobesilate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(clin. study of calcium dobesilate in treatment of diabetic
skin ulcer)

RN 20123-80-2 HCAPLUS
 CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

L219 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 2005:238842 HCAPLUS Full-text
 DOCUMENT NUMBER: 142:291452
 TITLE: Modulating cell activity by using an agent that reduces the level of cholesterol within a cell
 INVENTOR(S): Allen, Janet Marjorie; Overington, John Paul
 PATENT ASSIGNEE(S): Inpharmatica Limited, UK
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023305	A2	20050317	WO 2004-GB3875	20040910
WO 2005023305	A3	20050616		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2003-21228 A 20030910

ED Entered STN: 18 Mar 2005

AB The invention discloses methods for modulating the activity of cells, and compns. useful in such methods. In particular, the invention relates to the use of an agent that reduces the level of cholesterol within a cell to modulate the activity of the cell, and to methods involving such use.

IC ICM A61K045-00

ICS A61K031-785; A61P037-00

CC 1-12 (Pharmacology)

Section cross-reference(s): 63

IT Dermatophagoides

Pet animal

Pollen

(allergy to; cell activity modulation with agent reducing level of cell cholesterol)

IT Dermatitis

(atopic; cell activity modulation with agent reducing level of cell cholesterol)

IT AIDS (disease)

Allergy

Allergy inhibitors

Alzheimer's disease

Analgesics

Animal cell

Anti-AIDS agents

Anti-Alzheimer's agents

Anti-infective agents

Anti-inflammatory agents

Antiarthritics

Antiasthmatics

Antibacterial agents

Anticholesteremic agents

Antidiabetic agents

Antihypertensives

Antimalarials

Antiparkinsonian agents

Antirheumatic agents

Antitumor agents

Antiulcer agents

Antiviral agents

Asthma

Atherosclerosis

Autoimmune disease

Burn

Campylobacter

Cell membrane

Chlamydia

Cirrhosis

Clostridium difficile

Clostridium tetani

Connective tissue, disease

Diabetes mellitus

Digestive tract, disease

Drug delivery systems

Drug screening

Dysmenorrhea

Ebola virus

Eczema

Emphysema

Escherichia coli

Fabry disease

Food allergy

Gastrointestinal agents

Gout

Headache

Hepatitis

Hepatitis virus

Herpesviridae

Human

Human herpesvirus

Human herpesvirus 4

Human immunodeficiency virus

Hypercholesterolemia

Hyperparathyroidism
Hypertension
Immunomodulators
Infection
Inflammation
Influenza virus
Injury
Leishmania
Listeria
Marburg virus
Mast cell
Measles virus
Multiple sclerosis
Muscular dystrophy
Mycobacterium tuberculosis
Myositis
Neoplasm
Nervous system agents
Osteoarthritis
Pain
Papillomavirus
Parasite
Parasiticides
Parkinson's disease
Pathogen
Phosphorylation, biological
Plasmodium (malarial genus)
Psoriasis
Respiratory syncytial virus
Rheumatoid arthritis
Salmonella
Sarcoidosis
Sepsis
Shigella
Signal transduction, biological
Sjogren syndrome
Toxoplasma gondii
Trypanosoma
Trypanosomicides
Urticaria
Vibrio cholerae
Wound
Wound healing promoters

(cell activity modulation with agent reducing level of cell cholesterol)

IT Dermatitis

(contact; cell activity modulation with agent reducing level of cell cholesterol)

IT Arthritis

(psoriatic arthritis; cell activity modulation with agent reducing level of cell cholesterol)

IT 51-26-3, Thyropropic acid 51-49-0, Dextrothyroxine 59-67-6D, Nicotinic acid, derivs. 64-18-6D, Formic acid, hydroxylated statin esters 64-19-7D, Acetic acid, hydroxylated statin esters 65-85-0D, Benzoic acid, hydroxylated statin esters 78-41-1, Triparanol 79-09-4D, Propanoic acid, hydroxylated statin esters 83-46-5, β -Sitosterol 90-26-6, α -Phenylbutyramide 107-92-6D, Butanoic acid, hydroxylated statin esters 109-52-4D, Pentanoic acid, hydroxylated statin esters 111-14-8D, Heptanoic acid, hydroxylated statin esters 112-05-0D, Nonanoic acid, hydroxylated statin esters 124-07-2D, Octanoic acid,

hydroxylated statin esters 142-62-1D, Hexan-1-oic acid, hydroxylated
 statin esters 334-48-5D, Decanoic acid, hydroxylated statin esters
 503-49-1, Meglutol 541-15-1, Carnitine 597-71-7,
 Pentaerythritoltetraacetate 621-82-9D, Cinnamic acid, hydroxylated
 statin esters 637-07-0, Clofibrate 882-09-7, Clofibric acid
 943-45-3D, Fibric acid, derivs. 959-10-4, Xenbucin 1239-29-8,
 Furazabol 1976-28-9 2398-81-4, Oxiniacic acid 5868-05-3, Niceritrol
 6964-20-1, Tiadenol 9007-28-7, Chondroitin sulfate 9011-18-1, Dextran
 Sodium sulfate 9064-91-9, Detaxtran 10571-59-2, Nicoclonate
 11041-12-6, Cholestyramine 11042-64-1, γ -Oryzanol 14417-88-0,
 Melinamide 14929-11-4, Simfibrate 16816-67-4, Pantethine 17365-01-4,
 Etiroxate 20568-07-4 23288-49-5, Probucol 23602-78-0, Benfluorex
 23918-98-1, Eritadenine 25812-30-0, Gemfibrozil 27959-26-8, Nicomol
 30299-08-2, Clinofibrate 31637-97-5, Etofibrate 32839-30-8,
 Eicosapentaenoic acid 41859-67-0, Bezafibrate 42597-57-9, Ronifibrate,
 biological studies 49562-28-9, Fenofibrate 50925-79-6, Colestipol
 51037-30-0, Acipimox 52214-84-3, Ciprofibrate 54110-25-7, Pirozadil
 54504-70-0, Theofibrate 55285-45-5, Pirifibrate 56227-39-5, Polidexide
57775-26-5, Sultosilic acid 69047-39-8, Binifibrate
 72420-38-3, Acifran 73573-88-3, Mevastatin 73573-88-3D, Mevastatin,
 derivs. 75330-75-5, Lovastatin 75330-75-5D, Lovastatin, derivs.
 79902-63-9, Simvastatin 79902-63-9D, Simvastatin, derivs. 81093-37-0,
 Pravastatin 81093-37-0D, Pravastatin, derivs. 93957-54-1, Fluvastatin
 93957-54-1D, Fluvastatin, derivs. 134523-00-5, Atorvastatin
 134523-00-5D, Atorvastatin, derivs. 145599-86-6, Cerivastatin
 145599-86-6D, Cerivastatin, derivs. 147511-69-1, Pitavastatin
 147511-69-1D, Pitavastatin, derivs. 163222-33-1, Ezetimibe
 182815-44-7, Colesevelam hydrochloride 287714-41-4, Rosuvastatin
 287714-41-4D, Rosuvastatin, derivs. 433289-84-0 847849-65-4
 847849-66-5 847849-67-6 847849-68-7 847849-69-8 847849-69-8D,
 carboxylic acid esters 847849-70-1 847849-70-1D, carboxylic acid
 esters 847849-71-2 847849-71-2D, carboxylic acid esters 847849-72-3
 847849-72-3D, carboxylic acid esters 847849-73-4 847849-73-4D,
 carboxylic acid esters


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (cell activity modulation with agent reducing level of cell
 cholesterol)

IT 57775-26-5, Sultosilic acid

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (cell activity modulation with agent reducing level of cell
 cholesterol)

RN 57775-26-5 HCAPLUS

CN Benzenesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]- (CA
 INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
 (9 CITINGS)

11/839,520

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2004:378041 HCAPLUS Full-text

DOCUMENT NUMBER: 141:17539

TITLE: Calcium dobesilate (Cd) in pigmented purpuric
dermatosis (PPD): a pilot evaluation

AUTHOR(S): Agrawal, Subhav Kumar; Gandhi, Vijay; Bhattacharya,
Sambit Nath

CORPORATE SOURCE: Department of Dermatology and S.T.D., University
College of Medical Sciences and Guru Teg Bahadur
Hospital, New Delhi, India

SOURCE: Journal of Dermatology (2004), 31(2), 98-103
CODEN: JDMYAG; ISSN: 0385-2407

PUBLISHER: Japanese Dermatological Association

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 11 May 2004

AB Pigmented purpuric dermatosis (PPD) is a chronic disorder of unknown etiol.
It is quite common, and no therapy is significantly effective. Calcium
dobesilate (Cd) has been tried successfully in many vascular disorders. The
aim of this study was to evaluate the usefulness and efficacy of Cd in PPD.
Nine male (patients (7 with Schamberg's and 1 each with lichenoid dermatosis
of Gougerot and Blum and lichen aureus)) were given Cd 500 mg twice daily for
two initial weeks and then 500 mg once daily for a total period of three
months. All the patients were followed up for one year after cessation of
therapy. The improvement was moderate in 11.11% and mild in 66.67% of cases;
22.22% did not show any improvement. New lesions stopped appearing in two
weeks in all patients, and itching also improved in symptomatic cases without
any significant side effects. Based upon the results of this pilot study we
recommend Cd as the first line therapy for PPD.

CC 1-12 (Pharmacology)

ST calcium dobesilate pigmented purpuric dermatosis

IT Human

Skin, disease

(efficacy of calcium dobesilate in treatment of pigmented purpuric
dermatosis)

IT 20123-80-2, Calcium dobesilate


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of calcium dobesilate in treatment of pigmented purpuric
dermatosis)

IT 20123-80-2, Calcium dobesilate

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of calcium dobesilate in treatment of pigmented purpuric
dermatosis)

RN 20123-80-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2004:582074 HCAPLUS Full-text

DOCUMENT NUMBER: 141:293190

TITLE: Chronic venous diseases: Roles of various pathophysiological factors

AUTHOR(S): Boisseau, M. R.; de La Giclais, B.

CORPORATE SOURCE: Laboratoire de Pharmacologie, Biologie Vasculaire, Universite Victor Segalen Bordeaux 2, Bordeaux, 33076, Fr.

SOURCE: Clinical Hemorheology and Microcirculation (2004), 31(1), 67-74

CODEN: CHMIFQ; ISSN: 1386-0291

PUBLISHER: IOS Press

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

ED Entered STN: 21 Jul 2004

AB A review. Disturbances in haemodynamic, biochem. and enzymic factors have been observed in chronic venous diseases (CVD). These changes lead to the development of varices, telangiectasies and skin disorders. They affect vessels, blood, skin tissues and cells. It is now possible to describe their time course and interdependance of these changes. Orthostatism pressure on vein wall may lead to fluid leakage and edema, these resulting in vein enlargement. These processes may be further influenced by genetic or acquired risk factors. Skin microvessels suffer more from hypoxia than from hypertension. Indeed, hypoxia affects not only endothelial cells, but also red and white blood cells and modifies particularly, but not exclusively, TGF- β 1 production. This substance is, an important modulator of zinc dependent-metallo-proteinases and their tissue inhibitor of metallo-proteinases (TIMP) in the skin. Imbalance in this enzymic system seems to lead either to sclerosis or ulcer. Of course, other biochem. events (also in this review) play a role in vessel wall and skin deterioration in CVD. The aim of the present review is to assess the role of pathophysiol. factors in CVD and the influence of different therapies, including the venotropic agent calcium dobesilate, on some of these haemodynamic or biochem. aspects.

CC 14-0 (Mammalian Pathological Biochemistry)

Section cross-reference(s): 1

IT 20123-80-2, Calcium dobesilate

RL: FAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(roles of various pathophysiol. factors in chronic venous diseases)


IT 20123-80-2, Calcium dobesilate

RL: FAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(roles of various pathophysiol. factors in chronic venous diseases)

RN 20123-80-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2003:241333 HCAPLUS Full-text

DOCUMENT NUMBER: 138:395873

TITLE: An open trial of calcium dobesilate in patients with venous ulcers and stasis dermatitis

AUTHOR(S): Kaur, Charandeep; Sarkar, Rashmi; Kanwar, Amrinder J.; Attri, Ashok K.; Dabra, Ajay K.; Kochhar, Suman

CORPORATE SOURCE: Departments of Dermatology and Venereology, Surgery, and Radiology, Government Medical College, Chandigarh, India

SOURCE: International Journal of Dermatology (2003), 42(2), 147-152

CODEN: IJDEBB; ISSN: 0011-9059

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal


LANGUAGE: English

ED Entered STN: 28 Mar 2003

AB Venous leg ulcers and associated stasis dermatitis are a major cause of morbidity, economic loss, and decreased quality of life in afflicted patients. Hence, there has been a renewal of interest in the medical management of varicose veins and ulcers. Calcium dobesilate, a capillotropic agent, has been found to be beneficial in the treatment of varicose veins. This is an open pilot study of 25 patients (15 with venous ulcers with/without stasis dermatitis, 10 with stasis dermatitis only) who were given calcium dobesilate, 500 mg twice daily, for 8 wk. The clin. parameters were graded (0-4; 0, absent; 1, mild; 2, moderate; 3, severe; 4, very severe) both before and after therapy, and included pain, itching, tiredness, heaviness, paresthesia, cramps, and leg swelling. Evaluation also included subjective changes in tenderness, oozing, and pigmentation, and measurement of the circumference of the leg for swelling and malleolar edema (measured in millimeters). The venous ulcer sizes were also recorded both before and after therapy. Color Doppler studies were performed to confirm the diagnosis of varicose veins, determine the competence of the valves, and to rule out deep vein thrombosis. Serum biochem., hemogram, and urinalysis were performed both before and after treatment. The results were analyzed statistically using the Wilcoxon rank sum test and Student's t-test. A statistically significant improvement was observed post-therapeutically in the clin. parameters of pain, itching, tiredness, heaviness, and leg swelling. There was also a significant decrease

in ulcer size. The serum biochem., hemogram, and urinalysis remained unaffected. Color Doppler studies before treatment revealed venous valvular incompetence in 20 patients. They were repeated in only 10 patients after treatment, four of whom showed improved valvular competence. Recurrence of venous ulcers was seen in five of 12 patients who were followed up after therapy. No significant side-effects were noted. Calcium dobesilate is an effective adjuvant therapy, with an absence of significant side-effects, in patients with venous ulcers and stasis dermatitis. More double-blind trials are required in the future to substantiate and evaluate the role of the drug in these two indications.

- CC 1-9 (Pharmacology)
- ST calcium dobesilate antiulcer capillary varicose vein ulcer
dermatitis
- IT Capillary vessel
Dermatitis
Human
Leg
(calcium dobesilate in patients with venous leg ulcers and stasis
dermatitis)
- IT Antiulcer agents
(capillotropic; calcium dobesilate in patients with venous leg ulcers
and stasis dermatitis)
- IT Ulcer
(cutaneous; calcium dobesilate in patients with venous leg ulcers and
stasis dermatitis)
- IT Skin, disease
(ulcer; calcium dobesilate in patients with venous leg ulcers and
stasis dermatitis)
- IT Vein, disease
(varicose; calcium dobesilate in patients with venous leg ulcers and
stasis dermatitis)
- IT 20123-80-2, Calcium dobesilate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(calcium dobesilate in patients with venous leg ulcers and stasis
dermatitis)
- IT 20123-80-2, Calcium dobesilate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(calcium dobesilate in patients with venous leg ulcers and stasis
dermatitis)
- RN 20123-80-2 HCAPLUS
- CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009:1015029 HCAPLUS Full-text
 DOCUMENT NUMBER: 151:280249
 TITLE: Treatment of acne vulgaris, rosacea and rhinophym with inhibitors of the fibroblast growth factor receptor 2 and insulin-like growth factor 1 receptor signal pathways
 INVENTOR(S): Melnik, Bodo
 PATENT ASSIGNEE(S): Germany
 SOURCE: PCT Int. Appl., 39pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009101199	A2	20090820	WO 2009-EP51749	20090216
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			EP 2008-101654	A 20080215
			EP 2008-154022	A 20080403
			US 2008-123294P	P 20080407
			EP 2008-164431	A 20080916
			EP 2008-168765	A 20081110

ED Entered STN: 20 Aug 2009

AB A composition for the treatment of acne vulgaris, rosacea and/or rhinophym comprises at least one inhibitor of the FGFR2 signal pathway and/or IGFR1 signal pathway. Also claimed is a bovine milk or a product of bovine milk having a reduced content of hormones, especially progesterone and growth factors, like IGF-1 and IGF-2, FGF1, and FGF2, or having a modified casein which has a reduced influence on IGF-1 levels. Further, use of Metforming for the prevention of adenocarcinomas, cardiovascular diseases and neurodegenerative diseases, is also presented.

CC 1-10 (Pharmacology)

Section cross-reference(s): 2, 17, 63

IT Skin, disease

(rosacea, rhinophym; acne vulgaris, rosacea and rhinophym treatment with inhibitors of fibroblast growth factor receptor 2 and insulin-like receptor 1 signal pathways)

IT Acne

(vulgaris; acne vulgaris, rosacea and rhinophym treatment with inhibitors of fibroblast growth factor receptor 2 and insulin-like receptor 1 signal pathways)

IT 57-92-1, Streptomycin ~~88-46-0~~ 1143-38-0, Dithranol
 1403-66-3, Gentamicin 1404-04-2, Neomycin 1405-10-3, Neomycin sulfate

11/839,520

3895-92-9, Chelerythrine chloride 4449-51-8, Cyclopamine 7542-37-2,
Paromomycin 32986-56-4, Tobramycin 37517-28-5, Amikacin 56391-56-1,
Netilmicin 63590-19-2, (-)-Balanol 64048-12-0, GANT 58 70226-44-7D,
Heparan, sulfate derivs. 99533-80-9, K252a 109511-58-2, U0126
112953-11-4, UCN-01 120685-11-2, CGP41251 121263-19-2, Calphostin C
125313-65-7, Ro 31-7549 125314-64-9, Ro 31-8220 133052-90-1, GF109203X
133053-19-7, Go 6983 136194-77-9, Go 6976 151879-73-1, Aprinocarsen
152121-30-7, SB202190 152121-47-6, SB203580 152459-75-1, CGP53506
167869-21-8, PD 98059 169939-94-0, Ly333531 212631-79-3, PD 184352
219580-11-7, PD173074 365253-37-8, Ly317615 500579-04-4, GANT 61
914077-78-4 1184297-32-2, CGP 54345 1184297-33-3, BIRB 8796

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as inhibitor of FGFR2 signal pathway; acne vulgaris, rosacea and
rhinophym treatment with inhibitors of fibroblast growth factor
receptor 2 and insulin-like receptor 1 signal pathways)


IT 88-46-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as inhibitor of FGFR2 signal pathway; acne vulgaris, rosacea and
rhinophym treatment with inhibitors of fibroblast growth factor
receptor 2 and insulin-like receptor 1 signal pathways)

RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



L219 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:884915 HCAPLUS Full-text
DOCUMENT NUMBER: 151:190037
TITLE: Treatment of skin disorders with
EGFR inhibitors
INVENTOR(S): Alexandrescu, Doru Traian
PATENT ASSIGNEE(S): Georgetown University, USA
SOURCE: PCT Int. Appl., 47pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009091889	A1	20090723	WO 2009-US31101	20090115
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			

11/839,520

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2008-22067P

P 20080118

ED Entered STN: 23 Jul 2009

AB Methods and compns. for the treatment of skin disorders (e.g., genetic skin disorders) are provided. The methods and compns. include an EGFR inhibitor. For genetic skin disorders that exhibit a high percentage of penetrance, or complete penetrance, such as Darier's disease, the methods and compns. provided herein can be used to prevent or reduce manifestation of symptoms of the disease.

CC 1-12 (Pharmacology)

ST EGFR inhibitor Cetuximab Erlotinib skin disorder
cancer

IT Antibodies and Immunoglobulins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(EGFR binding; treatment of skin disorders with
EGFR inhibitors)

IT Disease, animal

(Hailey-Hailey, verrucous epidermal nevi, pityriasis rubra
pilaris, Netherton, idiopathic vulgaris, monilethrix, Tay's; treatment
of skin disorders with EGFR inhibitors)

IT Carcinoma

(bladder; treatment of skin disorders with EGFR
inhibitors)

IT Bladder, neoplasm

(carcinoma; treatment of skin disorders with EGFR
inhibitors)

IT Carcinoma

(cutaneous squamous cell; treatment of skin disorders
with EGFR inhibitors)

IT Keratosis

(epidermolytic hyperkeratosis; treatment of skin
disorders with EGFR inhibitors)

IT Skin, disease

(erythrokeratoderma variabilis; treatment of skin
disorders with EGFR inhibitors)

IT Skin, disease

(erythrokeratoderma variabilis, eythrokeratoderma
figurate variabilis, mutilating keratoderma of Vohwinkel,
genetic; treatment of skin disorders with EGFR
inhibitors)

IT Drug delivery systems

(feeding tube; treatment of skin disorders with
EGFR inhibitors)

IT Keratosis

(follicularis; treatment of skin disorders with
EGFR inhibitors)

IT Carboxylic acids

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(hydroxy, alpha and beta; treatment of skin disorders
with EGFR inhibitors)

IT Keratosis

(hyper-, palmoplantar; treatment of skin disorders
with EGFR inhibitors)

IT Keratosis

- (hyperkeratosis, lenticularis perstans; treatment of skin disorders with EGFR inhibitors)
- IT Pharmaceutical injections
(i.v. injections; treatment of skin disorders with EGFR inhibitors)
- IT Skin, disease
(ichthyosis, erythrodermic and nonerythrodermic autosomal recessive lamellar, nonbullous congenital, vulgaris, Harlequin; treatment of skin disorders with EGFR inhibitors)
- IT Epidermal growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; treatment of skin disorders with EGFR inhibitors)
- IT Skin
(keratinization, monogenic, polygenic inherited disorder, complex; treatment of skin disorders with EGFR inhibitors)
- IT Phototherapy
(laser therapy; treatment of skin disorders with EGFR inhibitors)
- IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; treatment of skin disorders with EGFR inhibitors)
- IT Transdermal drug delivery systems
(patches; treatment of skin disorders with EGFR inhibitors)
- IT Carcinoma
(pharyngeal squamous cell; treatment of skin disorders with EGFR inhibitors)
- IT Keratosis
(piliaris; treatment of skin disorders with EGFR inhibitors)
- IT Pharynx, neoplasm
Skin, neoplasm
(squamous cell carcinoma; treatment of skin disorders with EGFR inhibitors)
- IT Pharmaceutical emulsions
Topical drug delivery systems
(topical lotions; treatment of skin disorders with EGFR inhibitors)
- IT Pharmaceutical patches
(transdermal; treatment of skin disorders with EGFR inhibitors)
- IT Antitumor agents
Colorectal neoplasm
Dermatological agents
Esophagus, neoplasm
Human
Larynx, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Pharmaceutical creams
Pharmaceutical tablets
Prostate gland, neoplasm

Radiotherapy
 Sjogren-Larsson syndrome
 Stomach, neoplasm
 Syringes
 Topical drug delivery systems
 (treatment of skin disorders with EGFR inhibitors)

IT Antisense nucleic acids
 Corticosteroids
 Flavonoids
 Isoflavonoids
 Retinoids
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (treatment of skin disorders with EGFR inhibitors)

IT Cytotoxic agents
 (tyrphostins; treatment of skin disorders with EGFR
 inhibitors)

IT 339177-26-3, Panitumumab
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (ABX-EGF; treatment of skin disorders with EGFR
 inhibitors)

IT 205923-56-4, ERBITUX
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (Cetuximab; treatment of skin disorders with EGFR
 inhibitors)

IT 183319-69-9, TARCEVA
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (Erlotinib; treatment of skin disorders with EGFR
 inhibitors)


IT 60-18-4, Tyrosine, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (metabolites; treatment of skin disorders with EGFR
 inhibitors)

IT 51-21-8, 5-Fluorouracil 58-05-9, Leucovorin 91-19-0D, Quinoxaline,
 derivs., quinazolones, quinazolinamines 94-36-0, Benzoyl peroxide,
 biological studies 108-95-2D, Phenol, stibenoids 289-95-2D,
 Pyrimidine, Ph derivs. 15663-27-1, Cisplatin 41575-94-4, Carboplatin
 61825-94-3, Oxaliplatin 63177-57-1, Methyl
 2,5-dihydroxycinnamate 79217-60-0, Cyclosporin 97682-44-5, Irinotecan
 106685-40-9, Adapalene 118292-40-3, Tazarotene 153559-49-0, Bexarotene
 180288-69-1, Trastuzumab 184475-35-2, Gefitinib 231277-92-2, Lapatinib
 339186-68-4, Matuzumab 625853-93-2, ICR 62 667901-13-5, Zalutumumab
 780758-10-3, Nimotuzumab
 RL: PAC (Pharmacological activity); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (treatment of skin disorders with EGFR inhibitors)

IT 63177-57-1, Methyl 2,5-dihydroxycinnamate
 RL: PAC (Pharmacological activity); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (treatment of skin disorders with EGFR inhibitors)

RN 63177-57-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1079809 HCAPLUS Full-text
 DOCUMENT NUMBER: 149:362249
 TITLE: Cosmetic composition containing calcium dobesilate and others for treating acne and acari
 INVENTOR(S): Duan, Yadong
 PATENT ASSIGNEE(S): Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 19pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 101254156	A	20080903	CN 2007-10055373	20070301
PRIORITY APPLN. INFO.:			CN 2007-10055373	20070301

ED Entered STN: 08 Sep 2008

AB The cosmetic composition contains 0.001-40% calcium dobesilate, and a suitable amount of cosmetic matrix such as lipid, waxes, antioxidant, antiseptic, humectant, surfactant, perfume, and colorant. The cosmetic composition can also contains active constituents such as metronidazole, aureomycin, retinoic acid, *Stemona sessilifolia* fine powder or extract, *Salvia miltiorrhiza* fine powder or extract, tanshinone, vitamins, *Panax ginseng*, minoxidilum, *Glycyrrhiza uralensis*, sodium fluoride, stannous fluoride, *Panax notoginseng*, propolis, and *Zanthoxylum nitidum* etc. The cosmetic composition may be used to produce the cosmetic formulations (such as solution, soap-type agent, cream, tincture, film or gel), shampoo and toothpaste for nursing and moistening skin, growing hair, preventing phalacrosis, protecting gingiva, fixing tooth, preventing and treating facial blood streak, facial petechia, seborrheic dermatitis, and acne.

CC 62-4 (Essential Oils and Cosmetics)

Section cross-reference(s): 63

IT Acari

Acne

Agrimonia pilosa

Aloe barbadensis

Alopecia

Angelica dahurica

Angelica sinensis

Astragalus membranaceus

Capsicum frutescens

Carthamus tinctorius

Citrus

Cosmetic creams

Cosmetic emulsions

Cosmetic gels

Cosmetic liquids
 Curcuma longa
 Dictamnus dasycarpus
 Gastrodia elata
 Gingival disease
 Gynostemma pentaphyllum
 Human
 Hydnocarpus anthelminthicus
 Microsorium fortunei
 Natural products, pharmaceutical
 Paeonia lactiflora
 Panax ginseng
 Panax notoginseng
 Peach
 Pearl
 Platycladus orientalis
 Polygonum multiflorum
 Propolis
 Prunus persica
 Quisqualis indica
 Royal jelly
 Safflower
 Salvia miltiorrhiza
 Scutellaria baicalensis
Seborrhea
 Selinum monnieri
 Shampoos
 Sophora flavescens
 Stemona japonica
 Syzygium aromaticum
 Zanthoxylum nitidum
 Zingiber corallinum
 Zingiber officinale

(cosmetic composition containing calcium dobesilate and others for treating
 acne and acari)

IT Acaricides
 (cosmetic composition containing calcium dobesilate and others for treating
skin acne and acari)

IT Skin, disease
 (rosacea; cosmetic composition containing calcium dobesilate and others for
 treating acne and acari)

IT 50-81-7, Vitamin C, biological studies 51-75-2, Chlormethine 56-75-7,
 Chloromycetin 57-62-5, Aureomycin 60-54-8, Tetracycline 68-26-8,
 Vitamin A 79-57-2, Terramycin 94-36-0, Benzoyl peroxide, biological
 studies 114-07-8, Erythromycin 154-21-2, Lincomycin 302-79-4,
 Retinoic acid 443-48-1, Metronidazole 568-72-9, Tanshinone IIA
 1404-04-2, Neomycin 1406-18-4, Vitamin E 7681-49-4, Sodium fluoride,
 biological studies 7704-34-9, Sulfur, biological studies 7772-99-8,
 Stannous chloride, biological studies 10118-90-8, Minocycline
 10163-15-2, Sodium monofluorophosphate 19387-91-8, Tinidazole
20123-80-2, Calcium dobesilate 35825-57-1, Cryptotanshinone
 38304-91-5, Minoxidil 54693-68-4, Tanshinone 69659-80-9, Tanshinone
 IIA sodium sulfonate

RL: COS (Cosmetic use); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(cosmetic composition containing calcium dobesilate and others for treating
 acne and acari)

IT 20123-80-2, Calcium dobesilate


RL: COS (Cosmetic use); FAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(cosmetic composition containing calcium dobesilate and others for treating
 acne

and acari)

RN 20123-80-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

L219 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:39401 HCAPLUS Full-text

DOCUMENT NUMBER: 144:198760

TITLE: Manufacture of antiphlogistic and analgesic
skin medicine for painless injection and
 cleaning wound

INVENTOR(S): Zhang, Lixin; Liu, Jinzhou

PATENT ASSIGNEE(S): Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 7 pp.
 CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1628848	A	20050622	CN 2003-10114609	20031217
PRIORITY APPLN. INFO.:			CN 2003-10114609	20031217

ED Entered STN: 16 Jan 2006

AB The title medicine contains (by weight part) analgesic 0.001-10, disinfectant 0.001-10, hemostatic 0.001-10, anti-inflammatory agent 0.001-10 and solvent 20-99.996 (water or ethanol). The anodyne contains one or more of aspirin, procaine hydrochloride, triazolone, anadol, pentazocine lactate, fentanyl citrate and fortanodyn. The disinfectant contains one or more of iodine tincture, benzalkonium bromide, methyl violet and antibiotics. The hemostat contains one or more of etamsylate, carbazochrome, Vitamin K1, aminocaproic acid, aminomethylbenzoic acid and protamine. The anti-inflammatory agents contain one or more of ibuprofen, Somedon, aspirin, analgin, indomethacin or phenylbutazone. The title medicine has antiseptic, antiphlogistic, analgesic and hemostatic functions and can be used for painless injection and cleaning wound.


IC ICM A61K045-00

ICS A61P017-00; A61K033-18

CC 63-6 (Pharmaceuticals)

ST antiphlogistic analgesic skin medicine painless injection
 cleaning wound


- IT Quaternary ammonium compounds, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (alkylbenzyltrimethyl, bromides; manufacture of skin antiphlogistic
 and analgesic medicine for painless injection and cleaning wound)
- IT Analgesics
 Anti-inflammatory agents
 Antibiotics
 Disinfectants
 Hemostatics
 Human
Skin
 (manufacture of skin antiphlogistic and analgesic medicine for
 painless injection and cleaning wound)
- IT Protamines
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (manufacture of skin antiphlogistic and analgesic medicine for
 painless injection and cleaning wound)
- IT Drug delivery systems
 (transdermal; manufacture of skin antiphlogistic and
 analgesic medicine for painless injection and cleaning wound)
- IT 50-33-9, Phenylbutazone, biological studies 50-78-2, Aspirin 51-05-8,
 Procaine hydrochloride 53-86-1, Indomethacin 56-91-7,
 4-Aminomethylbenzoic acid 64-17-5, Ethanol, biological studies
 68-89-3, Analgin 69-81-8, Carbazochrome 990-73-8, Fentanyl citrate
 1319-82-0, Aminocaproic acid ~~2624-44-4~~, Etamsylate
 7553-56-2, Iodine, biological studies 8004-87-3, Methyl violet
 8075-54-5, Somedon 11104-38-4, Vitamin K1 14405-05-1, Anadol
 15687-27-1, Ibuprofen 17146-95-1, Pentazocine lactate 17719-89-0
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (manufacture of skin antiphlogistic and analgesic medicine for
 painless injection and cleaning wound)
- IT ~~2624-44-4~~, Etamsylate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (manufacture of skin antiphlogistic and analgesic medicine for
 painless injection and cleaning wound)
- RN 2624-44-4 HCAPLUS
- CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)
 (CA INDEX NAME)
- CM 1
- CRN 109-89-7
- CMF C4 H11 N



CM 2

CRN 88-46-0

CMF C6 H6 O5 S



L219 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:1297124 HCAPLUS Full-text
 DOCUMENT NUMBER: 144:57481
 TITLE: Preparation of polyvinyl alcohol hydrogel dressing
 containing drug and chitosan
 INVENTOR(S): Jing, Xiabin; Yu, Haijun; Chen, Xuesi; Yang, Lixin;
 Xu, Xiaoyi; Zhang, Peibiao
 PATENT ASSIGNEE(S): Changchun Institute of Applied Chemistry, Chinese
 Academy of Sciences, Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 20 pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1579559	A	20050216	CN 2004-10010849	20040514
CN 1320931	C	20070613		
PRIORITY APPLN. INFO.:			CN 2004-10010849	20040514

ED Entered STN: 12 Dec 2005

AB The invention relates to a method for preparing polyvinyl alc. (PVA) hydrogel dressing containing drug and chitosan. The dressing consists (by weight) solid ingredients (10-20%) including synthetic and natural solid polymers, humectant (1-10%), plasticizer (1-10%), drug (0.1-2%), and solvent (balance) selected from redistd. water, normal saline solution, and neutral phosphate buffer solution. The crosslinked PVA-hydrogel dressing is obtained by irradiation with ⁶⁰Co γ-ray or high energy electron beam. The dressing can slowly release the drug and chitosan with antibacterial activity, has high content of moisture and moderate mech. strength, has good permeability to light and air, and meets the requirement for wet treatment of various wounds. The product can be used not only as the long-term dressing for mild skin trauma or chronic diseases of skin, but also as instant occlusive dressing for severe skin wound.

IC ICM A61L015-28

ICS A61L015-44

CC 63-6 (Pharmaceuticals)

IT 50-70-4, Sorbitol, biological studies 55-56-1, Chlorhexidine 56-81-5, Glycerin, biological studies 57-15-8, Trichloro-tert-butyl alcohol 57-55-6, Propylene glycol, biological studies 107-21-1, Ethylene glycol, biological studies 1197-18-8, Tranexamic acid 1404-26-8, Polymyxin B 2624-44-4, Etamsylate 9000-07-1, Carrageenan 9002-18-0, Agar 9002-89-5, Polyvinyl alcohol 9003-01-4, Polyacrylic acid 9003-06-9, Acrylic acid-acrylamide copolymer 9003-39-8, Polyvinylpyrrolidone 9012-76-4, Chitosan 25322-68-3, Polyethylene glycol 85721-33-1, Ciprofloxacin 129313-99-1, Amycin B

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of polyvinyl alc. hydrogel dressing containing drug and

chitosan)

IT 2624-44-4, EtamsylateRL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of polyvinyl alc. hydrogel dressing containing drug and

chitosan)


RN 2624-44-4 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)
(CA INDEX NAME)

CM 1

CRN 109-89-7


CMF C4 H11 N



CM 2

CRN 88-46-0

CMF C6 H6 O5 S



L219 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:702268 HCAPLUS Full-text

DOCUMENT NUMBER: 141:253493

TITLE: Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids

AUTHOR(S): Allain, Herve; Ramelet, Albert A.; Polard, Elisabeth; Bentue-Ferrer, Daniele

CORPORATE SOURCE: Service de Pharmacologie, Faculte de Medecine, Universite de Rennes 1, Rennes, Fr.

SOURCE: Drug Safety (2004), 27(9), 649-660

CODEN: DRSAEA; ISSN: 0114-5916

PUBLISHER: Adis International Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

ED Entered STN: 27 Aug 2004

AB A review. The aim of the present review is to consider the adverse effects and the safety profile of calcium dobesilate. Calcium dobesilate (Doxium) is a veno-tonic drug, which is widely prescribed in more than 60 countries from Europe, Latin America, Asia and the Middle East for three main indications: chronic venous disease, diabetic retinopathy and the symptoms of hemorrhoidal attack. Data sources used for this review comprise the international literature (1970-2003), a postmarketing surveillance (PMS) report for calcium

dobesilate from OM Pharma (Geneva, Switzerland) covering the period 1974-1998, and periodic safety update reports (PSUR) covering the period 1995-2003 from the French Regulatory authorities pharmacovigilance database and OM Pharma. Data from the PMS report for 1974-1998 indicated that adverse events with calcium dobessilate did not occur very frequently and had the following distribution in terms of frequency: fever (26%), gastrointestinal disorders (12.5%), skin reactions (8.2%), arthralgia (4.3%), and agranulocytosis (4.3%). No deaths were attributed to calcium dobessilate in the PMS report. Using data on product use in the Swiss Compendium we estimated the prevalence of agranulocytosis to be 0.32 cases/million treated patients, i.e. ten times less than the calculated prevalence of agranulocytosis in the general population. Most adverse events are type B, i.e. rare and unrelated to the pharmacol. properties of calcium dobessilate. This review concludes that the risk of an adverse effect with calcium dobessilate 500-1500 mg/day is low and constant over time. The recently raised problem of agranulocytosis (a total of 13 known cases drawn from all data sources) appears to be related to methodol. bias. Such a review reinforces the need for a strong international pharmacovigilance organization using similar methods to detect and analyze the adverse effects of drugs.

CC 1-0 (Pharmacology)

IT 20123-80-2, Calcium dobessilate

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(safety of calcium dobessilate in chronic venous disease, diabetic retinopathy and hemorrhoids)

IT 20123-80-2, Calcium dobessilate


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(safety of calcium dobessilate in chronic venous disease, diabetic retinopathy and hemorrhoids)

RN 20123-80-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 91 THERE ARE 91 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:960660 HCAPLUS Full-text

DOCUMENT NUMBER: 138:19488

TITLE: Method and pharmaceutical compositions using anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases

11/839,520

INVENTOR(S): Hunter, William L.
 PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.
 SOURCE: U.S., 180 pp., Cont.-in-part of U.S. Appl. 2002
 37,919.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6495579	B1	20021217	US 1998-88546	19980601
US 20020037919	A1	20020328	US 1997-980549	19971201
US 6515016	B2	20030204		
CA 2607067	A1	19980611	CA 1997-2607067	19971202
EP 1070502	A2	20010124	EP 2000-123557	19971202
EP 1070502	A3	20011017		
EP 1070502	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1090637	A2	20010411	EP 2000-123537	19971202
EP 1090637	A3	20010912		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1092433	A2	20010418	EP 2000-123534	19971202
EP 1092433	A3	20010912		
EP 1092433	B1	20030806		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002226399	A	20020814	JP 2001-401899	19971202
EP 1582210	A2	20051005	EP 2005-11601	19971202
EP 1582210	A3	20051012		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1679937	A	20051012	CN 2005-10054770	19971202 <--
CN 101011576	A	20070808	CN 2006-10099927	19971202 <--
CN 101195028	A	20080611	CN 2006-10099895	19971202 <--
WO 9962510	A2	19991209	WO 1999-CA464	19990601
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020013298	A1	20020131	US 1999-368463	19990804
US 20020183380	A1	20021205	US 2002-67467	20020205
US 6689803	B2	20040210		
US 20030157187	A1	20030821	US 2002-172737	20020613
US 20050249770	A1	20051110	US 2005-102587	20050408
AU 2006220416	A1	20061026	AU 2006-220416	20060920
AU 2006220416	B2	20090205		
US 20080113035	A1	20080515	US 2007-891651	20070810
US 20080153900	A1	20080626	US 2007-891661	20070810
JP 2009161555	A	20090723	JP 2009-57154	20090310
PRIORITY APPLN. INFO.:				
			US 1996-32215P	P 19961202
			US 1997-63087P	P 19971024
			US 1997-980549	A2 19971201

11/839,520

CA 1997-2273240	A3 19971202
CN 1997-181581	A3 19971202
CN 2005-10054770	A3 19971202
EP 1997-945697	A3 19971202
EP 2000-123537	A3 19971202
JP 1998-524997	A3 19971202
JP 2001-401899	A3 19971202
US 1998-88546	A 19980601
US 1999-368463	B1 19990804
US 1999-368871	A1 19990804
US 2002-172737	B1 20020613
AU 2004-200715	A3 20040220
US 2005-102587	B1 20050408

ED Entered STN: 19 Dec 2002

AB Methods and compns. for treating or preventing inflammatory diseases, e.g. psoriasis or multiple sclerosis, are provided, comprising delivering to the site of inflammation an anti-microtubule agent (e.g. paclitaxel), or analog or derivative thereof.

IC ICM A61K031-425

INCL 514365000

CC 1-7 (Pharmacology)

Section cross-reference(s): 63

ST microtubule agent multiple sclerosis psoriasis antiinflammatory;
paclitaxel multiple sclerosis psoriasis antiinflammatory

IT Anti-inflammatory agents

Antiarthritics

Arthritis

Cell proliferation

Chondrocyte

Drug delivery systems

Human

Inflammation

Microtubule

Multiple sclerosis

Neutrophil

Permeation enhancers

Prostate gland, neoplasm

Psoriasis

T cell (lymphocyte)

(anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases, and pharmaceutical compns.)

IT Skin

(keratinocyte; anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases, and pharmaceutical compns.)

IT 50-04-4, Cortisone acetate 52-21-1, Prednisolone acetate 57-22-7,
Vincristine 59-05-2, Methotrexate 64-86-8, Colchicine 68-60-0,
Tetrahydro S 69-33-0, Tubercidin 107-41-5, Hexylene glycol 145-63-1,
Suramin 446-72-0, Genistein 459-73-4, Glycine ethyl ester 865-21-4,
Vinblastine 7689-03-4, Camptothecin 7784-18-1, Aluminum fluoride
7789-20-0, Deuterium oxide 9050-30-0D, Heparan sulfate, fragments
10540-29-1, Tamoxifen 27774-13-6, Vanadyl sulfate 37353-31-4, Vanadate
38213-69-3 52205-73-9 63177-57-1 66107-60-6, Baccatin
70539-42-3 77699-47-9, Herbimycin 86102-31-0, TIMP 100827-28-9,
Erbstatin 125697-93-0, Lavendustin C 149550-36-7, LY290181
152044-54-7, Epothilone B 174882-69-0, Pycnogenol 478183-56-1, BEOV
s-phosphate

RL: PAC (Pharmacological activity); BIOL (Biological study)

(anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases, and pharmaceutical compns.)


IT 63177-57-1

11/839,520

RL: PAC (Pharmacological activity); BIOL (Biological study)
(anti-microtubule agents for treating multiple sclerosis and other
inflammatory diseases, and pharmaceutical compns.)

RN 63177-57-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS
RECORD (15 CITINGS)
REFERENCE COUNT: 171 THERE ARE 171 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L219 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:783929 HCAPLUS Full-text

DOCUMENT NUMBER: 132:18780

TITLE: Compositions comprising antimicrotubule agents for
treating or preventing inflammatory diseases

INVENTOR(S): Hunter, William L.

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.

SOURCE: PCT Int. Appl., 340 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962510	A2	19991209	WO 1999-CA464	19990601
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6495579	B1	20021217	US 1998-88546	19980601
AU 2006220416	A1	20061026	AU 2006-220416	20060920
AU 2006220416	B2	20090205		
PRIORITY APPLN. INFO.:			US 1998-88546	A 19980601
			US 1996-32215P	P 19961202
			US 1997-63087P	P 19971024
			US 1997-980549	A2 19971201
			AU 2004-200715	A3 20040220

ED Entered STN: 10 Dec 1999

AB Methods and compns. for treating or preventing inflammatory diseases, e.g. psoriasis or multiple sclerosis, are provided, comprising the step of delivering to the site of inflammation an antimicrotubule agent, or analog or derivative thereof.

IC ICM A61K031-335
 ICS A61K031-425; A61K031-365; A61K031-045; A61K031-505; A61K033-16;
 A61K031-40; A61K031-22

CC 1-7 (Pharmacology)
 Section cross-reference(s): 63

IT Adhesion, biological
 Angiogenesis inhibitors
 Anti-inflammatory agents
 Antiarthritics
 Antitumor agents
 Astrocyte
 Cytotoxic agents
 Drug delivery systems
 Micelles
 Microtubule
 Neutrophil
 Permeation enhancers
Psoriasis
 Transplant rejection
 (antimicrotubule agents for treating or preventing inflammatory diseases)


IT Skin
 (keratinocyte; antimicrotubule agents for treating or preventing inflammatory diseases)

IT 50-04-4 52-21-1 57-22-7 59-05-2 64-86-8 145-63-1 446-72-0
 865-21-4, Vincalukoblastine 7689-03-4 9050-30-0D, fragments
 10540-29-1 27774-13-6 37353-31-4, Vanadate 38213-69-3 52205-73-9
63177-57-1 66107-60-6 77699-47-9, Herbimycin 86102-31-0
 100827-28-9 144676-04-0 174882-69-0, Pycnogenol
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (antimicrotubule agents for treating or preventing inflammatory diseases)

IT 63177-57-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (antimicrotubule agents for treating or preventing inflammatory diseases)

RN 63177-57-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 14 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1996:623128 HCAPLUS Full-text
 DOCUMENT NUMBER: 125:238664
 ORIGINAL REFERENCE NO.: 125:44353a, 44356a

TITLE: Treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compounds

INVENTOR(S): Stanwell, Caroline; Yuspa, Stuart H.; Burke, Terrence R., Jr.

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9625159	A1	19960822	WO 1996-US2301	19960214
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN				
US 5610185	A	19970311	US 1995-389845	19950217
CA 2212888	A1	19960822	CA 1996-2212888	19960214
CA 2212888	C	20061017		
AU 9649286	A	19960904	AU 1996-49286	19960214
AU 698414	B2	19981029		
EP 809493	A1	19971203	EP 1996-905555	19960214
EP 809493	B1	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11503111	T	19990323	JP 1996-525201	19960214
AT 223715	T	20020915	AT 1996-905555	19960214
ES 2183938	T3	20030401	ES 1996-905555	19960214
PRIORITY APPLN. INFO.:			US 1995-389845	A 19950217
			WO 1996-US2301	W 19960214
ED	Entered STN: 21 Oct 1996			
AB	Various hydroxylated aromatic compds., principally cinnamic acid derivs. and hydroxylated naphthoic acid and isoquinolinecarboxylic acid derivs. inhibit growth of hyperproliferative epithelial cells by crosslinking cellular proteins to form cornified envelope-like structures, resulting in cell death. The compds. are useful in control and prevention of hyperproliferative epithelial disorders, such as human papillomavirus-infected cell lesions, actinic keratosis, melanomas, and malignant and premalignant carcinomas. Thus, Me 2,5-dihydroxycinnamate (1 mM) induced cornification of primary mouse keratinocytes within 4 h. β -Phenylethyl 2,5-dihydroxycinnamate was prepared by reaction of 2,5-dihydroxybenzaldehyde with (carboxymethyl)triphenylphosphonium chloride β -phenylethyl ester.			
IC	ICM A61K031-215 ICS A61K031-235			
CC	1-6 (Pharmacology) Section cross-reference(s): 25			
ST	<u>skin</u> hyperproliferation treatment phenolic crosslinker; neoplasm inhibitor hydroxy arom compd			
IT	Virucides and Virustats (for human papillomavirus; treatment of hyperproliferative epithelial <u>skin diseases</u> by topical application of hydroxylated aromatic protein-crosslinking compds.)			
IT	Cell proliferation			

- (treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)
- IT Phenols, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)
- IT Skin, neoplasm
 (epidermis, treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)
- IT Skin, disease
 (epidermis, hyperproliferation, treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)
- IT Virus, animal
 (human papilloma, infection with; treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)
- IT 60741-49-3P 63177-57-1P, Methyl 2,5-dihydroxycinnamate 104594-70-9P, 2-Phenylethyl caffeate 146515-44-8P, Methyl 5,6-dihydroxy-2-naphthoate 169232-10-4P, 2-Phenylethyl 3,4-difluorocinnamate 169232-11-5P, 2-Phenylethyl 2,5-dihydroxycinnamate 169232-12-6P, 2-Phenylethyl 2,3,4-trihydroxycinnamate 169232-14-8P 169232-18-2P, 2-Phenylethyl 6,7-dihydroxy-2-naphthoate 169232-19-3P, 2-Phenylethyl 5,6-dihydroxy-2-naphthoate 169232-21-7P 170562-65-9P, 2-Phenylethyl 3-(3,4-dihydroxyphenyl)propanoate 182205-60-3P, 2-(2-Naphthyl)ethyl caffeate 182205-61-4P, 2-(1-Naphthyl)ethyl caffeate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)
- IT 60-12-8, β -Phenylethanol 60-19-5, Tyramine hydrochloride 103-80-0, Phenylacetyl chloride 331-39-5, Caffeic acid 773-99-9, 2-(1-Naphthyl)ethanol 1194-98-5, 2,5-Dihydroxybenzaldehyde 1485-07-0, 2-(2-Naphthyl)ethanol 2144-08-3, 2,3,4-Trihydroxybenzaldehyde 13677-79-7, 3,4,5-Trihydroxybenzaldehyde 72337-27-0, 6,7-Dimethoxy-2-naphthamide 126674-76-8, 5,6-Dimethoxy-2-naphthoic acid 132335-95-6 152152-17-5, 3,4-Difluorocinnamic acid 169232-24-0, Pentafluorophenyl 3-(3,4-dihydroxyphenyl)propanoate 182205-62-5, 5,6-Dihydroxy-2-naphthoic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)
- IT 113458-95-0P, 6,7-Dihydroxy-2-naphthoic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)
- IT 63177-57-1P, Methyl 2,5-dihydroxycinnamate 169232-11-5P, 2-Phenylethyl 2,5-dihydroxycinnamate


169232-14-8P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(treatment of hyperproliferative epithelial skin
diseases by topical application of hydroxylated aromatic
 protein-crosslinking compds.)


RN 63177-57-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)-, methyl ester (CA INDEX NAME)




RN 169232-11-5 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)-, 2-phenylethyl ester (CA INDEX NAME)



RN 169232-14-8 HCAPLUS

CN 2-Propenoic acid, 3-(2,4,5-trihydroxyphenyl)-, 2-phenylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)

L219 ANSWER 15 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1976:159773 HCAPLUS Full-text

DOCUMENT NUMBER: 84:159773

ORIGINAL REFERENCE NO.: 84:25899a,25902a

TITLE: Pharmacological study of some capillary acting substances

AUTHOR(S): Tarayre, J. P.; Laouressergues, H.; Vidal, M.; Tailhan,

11/839,520

Mrs. C.
CORPORATE SOURCE: Cent. Rech., P. Fabre S. A., Castres, Fr.
SOURCE: Annales Pharmaceutiques Francaises (1975), 33(10),
467-71
CODEN: APFRAD; ISSN: 0003-4509
DOCUMENT TYPE: Journal
LANGUAGE: French
ED Entered STN: 12 May 1984
AB In rats, aescin [6805-41-0] (60 and 120 mg/kg, orally), Na aescin [53028-06-1] (0.25-1 mg/kg, i.v.), diosmin [520-27-4] (600 mg/kg, orally), calcium dobesilate [20123-80-2] (500 mg/kg, orally), ethamsylate [2624-44-4] (500 mg/kg, orally), and folescitol [15687-22-6] (400 mg/kg, orally) increased capillary permeability in the histamine intradermal wheal test. Pyridinol carbamate [1882-26-4] (100-500 mg/kg, orally) had no effect. Only pyridinol carbamate and Na aescin decreased the localized swelling induced by plantar injection of dextran or carrageenin. Generalized edema from i.p. injection of dextran was decreased by aescin and pyridinol.
CC 1-5 (Pharmacodynamics)

=> d iall abeq tech abex hitstr 16-17
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' -
CONTINUE? (Y)/N:y

L219 ANSWER 16 OF 21 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
ACCESSION NUMBER: 2008-N22597 [77] WPIX
DOC. NO. CPI: C2008-413563 [77]
TITLE: New cinnamic amide derivative useful for treating
diseases responsive to modulation of potassium
channel, e.g., respiratory diseases,
convulsion, erectile dysfunction,
gastrointestinal dysfunction, ischemia,
schizophrenia and sleep disorder
DERWENT CLASS: B05
INVENTOR: CHRISTOPHERSEN P; DEMNITZ J; GRUNNET M; JENSEN T D; JONES
D S; MADSEN L S; NARDI A; NIELSEN E O; STROBAK D
PATENT ASSIGNEE: (NEUR-N) NEUROSEARCH AS
COUNTRY COUNT: 120

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008074755	A2	20080626	(200877)*	EN	45	[1]
WO 2008074755	A3	20081002	(200877)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008074755	A2	WO 2007-EP64015	20071217

PRIORITY APPLN. INFO: DK 2007-481 20070328
DK 2006-1657 20061218
US 2006-870781P 20061219

INT. PATENT CLASSIF.:
IPC ORIGINAL: A61K0031-00 [I,A]; A61K0031-00 [I,C]; A61P0015-00 [I,A];

A61P0015-00 [I,C]; C07C0205-00 [I,C]; C07C0205-56 [I,A];
 C07C0233-00 [I,C]; C07C0233-29 [I,A]; C07C0233-44 [I,A];
 C07C0233-55 [I,A]; C07C0261-00 [I,C]; C07C0261-04 [I,A];
 C07C0309-00 [I,C]; C07C0309-51 [I,A]; C07C0309-76 [I,A];
 C07C0311-00 [I,C]; C07C0311-16 [I,A]; C07C0311-46 [I,A];
 C07C0311-51 [I,A]
 ECLA: C07C0001-26+9/00; C07C0017-10+19/075; C07C0309-15;
 C07C0311-08; C07C0311-09; C07C0311-21; C07C0311-46;
 C07C0311-51
 ICO: M07C0529:40
 BASIC ABSTRACT:

WO 2008074755 A2 UPAB: 20081128

NOVELTY - A cinnamic amide derivative (I), is new.

DETAILED DESCRIPTION - A cinnamic amide derivative of formula (I), or its enantiomer, mixture of its enantiomers, or salt, is new.

R1=nitro, amino, hydroxy, carboxy, sulfonic acid, sulfonic acid alkyl ester, sulfamoyl, acetamido, methyl-sulfonyl-amino, phenyl-sulfonyl-amino, N-methyl-sulfonyl-carboxamide (methyl-sulfonyl-amino-carbonyl), N-phenyl-sulfonyl-carboxamide (phenyl-sulfonyl-amino-carbonyl), trifluoromethyl-sulfonyl-amino, trifluoromethyl-acetyl-amino, 2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl, tetrazolyl, tetrazolyl-methoxy, 5-oxo-4,5-dihydro-(1,2,4)oxadiazol-3-yl or N-cyano-carboxamide;

R2 and R3=phenyl (optionally substituted with halo and/or trifluoromethyl), H, halo, trifluoromethyl, or hydroxy;

R4 and R5=H, halo, trifluoromethyl, nitro and/or phenyl;or

R4 and R5 together with the aromatic ring to which they are attached=benzo-fused carbocyclic aromatic ring;

R' and R'a=H;or

R' and R'a together with the carbon atoms of the aromatic ring to which they are attached=bicyclic carbocyclic or heterocyclic ring selected from 2H-chromenyl (optionally substituted with oxo to form a 2-oxo-2H-chromenyl derivative), or indolyl.

INDEPENDENT CLAIMS are included for the following:

(1) use of a combination of a cinnamic amide derivative (I); and a phosphodiesterase inhibitor; or an agent that potentiates endothelium-derived hyperpolarizing factor-mediated responses; or their salts, for the manufacture of a medicament for the treatment or alleviation of sexual dysfunction; and

(2) a kit of parts comprising at least two separate unit dosage forms cinnamic amide derivative (I); and a phosphodiesterase inhibitor; or an agent that potentiates endothelium-derived hyperpolarizing factor-mediated responses; and optionally instructions for the simultaneous, sequential or separate administration of the cinnamic amide derivative (I), and the phosphodiesterase inhibitor, or the agent, to a patient.

ACTIVITY - Respiratory-Gen.; Anticonvulsant; Vasotropic; Cardiant; CNS-Gen.; Muscular-Gen.; Nephrotropic; Uropathic; Hepatotropic; Gastrointestinal-Gen.; Laxative; Antidiarrheic; Cerebroprotective; Vulnerary; Antianginal; Antiparkinsonian; Neuroleptic; Nootropic; Tranquilizer; Antidepressant; Antimanic; Neuroprotective; Analgesic; Gynecological; Hypnotic; Immunosuppressive; Antiarrhythmic; Cardiovascular-Gen.; Hypotensive; Relaxant; Antidiabetic; Tocolytic; Cytostatic; Antiinflammatory; Auditory; Antimigraine; Endocrine-gen.; Ophthalmological; Osteopathic; Angiogenesis-inhibitor; Antiarthritic; Antirheumatic; Antipsoriatic; Antianemic.

MECHANISM OF ACTION - Ion channel modulator e.g. calcium activated potassium (BK) channel modulator.

(E)-N-(5-chloro-2-(1H-tetrazol-5-yl)-phenyl)-3-naphthalen-2-yl-acrylamide (I') was tested for BK channel opening activity using BK channels heterologously expressed in *Xenopus laevis* oocytes in terms of current. BK current was activated by repeated step protocols. The compound (I') (1 μ M) was added. The compound (I') showed marked increased in current of 6-9 μ M at 80-134 seconds.

USE - In the manufacture of a pharmaceutical composition/medicament for treating respiratory disease, epilepsy, convulsions, seizures, absence seizures, vascular spasms, coronary artery spasms, motor neuron diseases, myokymia, renal disorders, polycystic kidney disease, bladder hyperexcitability, bladder spasms, urinogenital disorders, urinary incontinence, bladder outflow obstruction, erectile dysfunction, gastrointestinal dysfunction, gastrointestinal hypomotility disorders, gastrointestinal motility insufficiency, postoperative ileus, constipation, gastroesophageal reflux disorder, secretory diarrhea, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, ataxia, traumatic brain injury, stroke, Parkinson's disease, bipolar disorder, psychosis, schizophrenia, autism, anxiety, mood disorders, depression, manic depression, psychotic disorders, dementia, learning deficiencies, age related memory loss, memory and attention deficits, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), dysmenorrhea, narcolepsy, sleeping disorders, sleep apnea, Raynaud's disease, intermittent claudication, Sjogren's syndrome, xerostomia, arrhythmia, cardiovascular disorders, hypertension, myotonic dystrophy, myotonic muscle dystrophia, spasticity, xerostomia, diabetes Type II, hyperinsulinemia, premature labor, cancer, brain tumors, inflammatory bowel disease, irritable bowel syndrome, colitis, colitis Crohn', immune suppression, hearing loss, migraine, pain, neuropathic pain, inflammatory pain, trigeminal neuralgia, vision loss, rhinorrhoea, ocular hypertension (glaucoma), baldness, cardiac arrhythmia, atrial arrhythmia, ventricular arrhythmia, atrial fibrillation, ventricular fibrillation, tachyarrhythmia, atrial tachyarrhythmia, ventricular tachyarrhythmia, bradyarrhythmia, or any other abnormal rhythm, e.g. caused by myocardial ischemia, myocardial infarction, cardiac hypertrophy or cardiomyopathy disease/disorder/condition responsive to modulation of potassium channel in a mammal including a human, and for treating sexual dysfunction i.e. male dysfunction and female dysfunction (claimed); and also for treating diseases such as bone metabolic disease, disease that is responsive to inhibition of angiogenesis, an ophthalmic angiogenesis related diseases, rheumatoid arthritis, psoriasis and sickle-cell anemia, and pain.

ADVANTAGE - The compound are potent ion channel modulator and treats disease, disorder or condition responsive to modulation of potassium channels without any harmful side effects. The compounds show calcium activated potassium channel opening activity in sub-micromolar and micromolar range, i.e., from below 1-100 μ M.

MANUAL CODE: CPI: B14-C01; B14-C09B; B14-E02; B14-E09; B14-E10;
B14-F01; B14-F02; B14-F03; B14-F10; B14-G02; B14-G02D;
B14-H01; B14-J01; B14-J05; B14-J05D; B14-J07; B14-K01;
B14-L01; B14-L06; B14-N01; B14-N02; B14-N03; B14-N05;
B14-N07; B14-N10; B14-N14; B14-N16; B14-N17C;
B14-P02; B14-P03; B14-P04; B14-P04A; B14-S04A; B14-S16

TECH

ORGANIC CHEMISTRY - Preparation: No general method for preparation of cinnamic amide derivative (I) is given.

PHARMACEUTICALS - Preferred Components: The phosphodiesterase inhibitor is sildenafil, tadalafil or vardenafil. The agent that potentiates endothelium-derived hyperpolarizing factor-mediated responses is calcium dobesilate.

ABEX DEFINITIONS - Preferred Definitions: - R1=tetrazolyl; - R2=H, halo or 4-fluoro-phenyl; - R3=H or halo; - R4=H; and - R5=halo.

ADMINISTRATION - The composition is administered at a dosage of 0.1 μ g/kg to 10 mg/kg intravenously, and 1 mg/kg to 100 mg/kg per orally, or parenterally (including cutaneously, subcutaneously, intramuscularly, or intravenously).

SPECIFIC COMPOUNDS - 36 Compounds are specifically claimed as (I), e.g., (E)-N-(5-chloro-2-(1H-tetrazol-5-yl)-phenyl)-3-naphthalen-2-yl-acrylamide (I'), 6-chloro-2H-chromene-3-carboxylic

11/839,520

acid(5-chloro-2-(1H-tetrazol-5-yl)-phenyl)-amide;
 (E)-N-(5-chloro-2-hydroxy-phenyl)-3-(3-nitro-phenyl)-acrylamide;
 (E)-N-(5-chloro-2-(1H-tetrazol-5-yl)-phenyl)-3-(4-fluoro-3-trifluoromethyl-phenyl)-acrylamide; and 5-chloro-1H-indole-2-carboxylic acid
 (4'-fluoro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl)-amide.

EXAMPLE - To a stirred suspension of 3-(2-naphthylacrylic acid) (2.27 g) in dichloromethane (DCM), oxalyl chloride (1.3 ml) was added drop wise at 0 degrees C, followed by 1-2 drops of dry N,N-dimethylformamide (DMF). After work up, (E)-3-naphthalen-2-yl-acryloyl chloride (A1) (2.48 g, 100% yield) was obtained. A solution of compound (C1) (0.22 g) in dry toluene (TOL) (10 ml) was added drop wise to a mixture of 5-chloro-2-(1H-tetrazol-5-yl)-phenylamine (0.199 g) in pyridine (1 ml) and dry TOL (5 ml). After work up, (E)-N-(5-chloro-2-(1H-tetrazol-5-yl)-phenyl)-3-naphthalen-2-yl-acrylamide) (I') was obtained.

AN.S DCR-89832

CN.P CALCIUM DOBESILATE


CN.S Calcium; 2,5-dihydroxy-benzenesulfonate

SDCN R20556

CM 1

Ca

CM 2



L219 ANSWER 17 OF 21 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
 ACCESSION NUMBER: 1996-020345 [02] WPIX
 DOC. NO. CPI: C1996-006976 [02]
 TITLE: Opiate antagonist and calcium salt in compsn. - for treatment of endorphin-mediated pathologies
 DERWENT CLASS: B05; C03
 INVENTOR: CIORCI R L; MINOIA P; SCIORSCI R L
 PATENT ASSIGNEE: (CIOR-I) CIORCI R L; (MINO-I) MINOIA P; (SCIO-I) SCIORSCI R; (SCIO-I) SCIORSCI R L; (RAPH-I) RAPHAEL L G
 COUNTRY COUNT: 64

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 9531985	A2	19951130	(199602)*	EN	19[0]	
AU 9526149	A	19951218	(199611)	EN		
WO 9531985	A3	19960104	(199622)	EN		
EP 760661	A1	19970312	(199715)	EN	[0]	
IT 1269826	B	19970415	(199744)	IT		
JP 10500423	W	19980113	(199812)	JA	19[0]	

11/839,520

KR 97703148	A	19970703 (199829)	KO
US 5811451	A	19980922 (199845)	EN
HU 77920	T	19981028 (199850)	HU
EP 760661	B1	19981230 (199905)	EN
DE 69507029	E	19990211 (199912)	DE
ES 2128735	T3	19990516 (199926)	ES
AU 708778	B	19990812 (199944)	EN
CN 1151116	A	19970604 (200131)	ZH
CN 1083264	C	20020424 (200519)	ZH
JP 2007210995	A	20070823 (200757)	JA 11

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9531985 A2		WO 1995-EP1931	19950522
IT 1269826 B		IT 1994-MI1048	19940524
AU 9526149 A		AU 1995-26149	19950522
AU 708778 B		AU 1995-26149	19950522
CN 1151116 A		CN 1995-193758	19950522
CN 1083264 C		CN 1995-193758	19950522
DE 69507029 E		DE 1995-607029	19950522
EP 760661 A1		EP 1995-920851	19950522
EP 760661 B1		EP 1995-920851	19950522
DE 69507029 E		EP 1995-920851	19950522
ES 2128735 T3		EP 1995-920851	19950522
JP 10500423 W		JP 1995-530058	19950522
WO 9531985 A3		WO 1995-EP1931	19950522
EP 760661 A1		WO 1995-EP1931	19950522
JP 10500423 W		WO 1995-EP1931	19950522
KR 97703148 A		WO 1995-EP1931	19950522
US 5811451 A		WO 1995-EP1931	19950522
HU 77920 T		WO 1995-EP1931	19950522
EP 760661 B1		WO 1995-EP1931	19950522
DE 69507029 E		WO 1995-EP1931	19950522
HU 77920 T		HU 1996-3228	19950522
KR 97703148 A		KR 1996-706602	19961121
US 5811451 A		US 1996-737902	19961121
JP 2007210995 A Div Ex		JP 1995-530058	19950522
JP 2007210995 A		JP 2006-303392	20061108

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 708778 B	Previous Publ	AU 9526149 A
DE 69507029 E	Based on	EP 760661 A
ES 2128735 T3	Based on	EP 760661 A
AU 9526149 A	Based on	WO 9531985 A
EP 760661 A1	Based on	WO 9531985 A
JP 10500423 W	Based on	WO 9531985 A
KR 97703148 A	Based on	WO 9531985 A
US 5811451 A	Based on	WO 9531985 A
HU 77920 T	Based on	WO 9531985 A
EP 760661 B1	Based on	WO 9531985 A
DE 69507029 E	Based on	WO 9531985 A
AU 708778 B	Based on	WO 9531985 A

PRIORITY APPLN. INFO: IT 1994-MI1048 19940524
INT. PATENT CLASSIF.:

11/839,520

MAIN: A61K031-485; A61K045-06
SECONDARY: A61K031-00
IPC ORIGINAL: A61K0031-185 [I,C]; A61K0031-191 [I,A]; A61K0031-485
[I,A]; A61K0031-485 [I,C]; A61K0031-69 [I,A]; A61K0031-69
[I,C]; A61K0033-06 [I,A]; A61K0033-06 [I,C]; A61K0038-43
[I,C]; A61K0038-48 [I,A]; A61K0045-00 [I,C]; A61K0045-06
[I,A]; A61P0001-00 [I,C]; A61P0001-04 [I,A]; A61P0001-06
[I,A]; A61P0013-00 [I,A]; A61P0013-00 [I,C]; A61P0015-00
[I,A]; A61P0015-00 [I,C]; A61P0017-00 [I,A]; A61P0017-00
[I,C]; A61P0017-02 [I,A]; A61P0019-00 [I,C]; A61P0019-02
[I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0021-00
[I,A]; A61P0021-00 [I,C]; A61P0025-00 [I,A]; A61P0025-00
[I,C]; A61P0025-02 [I,A]; A61P0025-28 [I,A]; A61P0029-00
[I,A]; A61P0029-00 [I,C]; A61P0031-00 [I,A]; A61P0031-00
[I,C]; A61P0037-00 [I,C]; A61P0037-02 [I,A]; A61P0043-00
[I,A]; A61P0043-00 [I,C]; A61P0009-00 [I,C]; A61P0009-10
[I,A]
IPC RECLASSIF.: A61K0031-185 [I,C]; A61K0031-19 [I,A]; A61K0031-195 [I,A]
; A61K0031-485 [I,A]; A61K0031-485 [I,C]; A61K0038-00
[I,A]; A61K0038-00 [I,C]; A61K0038-08 [I,A]; A61K0038-08
[I,C]; A61K0038-33 [I,A]; A61K0038-33 [I,C]; A61K0038-43
[I,C]; A61K0038-46 [I,A]; A61K0038-48 [I,A]; A61K0045-00
[I,C]; A61K0045-06 [I,A]; A61P0001-00 [I,C]; A61P0001-04
[I,A]; A61P0013-00 [I,C]; A61P0013-02 [I,A]; A61P0015-00
[I,A]; A61P0015-00 [I,C]; A61P0015-14 [I,A]; A61P0025-00
[I,A]; A61P0025-00 [I,C]; A61P0025-28 [I,A]; A61P0029-00
[I,A]; A61P0029-00 [I,C]; A61P0031-00 [I,C]; A61P0031-04
[I,A]; A61P0031-12 [I,A]; A61P0037-00 [I,A]; A61P0037-00
[I,C]; A61P0043-00 [I,A]; A61P0043-00 [I,C]
ECLA: A61K0031-485+M; A61K0038-08+M; A61K0038-33+M
USCLASS NCLM: 514/443.000
NCLS: 514/816.000; 514/823.000
JAP. PATENT CLASSIF.:
MAIN/SEC.: A61K0031-191; A61K0031-485; A61K0031-69; A61K0033-06;
A61K0037-547; A61K0045-06; A61P0001-04; A61P0001-06;
A61P0013-00; A61P0015-00; A61P0017-00; A61P0017-02;
A61P0019-02; A61P0019-08; A61P0019-10; A61P0021-00;
A61P0025-00; A61P0025-02; A61P0025-28; A61P0029-00;
A61P0031-00; A61P0037-02; A61P0043-00 111; A61P0043-00
121; A61P0043-00 171; A61P0009-10
FTERM CLASSIF.: 4C084; 4C086; 4C201; 4C206; 4C086/AA01; 4C206/AA01;
4C084/AA02; 4C086/AA02; 4C206/AA02; 4C084/AA03;
4C084/AA20; 4C084/AA24; 4C084/BA33; 4C084/BA44;
4C084/BA50; 4C086/CB23; 4C206/DA02; 4C086/DA43;
4C084/DB75; 4C084/DC03; 4C086/HA04; 4C086/HA14;
4C086/HA20; 4C084/MA02; 4C086/MA02; 4C206/MA02;
4C086/MA03; 4C206/MA03; 4C086/MA04; 4C206/MA04;
4C206/MA11; 4C084/MA17; 4C206/MA17; 4C206/MA25;
4C206/MA30; 4C084/MA35; 4C084/MA52; 4C084/MA66;
4C084/NA14; 4C086/NA14; 4C206/NA14; 4C084/ZA02.2;
4C086/ZA02; 4C206/ZA02; 4C084/ZA16.2; 4C086/ZA16;
4C206/ZA16; 4C084/ZA20.2; 4C086/ZA20; 4C084/ZA22.2;
4C086/ZA22; 4C206/ZA22; 4C084/ZA36.2; 4C086/ZA36;
4C206/ZA36; 4C084/ZA40.2; 4C086/ZA40; 4C206/ZA40;
4C084/ZA68.2; 4C086/ZA68; 4C206/ZA68; 4C084/ZA73.2;
4C086/ZA73; 4C206/ZA73; 4C084/ZA81.2; 4C086/ZA81;
4C206/ZA81; 4C084/ZA89.2; 4C086/ZA89; 4C206/ZA89;
4C084/ZA94.2; 4C086/ZA94; 4C206/ZA94; 4C084/ZA96.2;
4C086/ZA96; 4C206/ZA96; 4C084/ZA97.2; 4C086/ZA97;
4C206/ZA97; 4C084/ZB07.2; 4C086/ZB07; 4C206/ZB07;

11/839,520

4C084/ZB11.2; 4C086/ZB11; 4C206/ZB11; 4C084/ZB32.2;
4C086/ZB32; 4C206/ZB32; 4C084/ZC21.2; 4C084/ZC39.2;
4C086/ZC39; 4C206/ZC39; 4C084/ZC41.2; 4C086/ZC41;
4C206/ZC41; 4C084/ZC61.2; 4C086/ZC61; 4C206/ZC61;
4C084/ZC75.2; 4C086/ZC75; 4C206/ZC75

BASIC ABSTRACT:

WO 1995031985 A2 UPAB: 20050702

A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia, nervous conducibility disturbances, Alzheimer's disease, cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia, hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception. MANUAL CODE: CPI: B04-A04; B05-A01B; B14-L06; C04-A04; C05-A01B; C14-L06

Member(0006)

ABEQ JP 10500423 W UPAB 20050702

A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia, nervous conducibility disturbances, Alzheimer's disease, cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia, hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception.

Member(0008)

ABEQ US 5811451 A UPAB 20050702

A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia,

nervous conducibility disturbances, Alzheimer's disease, cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia, hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception.

Member(0010)

ABEQ EP 760661 B1 UPAB 20050702

A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia, nervous conducibility disturbances, Alzheimer's disease, cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia, hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception.

Member(0014)

ABEQ CN 1151116 A UPAB 20050702

A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia, nervous conducibility disturbances, Alzheimer's disease, cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia,

hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception.

AN.S DCR-89832

CN.P CALCIUM DOBESILATE


CN.S Calcium; 2,5-dihydroxy-benzenesulfonate

SDCN R20556

CM 1

Ca

CM 2



=> d ibib ab kwic hitstr 18-19

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' -
CONTINUE? (Y)/N:y

L219 ANSWER 18 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2009:83827 USPATFULL Full-text

TITLE: CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM
MULTI-ARMED OLIGOMERS

INVENTOR(S): Bezwada, Rao S., Hillsborough, NJ, UNITED STATES

PATENT ASSIGNEE(S): BEZWADA BIOMEDICAL, LLC, Hillsborough, NJ, UNITED
STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090076174	A1	20090319
APPLICATION INFO.:	US 2008-203761	A1	20080903 (12)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-969787P	20070904 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: FELDMANGALE, P.A., 1700 Market Street, Suite # 3130,
 Philadelphia, PA, 19103, US
 NUMBER OF CLAIMS: 42
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1464

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the biologically active compound as such with no change in native chemical structure.

CLM What is claimed is:

40. A therapeutic method for treating psoriasis, inflammatory bowel disease, skin cancer, or a brain tumor in a patient, comprising: administering to a patient in need of. . .

IT 50-27-1, Estriol 50-60-2, Phentolamine 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological studies 51-49-0, Dextrothyroxine 51-61-6, Dopamine, biological studies 52-53-9, Verapamil 53-16-7, Estrone, biological studies 53-86-1, Indomethacin 54-03-5, Hexobendine 54-31-9, Furosemide 54-49-9, Metaraminol 56-53-1, Diethylstilbestrol 58-74-2, Papaverine 59-92-7, Levodopa, biological studies 60-99-1, Levomepromazine 61-68-7, Mefenamic acid 62-44-2, Phenacetin 63-12-7, Benzquinamide 65-45-2, Salicylamide 66-97-7, Psoralen 69-72-7, Salicylic acid, biological studies 70-30-4, Hexachlorophene 72-33-3, Mestranol 77-07-6, Levorphanol 77-09-8, Phenolphthalein 80-03-5, Acediasulfone 81-81-2, Warfarin 82-02-0, Khellin 83-73-8, Diiodohydroxyquinoline 83-89-6, Mepacrine 84-16-2, Hexestrol 84-17-3, Dienestrol 86-42-0, Amodiaquine 87-28-5, 2-Hydroxyethyl salicylate 88-04-0, Chloroxylenol 89-57-6, Mesalazine 90-05-1, Guaiacol 90-33-5, Hymecromone 90-34-6, Primaquine 94-09-7, Benzocaine 94-23-5, Parethoxycaine 96-84-4, Iophenoic acid 97-23-4, Dichlorophen 97-24-5, Fenticlor 97-44-9, Acetarsol 99-45-6, Adrenalone 101-93-9, Phenacaine 103-90-2 104-14-3, Octopamine 104-46-1, Anethole 115-33-3, Oxyphenisatin acetate 119-36-8, Methyl salicylate 127-35-5, Phenazocine 129-20-4, Oxyphenbutazone 130-26-7, Clioquinol 130-79-0, Dimestrol 136-70-9, Protokylol 136-77-6, Hexylresorcinol 138-41-0, Carzenide 138-56-7, Trimethobenz-amide 144-14-9, Anileridine 147-27-3, Dimoxyline 148-24-3, Oxyquin-oline, biological studies 152-72-7, Acenocoumarol 153-87-7, Oxyperline 154-23-4, Cianidanol 298-81-7, Methoxsalen 304-84-7, Etamivan 322-35-0, Benserazide 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid 365-26-4, Oxilofrine 370-14-9, Pholedrine 390-28-3, Methoxamine 395-28-8, Isoxsuprine 404-86-4, Capsaicin 435-97-2, Phenprocoumon 447-41-6, Buphenine 452-35-7, Ethoxzolamide 469-79-4, Ketobemidone 482-27-9, Isopimpinellin 484-20-8, Bergapten 486-47-5, Ethaverine 486-60-2, Bergaptol 487-48-9, Salacetamide 490-79-9, Gentisic acid 491-38-3D, Chromone, derivs. 499-67-2, Proxymetacaine 501-36-0, Resveratrol 514-68-1, Estriol succinate 520-27-4, Diosmin 524-99-2, Medrylamine 530-08-5, Isoetarine 530-59-6, Sinapic acid 530-78-9, Flufenamic acid 532-03-6, Methocarbamol 533-22-2, Hydroxystilbamidine isethionate 536-21-0, Norfenefrine 539-08-2, Lactylphenetidin 548-00-5, Ethyl biscoum-acetate 552-94-3, Salsalate 555-30-6, Methyldopa 569-57-3, Chlorotrianisene 575-74-6, Buclosamide 579-23-7, Cyclovalone 586-06-1, Orciprenaline 599-79-1, Salazosulfapyridine 606-17-7, Adipiodone 635-41-6, Trimetozine 709-55-7, Etilefrine 738-70-5,

Trimethoprim 979-32-8, Estradiol valerate 1076-38-6,
 4-Hydroxycoumarin 1134-47-0, Baclofen 1135-24-6, Ferulic acid
 1143-38-0, Dithranol 1227-61-8, Mefexamide 1406-18-4, Vitamin E
 1421-14-3, Propanidid 1477-19-6, Benzarone 1981-58-4, Sulmet
 2295-58-1, Flopropione 2321-07-5, Fluorescein 2618-25-9, Ioglycamic
 acid ~~2624-44-4~~, Etamsylate 3115-05-7, Iobenzamic acid
 3215-70-1, Hexoprenaline 3380-34-5, Triclosan 3625-06-7, Mebeverine
 3703-79-5, Bamethan 3735-45-3 4008-48-4, Nitroxo-line 4350-09-8,
 Oxitriptan 4991-65-5, Tioxolone 5011-34-7, Trimetazidine 5104-49-4,
 Flurbiprofen 6808-72-6, Glaziovine 7004-98-0, Epimestrol 7400-08-0,
 4-Hydroxycinnamic acid 7683-59-2, Isoprenaline 8067-69-4, Halquinols
 10238-21-8, Glibenclamide 10397-75-8, Iocarmic acid 13392-18-2,
 Fenoterol 13460-98-5, Theo-drenaline 13739-02-1, Diacerein
 15301-40-3, Actinoquinol 15307-86-5, Diclofenac 15686-51-8,
 Clemastine 15687-22-6 15687-27-1, Ibuprofen 15687-41-9, Oxyfedrine
 16034-77-8, Iocetamic acid 16110-51-3, Cromoglicic acid 16662-47-8,
 Gallopamil 17365-01-4, Etiroxate 18559-94-9, Salbutamol 19035-45-1
 20168-99-4, Cinmetacin 22071-15-4, Ketoprofen 22345-47-7, Tofisopam
 22494-42-4, Diflunisal 22619-35-8, Tiocloamarol 22888-70-6, Silibinin
 23031-25-6, Terbutaline 23210-56-2, Ifenprodil 23887-46-9, Cinepazide
 25803-14-9, Clometacin 26171-23-3, Tolmetin 26652-09-5, Ritodrine
 26750-81-2, Alibendol 28395-03-1, Bumetanide 30418-38-3, Tretoquinol
 30751-05-4, Troxipide 30964-13-7, Cynarine 31127-82-9, Iodoxamic acid
 31848-01-8, Morclofone 32828-81-2, Picotamide 32953-89-2, Rimiterol
 33005-95-7, Tiaprofenic acid 34368-04-2, Dobutamine 34633-34-6,
 Bifluranol 35212-22-7, Ipriflavone 35795-16-5, Trimazosin
 35898-87-4, Dilazep 36330-85-5, Fenbufen 36894-69-6, Labetalol
 37106-97-1, Bentiromide 39718-89-3, Alminoprofen 40828-46-4, Suprofen
 41340-25-4, Etodolac 42794-76-3, Midodrine 42924-53-8, Nabumetone
 46817-91-8, Viloxazine 51022-74-3, Iotroxic acid 52443-21-7,
 Glucametacin 52479-85-3, Exifone 53164-05-9, Acemetacin 53370-90-4,
 Exalamide 53597-27-6, Fendosal 53716-49-7, Carprofen 53731-36-5,
 Floredil 53808-87-0, Tetroxoprim 53902-12-8, Tranilast 54063-40-0,
 Fenoxedil 54063-54-6, Reproterol 55905-53-8, Clebopride 57526-81-5,
 Prenalterol 59170-23-9, Bevantolol 62666-20-0, Progabide
 63590-64-7, Terazosin 65271-80-9, Mitoxantrone 66564-14-5,
 Cinitapride 67227-57-0, Fenoldopam mesylate 68302-57-8, Amlexanox
 68767-14-6, Loxoprofen 69049-73-6, Nedocromil 71771-90-9, Denopamine
 73573-87-2, Formo-terol 73590-58-6, Omeprazole 74103-06-3, Ketorolac
 74150-27-9, Pimoben-dan 74191-85-8, Doxazosin 75659-07-3, Dilevalol
 80573-04-2, Balsalazide 81801-12-9, Xamoterol 81840-15-5, Vesnarinone
 82640-04-8, Raloxifene hydrochloride 82952-64-5, Trimetrexate
 glucuronate 86197-47-9, Dopexamine 86880-51-5, Epanolol 89365-50-4,
 Salmeterol 89796-99-6, Aceclofenac 106133-20-4, Tamsulosin
 120014-06-4, Donepezil

(controlled-release of biol. active compds. from multi-armed oligomers
 for cosmetics and pharmaceutical composition)

IT ~~2624-44-4~~, Etamsylate

(controlled-release of biol. active compds. from multi-armed oligomers
 for cosmetics and pharmaceutical composition)

RN 2624-44-4 USPATFULL

CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)
 (CA INDEX NAME)

CM 1

CRN 109-89-7


CMF C4 H11 N



CM 2

CRN 88-46-0

CMF C6 H6 O5 S



L219 ANSWER 19 OF 21 USPATFULL on STN
 ACCESSION NUMBER: 2005:208563 USPATFULL Full-text
 TITLE: Method of preparation of mixed phase co-crystals with active agents
 INVENTOR(S): Goldman, David, Portland, CT, UNITED STATES
 PATENT ASSIGNEE(S): MedCrystalForms, LLC, Hunt Valley, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050181041	A1	20050818
APPLICATION INFO.:	US 2004-8034	A1	20041209 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-528232P	20031209 (60)
	US 2004-559862P	20040406 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH STETSON AVENUE, CHICAGO, IL, 60601-6780, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	2916	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new physical/crystal form with unique properties useful for the delivery of the active agent, as well as compositions comprising the mixed phase co-crystals.

CLM What is claimed is:


- . . . antimigraine drugs, antinauseant drugs, antineoplastic drugs, antineoplastic adjuncts, antiparkinsonian drugs, antipheochromocytoma drugs, antipneumocystis drugs, antiprostatic hypertrophy drugs, antiprotozoal drugs, antipuritics, antipsoriatic drugs,

antipsychotic drugs, antipyretics, antirickettsial drugs, antiseborrheic drugs, antiseptics, antispasmodic drugs, antithrombotic drugs, antitussive drugs, antiulcerative drugs, antiurolithic drugs, antiviral.

IT 50-21-5, Lactic acid, biological studies 50-70-4, Sorbitol, biological studies 50-70-4D, Sorbitol, esters 50-81-7, Ascorbic acid, biological studies 50-99-7, D-Glucose, biological studies 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-50-1, biological studies 57-88-5, Cholesterol, biological studies 63-42-3, Lactose 65-85-0, Benzoic acid, biological studies 68-11-1, Thioglycolic acid, biological studies 69-65-8, D-Mannitol 69-72-7, Salicylic acid, biological studies 69-93-2, Uric acid, biological studies 77-92-9, Citric acid, biological studies 79-10-7, Acrylic acid, biological studies 87-69-4, Tartaric acid, biological studies 87-99-0, Xylitol ~~88-46-0~~, Hydroquinonesulfonic acid 89-65-6, IsoAscorbic acid 107-92-6, Butyric acid, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-27-0, Isopropyl myristate 115-77-5D, Pentaerythritol, esters 115-83-3, Pentaerythritol tetrastearate 124-04-9, Adipic acid, biological studies 138-36-3, p-Bromophenylsulfonic acid 142-91-6, Isopropyl palmitate 144-62-7, Oxalic acid, biological studies 526-95-4, D-Gluconic acid 544-35-4, Ethyl linoleate 544-63-8, Myristic acid, biological studies 546-93-0, Magnesium carbonate 585-88-6, Maltitol 1309-48-4, Magnesium oxide, biological studies 1327-43-1, Magnesium aluminum silicate 1338-41-6, Sorbitan monostearate 7631-86-9, Silica, biological studies 7778-18-9, Calcium sulfate 8007-43-0, Sorbitan sesquioleate 9002-96-4 9003-39-8, Povidone 9004-53-9, Dextrins 9004-54-0, Dextran, biological studies 9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9004-81-3, Polyethylene glycol laurate 9004-95-9, Polyethylene glycol cetyl ether 9004-98-2, Polyethylene glycol oleyl ether 9004-99-3, Polyethylene glycol stearate 9005-00-9, Polyethylene glycol stearyl ether 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-64-5, Polysorbate 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9005-82-7, Amylose 9009-32-9, Polyglyceryl stearate 9011-21-6, Polyethylene glycol glyceryl stearate 9011-29-4, Polyethylene glycol sorbitan hexastearate 9036-19-5, Polyethylene glycol octylphenyl ether 9050-36-6, Maltodextrin 9062-73-1, Polyethylene glycol sorbitan laurate 9063-38-1, Sodium starch glycolate 10043-35-3, Boric acid, biological studies 10103-46-5, Calcium phosphate 12619-70-4, Cyclodextrin 12772-47-3, Pentaerythritol oleate 13081-97-5, Pentaerythritol distearate 14807-96-6, Talc, biological studies 18641-57-1, Compritol 888ATO 22882-95-7, Isopropyl linoleate 25168-73-4, Sucrose monostearate 25339-99-5, Sucrose monolaurate 25637-97-2, Sucrose dipalmitate 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan trioleate 26446-38-8, Sucrose monopalmitate 26658-19-5, Sorbitan tristearate 27195-16-0, Sucrose distearate 27321-96-6, Polyethylene glycol cholesteryl ether 36928-92-4 37353-59-6, Hydroxymethyl cellulose 51938-44-4, Sorbitan sesquistearate 54392-26-6, Sorbitan monoisostearate 57307-93-4, Pentaerythritol caprylate 59070-56-3 61725-93-7, Polyglyceryl distearate 64044-51-5 67660-31-5 68958-64-5, Polyethylene glycol glyceryl trioleate 69070-98-0, Polyoxyethylene sorbitan tetraoleate 74504-64-6, Polyglyceryl laurate 74811-65-7, Croscarmellose sodium 83138-62-9, Polyglyceryl isostearate 98913-68-9, Pentaerythritol isostearate 110540-43-7, Polyglyceryl pentaoleate 121548-04-7, Gelucire 44/14 354575-58-9, Polyethylene glycol sorbitan tetrastearate 403821-12-5, Polyglyceryl trioleate 691397-13-4, Pluronic 854602-44-1

11/839,520

(preparation of mixed phase co-crystals with pharmaceuticals)
IT ~~88-46-0~~, Hydroquinonesulfonic acid
(preparation of mixed phase co-crystals with pharmaceuticals)
RN 88-46-0 USPATFULL
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



=> d ibib ed ab ind 20-21

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' -
CONTINUE? (Y)/N:y

L219 ANSWER 20 OF 21 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2007190672 EMBASE Full-text
TITLE: Pharmacological treatments for basal cell carcinoma.
AUTHOR: Lee, Seongmu; Goldberg, Robert A.; Leibovitch, Igal, Dr.
(correspondence)
CORPORATE SOURCE: Division of Orbital and Ophthalmic Plastic and
Reconstructive Surgery, David Geffen School of Medicine at
UCLA, Jules Stein Eye Institute, 100 Stein Plaza #2-267,
Los Angeles, CA 90095-7006, United States. leibovitch@gmail
.com
AUTHOR: Selva, Dinesh; Leibovitch, Igal, Dr. (correspondence)
CORPORATE SOURCE: Department of Ophthalmology and Visual Sciences, University
of Adelaide, SA, Australia. leibovitch@gmail.com
AUTHOR: Selva, Dinesh
CORPORATE SOURCE: South Australian Institute of Ophthalmology, Adelaide, SA,
Australia.
AUTHOR: Huilgol, Shyamala C.
CORPORATE SOURCE: Department of Dermatology, Royal Adelaide Hospital,
University of Adelaide, SA, Australia.
SOURCE: Drugs, (2007) Vol. 67, No. 6, pp. 915-934.
Refs: 167
ISSN: 0012-6667; E-ISSN: 0012-6667 CODEN: DRUGAY
COUNTRY: New Zealand
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 016 Cancer
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 15 May 2007
Last Updated on STN: 15 May 2007
ED Entered STN: 15 May 2007

Last Updated on STN: 15 May 2007

AB Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer, and its incidence continues to rise. Current management options are numerous and focus on tumour eradication while maximising cosmetic and functional capacity. Although surgery continues to be considered the main treatment modality, new pharmacological agents, such as immunomodulators, topical chemotherapeutic agents and photodynamic therapy, have emerged and show promising results. Pharmacological agents offer the potential for lower morbidity and improved tissue preservation compared with surgery and radiotherapy. However, pharmacological treatments possess higher failure rates when compared with surgery, and most studies have investigated only low-risk lesions. Several prospective, randomised, double-blind, vehicle-controlled studies have established the efficacy of imiquimod for superficial BCC. This review summarises the evidence regarding the mechanism, efficacy and safety of pharmacological agents based on the literature from the past 10 years. Experimental treatments that have been successfully utilised in the treatment of BCC are also discussed. Treatment of BCC with other agents, such as tazarotene, glycoalkaloid (BEC-5) cream, cidofovir and calcium dobesilate have been reported, but further studies are needed to ascertain the efficacy and adverse-effect profiles of these treatments. .COPYRG. 2007 Adis Data Information BV. All rights reserved.

CT Medical Descriptors:

actinic keratosis: DT, drug therapy
 angioneurotic edema: SI, side effect
 application site stinging: SI, side effect
 application site burning: SI, side effect
 application site discharge: SI, side effect
 application site discomfort: SI, side effect
 application site erythema: SI, side effect
 application site hyperpigmentation: SI, side effect
 application site pain: SI, side effect
 application site pruritus: SI, side effect
 application site rash: SI, side effect
 application site reaction: SI, side effect
 application site scabbing: SI, side effect
 application site stinging: SI, side effect
 application site ulcer: SI, side effect
 *basal cell carcinoma: DT, drug therapy
 *basal cell carcinoma: RT, radiotherapy
 *basal cell carcinoma: SU, surgery
 *basal cell carcinoma: TH, therapy
 bullous pemphigoid: SI, side effect
 cancer recurrence
 cancer risk
 chill: SI, side effect
 clinical feature
 clinical trial
 combination chemotherapy
 contact dermatitis: SI, side effect
 controlled clinical trial
 crusting: SI, side effect
 cryotherapy
 curettage
 desiccation
 desquamation: SI, side effect
 dosage schedule comparison
 drug absorption
 drug efficacy
 drug formulation
 drug hypersensitivity: SI, side effect

drug mechanism
 drug safety
 drug tolerability
 drug withdrawal
 edema: SI, side effect
 electrode
 erosion: SI, side effect
 erythema: SI, side effect
 fatigue: SI, side effect
 fever: SI, side effect
 flu like syndrome: DT, drug therapy
 flu like syndrome: SI, side effect
 follow up
 headache: SI, side effect
 heart muscle ischemia: SI, side effect
 histopathology
 human
 hyperpigmentation: SI, side effect
 hyperthermia: SI, side effect
 hypertrophic scar: SI, side effect
 hypopigmentation: SI, side effect
 injection site discomfort: SI, side effect
 injection site edema: SI, side effect
 injection site erythema: SI, side effect
 injection site reaction: SI, side effect
 leakage: SI, side effect
 leukopenia: SI, side effect
 monotherapy
 multimodality cancer therapy
 myalgia: SI, side effect
 nausea: SI, side effect
 nausea and vomiting: SI, side effect
 nonhuman
 pain: SI, side effect
 papular rash: SI, side effect
 *photodynamic therapy
 photosensitivity: SI, side effect
 pruritus: SI, side effect
psoriasis: SI, side effect
 randomized controlled trial
 review
 rigor: SI, side effect
 side effect: SI, side effect
 single drug dose
 skin disease: SI, side effect
 skin edema: SI, side effect
 skin induration: SI, side effect
 skin irritation: SI, side effect
 skin manifestation: SI, side effect
 skin pigmentation
 skin ulcer: SI, side effect
 thrombocytopenia: SI, side effect
 tissue preservation
 treatment failure
 unspecified side effect: SI, side effect
 vomiting: SI, side effect
 CT Drug Descriptors:
 acetylsalicylic acid: DT, drug therapy
 acetylsalicylic acid: PD, pharmacology
 adrenalin: AE, adverse drug reaction

adrenalin: CT, clinical trial
adrenalin: CB, drug combination
adrenalin: DT, drug therapy
alkaloid derivative: DT, drug therapy
alkaloid derivative: PD, pharmacology
alpha2a interferon: AE, adverse drug reaction
alpha2a interferon: CT, clinical trial
alpha2a interferon: CB, drug combination
alpha2a interferon: DT, drug therapy
alpha2a interferon: IL, intralesional drug administration
alpha2b interferon: AE, adverse drug reaction
alpha2b interferon: CT, clinical trial
alpha2b interferon: AD, drug administration
alpha2b interferon: CB, drug combination
alpha2b interferon: DO, drug dose
alpha2b interferon: DT, drug therapy
alpha2b interferon: DL, intradermal drug administration
alpha2b interferon: IL, intralesional drug administration
aminolaevulinic acid: AE, adverse drug reaction
aminolaevulinic acid: DT, drug therapy
aminolaevulinic acid: PD, pharmacology
antineoplastic agent: DT, drug therapy
antineoplastic agent: IL, intralesional drug administration
antineoplastic agent: IV, intravenous drug administration
antineoplastic agent: TP, topical drug administration
bleomycin: AE, adverse drug reaction
bleomycin: DT, drug therapy
bleomycin: IL, intralesional drug administration
celecoxib: DT, drug therapy
celecoxib: PD, pharmacology
cidofovir: DT, drug therapy
cidofovir: PD, pharmacology
cidofovir: TP, topical drug administration
dobesilate calcium: DT, drug therapy
dobesilate calcium: PD, pharmacology
fluorouracil: AE, adverse drug reaction
fluorouracil: CT, clinical trial
fluorouracil: CB, drug combination
fluorouracil: DT, drug therapy
fluorouracil: PR, pharmaceuticals
fluorouracil: PD, pharmacology
fluorouracil: TP, topical drug administration
glycoalkaloid: AE, adverse drug reaction
glycoalkaloid: DT, drug therapy
glycoalkaloid: TP, topical drug administration
imiquimod: AE, adverse drug reaction
imiquimod: CT, clinical trial
imiquimod: DO, drug dose
imiquimod: DT, drug therapy
imiquimod: PK, pharmacokinetics
imiquimod: PD, pharmacology
interferon: AE, adverse drug reaction
interferon: CT, clinical trial
interferon: DT, drug therapy
interferon: PD, pharmacology
methylaminolaevulinic acid: AE, adverse drug reaction
methylaminolaevulinic acid: CT, clinical trial
methylaminolaevulinic acid: DT, drug therapy
methylaminolaevulinic acid: PD, pharmacology
nonsteroid antiinflammatory agent: CT, clinical trial

nonsteroid antiinflammatory agent: DT, drug therapy
 paracetamol: DT, drug therapy
 photofrin: AE, adverse drug reaction
 photofrin: DT, drug therapy
 photofrin: PD, pharmacology
 photosensitizing agent: AE, adverse drug reaction
 photosensitizing agent: CT, clinical trial
 photosensitizing agent: DT, drug therapy
 photosensitizing agent: PD, pharmacology
 photosensitizing agent: TP, topical drug administration
 placebo
 recombinant alpha interferon: AE, adverse drug reaction
 recombinant alpha interferon: CT, clinical trial
 recombinant alpha interferon: DT, drug therapy
 recombinant alpha interferon: TU, intratumoral drug administration
 tazarotene: CT, clinical trial
 tazarotene: DT, drug therapy
 tazarotene: PD, pharmacology
 tazarotene: TP, topical drug administration
 RN (acetylsalicylic acid) 493-53-8, 50-78-2, 53663-74-4, 53664-49-6,
 63781-77-1; (adrenalin) 51-43-4, 55-31-2, 6912-68-1; (alpha2a interferon)
 76543-88-9; (alpha2b interferon) 99210-65-8; (bleomycin) 11056-06-7;
 (celecoxib) 169590-42-5; (cidofovir) 113852-37-2; (dobesilate calcium)
 20123-80-2; (fluorouracil) 51-21-8; (imiquimod) 99011-02-6;
 (paracetamol) 103-90-2; (photofrin) 85189-42-0; (tazarotene) 118292-40-3
 CN aspirin

L219 ANSWER 21 OF 21 DRUGU COPYRIGHT 2009 THOMSON REUTERS on STN

ACCESSION NUMBER: 2002-47264 DRUGU T S Full-text

TITLE: Clinical evaluation of the efficacy and safety of calcium
 dobesilate in patients with chronic venous insufficiency of
 the lower limbs.

AUTHOR: Arceo A; Berber A; Trevino C

CORPORATE SOURCE: BASF-Pharma

LOCATION: Mexico City, Mexico

SOURCE: Angiology (53, No. 5, 539-544, 2002) 2 Fig. 52 Ref.
 CODEN: ANGIAB ISSN: 0003-3197

AVAIL. OF DOC.: R. Guttierrez de Velasco 213, Fracc. Res. Alameda, Leon, Gto.
 CP 37210, Mexico. (Email: adalarce@prodigy.net.mx).

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

AB The efficacy of calcium dobesilate (Doxium) was investigated in the treatment
 of 352 patients with chronic venous insufficiency (CVI). A significant
 improvement in subjective complaints such as edema and in reduction of body
 weight occurred in CVI patients. Most showed a considerable reduction in or
 disappearance of symptoms. Reduction in the volume of edema represented a
 reduction in the volume of total body water, possibly explaining, in addition
 to other factors, the significant reduction in body weight. Side-effects
 included headache, epigastralgia, dizziness, nausea and pyrosis. It was
 concluded that calcium dobesilate is an interesting therapeutic option and
 can be an alternative to phytotherapy and surgical procedures.

AN 2002-47264 DRUGU T S Full-text

T Therapeutics

S Adverse Effects

35 Adverse Reactions

58 Vasoactive

CT [01] CALCIUM-DOBESILATE *TR; CALCIUM-DOBESILATE *AE; DOBESILAT *RN; DOXIUM
 *TR; DOXIUM *AE; CHRON. *TR; VENOUS *TR; INSUFFICIENCY *TR;

11/839,520

VASCULAR-DISEASE *TR; HEADACHE *AE; EPIGASTRALGIA *AE; DIZZINESS *AE;
NAUSEA *AE; PYROSIS *AE; GASTROENTEROPATHY *AE; GASTROENTEROPATHY *AE;
ESOPHAGUS-DISEASE *AE; CASES *FT; IN-VIVO *FT; SYMPTOMATOLOGY *FT;
BODY-WEIGHT *FT; HEMOSTATICS *FT; TR *FT; AE *FT

RN: 20123-80-2

=> d que nos 170

```

L11 (      5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L12      SEL  PLU=ON  L11 1- RN :      82 TERMS
L13 (      82)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L12
L14      STR
L15 (      28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
L16 (      270)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (1007839-71-5/CRN OR
      1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
      1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
      1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
      1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
      1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
      1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
      21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
      8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
      79122-68-2/CRN OR 88-46-0/CRN)
L17      293 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L15 OR L16
L18      129 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L17 NOT PMS/CI
L21      QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22      QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23      QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24      QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25      QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26      QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27      QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28      QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29      QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
      U,AUTH
L31      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33      QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34      QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38      QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42      QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44      QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46      QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50      QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51      QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS, SO,
      PA
L53      QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54      QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L55      QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56      QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L57      QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L58      QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L59      780 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L18
L60      11 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 (L)((L53 OR L54

```

```

OR L55 OR L56))
L61      10 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L58
L62      6  SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L57
L63      QUE SPE=ON  ABB=ON  PLU=ON  "DERMATOLOGICAL AGENTS"+PFT,
        OLD,NEW/CT
L64      3  SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L63
L65      1  SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L64 AND (L55 OR L56)
L66      7  SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND (L55 OR L56)
L67      20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L60 OR L61 OR L62)
        OR (L64 OR L65 OR L66)
L68      20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L67 AND (L53 OR L54
        OR L55 OR L56)
L69      20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L67 OR L68)
L70      14 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L69 AND (L21 OR L22
        OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
        OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
        OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
        OR L50 OR L51)

=> d que nos 1122
L9        STR
L19       34 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (1595296-K/AN.S OR
        1595296-M/AN.S OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K
        /AN.S OR 1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR
        9091-U/AN.S OR DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/A
        N.S OR DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S
        OR DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S
        OR DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR
        DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR
        DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR
        DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR
        DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR
        DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/A
        N.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR
        DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/
        AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR
        12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.
        S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR
        1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K
        /AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR
        1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M
        /AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR
        1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K
        /AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR
        1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M
        /AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR
        1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/
        AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR
        528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR
        86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR
        91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S
        OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S
        )
L21      QUE SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22      QUE SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23      QUE SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24      QUE SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25      QUE SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26      QUE SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH

```

11/839,520

L27	QUE	SPE=ON	ABB=ON	PLU=ON	GIMENEZ, G?/AU,AUTH
L28	QUE	SPE=ON	ABB=ON	PLU=ON	GALLEGO, G?/AU,AUTH
L29	QUE	SPE=ON	ABB=ON	PLU=ON	MORGAN, I?/AU,AUTH
L30	QUE	SPE=ON	ABB=ON	PLU=ON	SAENZ DE TEJADA MORGAN, I?/AU,AUTH
L31	QUE	SPE=ON	ABB=ON	PLU=ON	SAENZDETEJADA, I?/AU,AUTH
L32	QUE	SPE=ON	ABB=ON	PLU=ON	SAENZ, I?/AU,AUTH
L33	QUE	SPE=ON	ABB=ON	PLU=ON	DETEJADA, I?/AU,AUTH
L34	QUE	SPE=ON	ABB=ON	PLU=ON	DE TEJADA, I?/AU,AUTH
L35	QUE	SPE=ON	ABB=ON	PLU=ON	ANGULO FRUTOS, J?/AU,AUTH
L36	QUE	SPE=ON	ABB=ON	PLU=ON	ANGULOFRUTOS, J?/AU,AUTH
L37	QUE	SPE=ON	ABB=ON	PLU=ON	ANGULO, J?/AU,AUTH
L38	QUE	SPE=ON	ABB=ON	PLU=ON	FRUTOS, J?/AU,AUTH
L39	QUE	SPE=ON	ABB=ON	PLU=ON	VALVERDE LOPEZ, S?/AU,AUTH
L40	QUE	SPE=ON	ABB=ON	PLU=ON	VALVERDELOPEZ, S?/AU,AUTH
L41	QUE	SPE=ON	ABB=ON	PLU=ON	VALVERDE, S?/AU,AUTH
L42	QUE	SPE=ON	ABB=ON	PLU=ON	LOPEZ, S?/AU,AUTH
L43	QUE	SPE=ON	ABB=ON	PLU=ON	ROMERO GARRIDO, A?/AU,AUTH
L44	QUE	SPE=ON	ABB=ON	PLU=ON	ROMEROGARRIDO, A?/AU,AUTH
L45	QUE	SPE=ON	ABB=ON	PLU=ON	ROMERO, A?/AU,AUTH
L46	QUE	SPE=ON	ABB=ON	PLU=ON	GARRIDO, A?/AU,AUTH
L47	QUE	SPE=ON	ABB=ON	PLU=ON	LOZANO PUERTO, R?/AU,AUTH
L48	QUE	SPE=ON	ABB=ON	PLU=ON	LOZANOPUERTO, R?/AU,AUTH
L49	QUE	SPE=ON	ABB=ON	PLU=ON	LOZANO, R?/AU,AUTH
L50	QUE	SPE=ON	ABB=ON	PLU=ON	PUERTO, R?/AU,AUTH
L51	QUE	SPE=ON	ABB=ON	PLU=ON	(ACTION(1W)MEDICINE#)/CS,SO,PA
L53	QUE	SPE=ON	ABB=ON	PLU=ON	SKIN
L54	QUE	SPE=ON	ABB=ON	PLU=ON	?DERM?
L55	QUE	SPE=ON	ABB=ON	PLU=ON	?PSORIA?
L56	QUE	SPE=ON	ABB=ON	PLU=ON	ANTIPSORIA?
L58	QUE	SPE=ON	ABB=ON	PLU=ON	A61P0017-06/IPC
L74	QUE	SPE=ON	ABB=ON	PLU=ON	(B14-N17C OR C14-N17C OR B12-A07 OR C12-A07)/MC
L106	1009	SEA FILE=WPIX	SPE=ON	ABB=ON	PLU=ON (R00180/SDCN OR R03057/SDCN OR R10974/SDCN OR R18653/SDCN OR R18808/SDCN OR RACANB/SDCN OR RACRCN/SDCN OR RACRCO/SDCN OR RACRCQ/SDCN OR RACRCY/SDCN OR RACRCZ/SDCN OR RACRDB/SDCN OR RACRDC/SDCN OR RACRDE/SDCN OR RACRDF/SDCN OR RACRDG/SDCN OR RACRDH/SDCN OR RACRDN/SDCN OR RACRDO/SDCN OR RACRDQ/SDCN OR RACRDR/SDCN OR RACRDS/SDCN OR RACRDV/SDCN OR RACRD0/SDCN OR RADRS8/SDCN OR RAF0PZ/SDCN OR RA0DJE/SDCN OR RA0HDM/SDCN OR RA00C8/SDCN OR RA00GT/SDCN OR RA00H3/SDCN OR RA00TQ/SDCN OR RA0120/SDCN OR RA0120/SDCN OR RA02SP/SDCN OR RA040B/SDCN OR RA088T/SDCN OR RA1HNP/SDCN OR RA1YR6/SDCN OR RA6EV7/SDCN OR R00076/SDCN OR R00122/SDCN OR R00137/SDCN OR R00291/SDCN OR R00689/SDCN OR R01330/SDCN OR R01987/SDCN OR R02044/SDCN OR R02049/SDCN OR R02069/SDCN OR R03442/SDCN OR R04259/SDCN OR R06973/SDCN OR R09011/SDCN OR R10769/SDCN OR R11063/SDCN OR R12996/SDCN OR R20748/SDCN OR R21749/SDCN OR R23692/SDCN OR RAAJSH/SDCN OR RAALE1/SDCN OR RAAMCC/SDCN OR RAAMCD/SDCN OR RAAMCE/SDCN OR RAAMCF/SDCN OR RAAMCG/SDCN OR RAAMCI/SDCN OR RAAMCK/SDCN OR RAAMCN/SDCN OR RAAMCO/SDCN OR RAAMCP/SDCN OR RAAMCQ/SDCN OR RAAMCR/SDCN OR RAAMCS/SDCN OR RAAMCT/SDCN OR RAAMCW/SDCN OR RAAMCX/SDCN OR RAAMCY/SDCN OR RAAMCZ/SDCN OR RAAMDF/SDCN OR RAAMDG/SDCN OR RAAMDJ/SDCN OR RAAMD L/SDCN OR RAAMD M/SDCN OR RAAMD N/SDCN OR RAAMDO/SDCN OR RAAMDP/SDCN OR RAAMDR/SDCN OR RAAMDS/SDCN OR RAAMDT/SDCN OR RAAMDU/SDCN OR RAAMD0/SDCN OR RAAMD1/SDCN OR RAAMD2/SDCN OR RAAMD6/SDCN OR RAAM1I/SDCN OR RAAM1J/SDCN OR RAAM1K/SDCN OR RAAM1L/SDCN OR RAAM1M/SDCN OR RAAM1N/SDCN OR

RAAM1O/SDCN OR RAAM1P/SDCN OR RAAM1Q/SDCN OR RAAM1R/SDCN OR
 RAAM1S/SDCN OR RAAM1T/SDCN OR RAAM1U/SDCN OR RAAM1V/SDCN OR
 RAAM1W/SDCN OR RAAM1X/SDCN OR RAAM1Y/SDCN OR RAAM1Z/SDCN OR
 RAAM2A/SDCN OR RAAM2B/SDCN OR RAAM2C/
 L107 418 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RA02SP/SDCN OR R18653/SD
 CN OR R01614/SDCN OR R04292/SDCN OR R13080/SDCN OR R23692/SDCN
 OR RA0DWB/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA01SC/SDCN OR
 RA02JW/SDCN OR RA04OB/SDCN OR RA1C7N/SDCN OR RA28R6/SDCN OR
 RA5D1M/SDCN OR R00095/SDCN OR R00298/SDCN OR R03361/SDCN OR
 R04116/SDCN OR R04227/SDCN OR R04654/SDCN OR R09668/SDCN OR
 RA0K9J/SDCN OR RA00C8/SDCN OR RA01E9/SDCN OR RA1HNP/SDCN OR
 RA43CA/SDCN OR RA74YB/SDCN OR RA74YC/SDCN OR RA74YE/SDCN OR
 RA74YZ/SDCN OR RA74Y7/SDCN OR RA74Y8/SDCN OR RA74ZA/SDCN OR
 RA74ZI/SDCN OR RA74ZY/SDCN OR RA74ZZ/SDCN OR RA74Z0/SDCN OR
 RA74Z1/SDCN OR RA74Z2/SDCN OR RA74Z3/SDCN OR RA74Z4/SDCN OR
 RA74Z5/SDCN OR RA74Z7/SDCN OR RA74Z8/SDCN OR RA74Z9/SDCN OR
 RA750A/SDCN OR RA750B/SDCN OR RA7500/SDCN OR RA7501/SDCN OR
 RA7502/SDCN OR RA7503/SDCN OR RA7505/SDCN OR RA7506/SDCN OR
 RA7507/SDCN OR RA7508/SDCN OR R00271/SDCN OR R00991/SDCN OR
 RA0CGV/SDCN OR RA0C4V/SDCN OR RA0HNY/SDCN OR RA0IKS/SDCN OR
 RA0KH3/SDCN OR RA0LMH/SDCN OR RA0MTA/SDCN OR RA0WLX/SDCN OR
 RA006H/SDCN OR RA01BE/SDCN OR RA01Q7/SDCN OR RA01SX/SDCN OR
 RA015V/SDCN OR RA02DZ/SDCN OR RA021Q/SDCN OR RA027G/SDCN OR
 RA027I/SDCN OR RA027J/SDCN OR RA03SR/SDCN OR RA03YX/SDCN OR
 RA03YY/SDCN OR RA05GM/SDCN OR RA05JM/SDCN OR RA05WC/SDCN OR
 RA07GX/SDCN OR RA1HN1/SDCN OR RA1QEQ/SDCN OR RA1QSX/SDCN OR
 RA1YFH/SDCN OR RA13IL/SDCN OR RA13XQ/SDCN OR RA152R/SDCN OR
 RA18TQ/SDCN OR RA2VNT/SDCN OR RA20DZ/SDCN OR RA3ITX/SDCN OR
 RA3SGW/SDCN OR RA41J1/SDCN OR RA44DH/SDCN OR RA6SD5/SDCN OR
 RA6VEH/SDCN OR RA6VEI/SDCN OR RA6VEJ/SDCN OR RA6VEK/SDCN OR
 RA6VEL/SDCN OR RA6VEM/SDCN OR RA6VEN/SDCN OR RA6VEO/SDCN OR
 RA6VEP/SDCN OR RA6VER/SDCN OR RA6VES/SDCN OR RA6VET/SDCN OR
 RA6VEU/SDCN OR RA6VEV/SDCN OR RA6VEW/SDCN OR RA6VEX/SDCN OR
 RA6VEY/SDCN OR RA6VEZ/SDCN OR RA6VFA/SDCN OR RA6VFB/SDCN OR
 RA6VFC/SDCN OR RA6VFD/SDCN OR RA6VFE/SDCN OR RA6VFF/SDCN OR
 RA6VFG/SDCN OR RA6VFH/SDCN OR RA6VFI/SDCN OR RA6VFJ/SDCN OR
 RA6VFK/SDCN OR RA6VFL
 L108 324 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RA00C8/SDCN OR RA0ETL/SD
 CN OR RA0ETQ/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA0K9J/SDCN
 OR RA0YL4/SDCN OR RA00GT/SDCN OR RA02JW/SDCN OR RA02SP/SDCN OR
 RA04OB/SDCN OR RA1HNP/SDCN OR RA28R6/SDCN OR RA43CA/SDCN OR
 R00477/SDCN OR R00669/SDCN OR R01119/SDCN OR R03562/SDCN OR
 R04115/SDCN OR R04292/SDCN OR R09668/SDCN OR R13080/SDCN OR
 R18653/SDCN OR R23692/SDCN OR RA00H1/SDCN OR RA00NS/SDCN OR
 RA01SC/SDCN OR RA012P/SDCN OR RA043B/SDCN OR RA043C/SDCN OR
 RA043E/SDCN OR RA043F/SDCN OR RA043G/SDCN OR RA043H/SDCN OR
 RA043I/SDCN OR RA043J/SDCN OR RA043K/SDCN OR RA043L/SDCN OR
 RA043M/SDCN OR RA043N/SDCN OR RA043O/SDCN OR RA043P/SDCN OR
 RA1C7N/SDCN OR RA1ILG/SDCN OR RA1ILH/SDCN OR RA1ILU/SDCN OR
 RA1ILW/SDCN OR RA1ILX/SDCN OR RA1ILY/SDCN OR RA1ILZ/SDCN OR
 RA1IMB/SDCN OR RA1IMK/SDCN OR RA1IMO/SDCN OR RA1IM0/SDCN OR
 RA1IM2/SDCN OR RA1IM4/SDCN OR RA1IM9/SDCN OR RA1INB/SDCN OR
 RA1IND/SDCN OR RA1IN0/SDCN OR RA1IN2/SDCN OR RA1IN5/SDCN OR
 RA1IN6/SDCN OR RA1IN7/SDCN OR RA100A/SDCN OR RA100C/SDCN OR
 RA100D/SDCN OR RA100F/SDCN OR RA1000/SDCN OR RA1002/SDCN OR
 RA1003/SDCN OR RA1004/SDCN OR RA1005/SDCN OR RA1006/SDCN OR
 RA1007/SDCN OR RA1008/SDCN OR RA1009/SDCN OR RA1WSI/SDCN OR
 RA1WSJ/SDCN OR RA1WSQ/SDCN OR RA1WTY/SDCN OR RA17JY/SDCN OR
 RA17KF/SDCN OR RA17KG/SDCN OR RA17K3/SDCN OR RA195G/SDCN OR
 RA195H/SDCN OR RA195I/SDCN OR RA195J/SDCN OR RA195K/SDCN OR

RA195L/SDCN OR RA195M/SDCN OR RA195N/SDCN OR RA195O/SDCN OR
 RA2FSP/SDCN OR RA250K/SDCN OR RA250R/SDCN OR RA250S/SDCN OR
 RA250T/SDCN OR RA250V/SDCN OR RA250W/SDCN OR RA250X/SDCN OR
 RA250Y/SDCN OR RA2510/SDCN OR RA2511/SDCN OR RA2512/SDCN OR
 RA2513/SDCN OR RA2514/SDCN OR RA2515/SDCN OR RA2516/SDCN OR
 RA2517/SDCN OR RA2518/SDCN OR RA2519/SDCN OR RA33DB/SDCN OR
 RA33DC/SDCN OR RA33DD/SDCN OR RA33DO/SDCN OR RA33DP/SDCN OR
 RA33DW/SDCN OR RA33D7/SDCN OR RA33D8/SDCN OR RA33EN/SDCN OR
 RA33ER/SDCN OR RA33ES/SDCN OR RA33E1/S
 L109 1658 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (L106 OR L107 OR L108)
 L112 1685 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L109 OR L19
 L114 22 SEA FILE=WPIX SUB=L112 SSS FUL L9
 L118 16 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RASW2T/DCN OR RASW2U/DCN
 OR RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW3A/DCN OR
 RASW3B/DCN OR RASW3C/DCN OR RASW3D/DCN OR RASW3E/DCN OR
 RASW3F/DCN OR RASW3G/DCN OR RASW3H/DCN OR RASW39/DCN OR
 RAUHHC/DCN OR RAUHHD/DCN OR RAUHHE/DCN OR RAUHHF/DCN OR
 RAUHHG/DCN OR RAUHHH/DCN OR RAUHH9/DCN OR RA2Y7A/DCN) OR
 L114/DCR
 L119 6 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L118 AND (L58 OR L74 OR
 (L55 OR L56))
 L120 14 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L118 AND (L53 OR L54 OR
 L55 OR L56)
 L121 14 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (L119 OR L120)
 L122 13 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L121 AND (L21 OR L22 OR
 L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
 L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR
 L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR
 L50 OR L51)

 => d que nos 1165
 L11 (5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
 L12 SEL PLU=ON L11 1- RN : 82 TERMS
 L13 (82)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L12
 L14 STR
 L15 (28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
 L16 (270)SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (1007839-71-5/CRN OR
 1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
 1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
 1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
 1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
 1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
 1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
 21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
 8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
 79122-68-2/CRN OR 88-46-0/CRN)
 L17 293 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L15 OR L16
 L18 129 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L17 NOT PMS/CI
 L21 QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
 L22 QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
 L23 QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
 L24 QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
 L25 QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
 L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
 L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
 L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
 L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
 L30 QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
 U,AUTH

L31 QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
 L32 QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
 L33 QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
 L34 QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH
 L35 QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU,AUTH
 L36 QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU,AUTH
 L37 QUE SPE=ON ABB=ON PLU=ON ANGULO, J?/AU,AUTH
 L38 QUE SPE=ON ABB=ON PLU=ON FRUTOS, J?/AU,AUTH
 L39 QUE SPE=ON ABB=ON PLU=ON VALVERDE LOPEZ, S?/AU,AUTH
 L40 QUE SPE=ON ABB=ON PLU=ON VALVERDELOPEZ, S?/AU,AUTH
 L41 QUE SPE=ON ABB=ON PLU=ON VALVERDE, S?/AU,AUTH
 L42 QUE SPE=ON ABB=ON PLU=ON LOPEZ, S?/AU,AUTH
 L43 QUE SPE=ON ABB=ON PLU=ON ROMERO GARRIDO, A?/AU,AUTH
 L44 QUE SPE=ON ABB=ON PLU=ON ROMEROGARRIDO, A?/AU,AUTH
 L45 QUE SPE=ON ABB=ON PLU=ON ROMERO, A?/AU,AUTH
 L46 QUE SPE=ON ABB=ON PLU=ON GARRIDO, A?/AU,AUTH
 L47 QUE SPE=ON ABB=ON PLU=ON LOZANO PUERTO, R?/AU,AUTH
 L48 QUE SPE=ON ABB=ON PLU=ON LOZANOPUERTO, R?/AU,AUTH
 L49 QUE SPE=ON ABB=ON PLU=ON LOZANO, R?/AU,AUTH
 L50 QUE SPE=ON ABB=ON PLU=ON PUERTO, R?/AU,AUTH
 L51 QUE SPE=ON ABB=ON PLU=ON (ACTION(1W)MEDICINE#)/CS,SO,
 PA
 L53 QUE SPE=ON ABB=ON PLU=ON SKIN
 L54 QUE SPE=ON ABB=ON PLU=ON ?DERM?
 L55 QUE SPE=ON ABB=ON PLU=ON ?PSORIA?
 L56 QUE SPE=ON ABB=ON PLU=ON ANTIPSORIA?
 L57 QUE SPE=ON ABB=ON PLU=ON PSORIASIS+PFT,OLD,NEW,NT/CT
 L58 QUE SPE=ON ABB=ON PLU=ON A61P0017-06/IPC
 L59 780 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L18
 L63 QUE SPE=ON ABB=ON PLU=ON "DERMATOLOGICAL AGENTS"+PFT,
 OLD,NEW/CT
 L64 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L59 AND L63
 L126 STR
 L128 SCR 1812 OR 1758
 L130 1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
 L131 1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI
 L141 STR
 L143 173 SEA FILE=REGISTRY SSS FUL L141
 L144 170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
 L145 146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES
 L146 STR
 L148 160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
 L149 133 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L145 AND L148
 L150 1427 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L131 OR L149
 L151 1760 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L150
 L152 11 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L151 AND L58
 L153 8 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L151 AND L57
 L154 9 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L151 AND (L55 OR L56)

 L155 14 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON (L152 OR L153 OR
 L154)
 L156 QUE SPE=ON ABB=ON PLU=ON "SKIN, DISEASE"+PFT,OLD,NEW,
 NT/CT
 L157 95 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L151 AND (L156 OR L64
 OR (L53 OR L54 OR L55 OR L56 OR L57))
 L158 316 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L151 (L) (THU OR PKT
 OR PAC OR DMA OR BAC)/RL
 L159 63 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L157 AND L158
 L160 QUE SPE=ON ABB=ON PLU=ON DISEAS? OR DISORDER? OR SYND
 ROM? OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB

11/839,520

```
? OR DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)
L161      18 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L159 AND ((L53 OR
          L54) (3A) L160)
L162      27 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L155 OR L161
L163      27 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L162 AND ((L53 OR L54
          OR L55 OR L56 OR L57 OR L58) OR L64)
L164      27 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L162 OR L163)
L165      14 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L164 AND (L21 OR L22
          OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
          OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
          OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
          OR L50 OR L51)
```

=> d his 1213

```
(FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:20:08 ON 25 SEP 2009)
L213      3 S L212 AND L21-L51
```

=> d que nos 1213

```
L21      QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22      QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23      QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24      QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25      QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26      QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27      QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28      QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29      QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
          U,AUTH
L31      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32      QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33      QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34      QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38      QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42      QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44      QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46      QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50      QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51      QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS, SO,
          PA
L55      QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56      QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L126      STR
L128      SCR 1812 OR 1758
L130      1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131      1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141      STR
```

L143 173 SEA FILE=REGISTRY SSS FUL L141
 L144 170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
 L145 146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES
 L146 STR
 L148 160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
 L149 133 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L145 AND L148
 L150 1427 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L131 OR L149
 L186 QUE SPE=ON ABB=ON PLU=ON EPIDERMOPOIESIS
 L204 QUE SPE=ON ABB=ON PLU=ON WILLAN (1A) LEpra
 L205 QUE SPE=ON ABB=ON PLU=ON PARAPSORIA?
 L210 333 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L150 AND (USPATFULL
 OR USPAT2 OR USPATOLD)/LC
 L211 409 SEA L210
 L212 5 SEA L211 AND (L55/CLM OR L56/CLM OR L186/CLM OR L204/CLM OR
 L205/CLM)
 L213 3 SEA L212 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
 L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
 L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
 L46 OR L47 OR L48 OR L49 OR L50 OR L51)

=> d que nos 1175

L21 QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
 L22 QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
 L23 QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
 L24 QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
 L25 QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
 L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
 L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
 L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
 L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
 L30 QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
 U,AUTH
 L31 QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
 L32 QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
 L33 QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
 L34 QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH
 L35 QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU,AUTH
 L36 QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU,AUTH
 L37 QUE SPE=ON ABB=ON PLU=ON ANGULO, J?/AU,AUTH
 L38 QUE SPE=ON ABB=ON PLU=ON FRUTOS, J?/AU,AUTH
 L39 QUE SPE=ON ABB=ON PLU=ON VALVERDE LOPEZ, S?/AU,AUTH
 L40 QUE SPE=ON ABB=ON PLU=ON VALVERDELOPEZ, S?/AU,AUTH
 L41 QUE SPE=ON ABB=ON PLU=ON VALVERDE, S?/AU,AUTH
 L42 QUE SPE=ON ABB=ON PLU=ON LOPEZ, S?/AU,AUTH
 L43 QUE SPE=ON ABB=ON PLU=ON ROMERO GARRIDO, A?/AU,AUTH
 L44 QUE SPE=ON ABB=ON PLU=ON ROMEROGARRIDO, A?/AU,AUTH
 L45 QUE SPE=ON ABB=ON PLU=ON ROMERO, A?/AU,AUTH
 L46 QUE SPE=ON ABB=ON PLU=ON GARRIDO, A?/AU,AUTH
 L47 QUE SPE=ON ABB=ON PLU=ON LOZANO PUERTO, R?/AU,AUTH
 L48 QUE SPE=ON ABB=ON PLU=ON LOZANOPUERTO, R?/AU,AUTH
 L49 QUE SPE=ON ABB=ON PLU=ON LOZANO, R?/AU,AUTH
 L50 QUE SPE=ON ABB=ON PLU=ON PUERTO, R?/AU,AUTH
 L51 QUE SPE=ON ABB=ON PLU=ON (ACTION(1W)MEDICINE#)/CS, SO,
 PA
 L55 QUE SPE=ON ABB=ON PLU=ON ?PSORIA?
 L56 QUE SPE=ON ABB=ON PLU=ON ANTIPSORIA?
 L58 QUE SPE=ON ABB=ON PLU=ON A61P0017-06/IPC
 L74 QUE SPE=ON ABB=ON PLU=ON (B14-N17C OR C14-N17C OR B12
 -A07 OR C12-A07)/MC

L126 STR
 L128 SCR 1812 OR 1758
 L141 STR
 L169 82 SEA FILE=WPIX SSS FUL (L128 AND L126)
 L171 15 SEA FILE=WPIX SSS FUL L141
 L172 97 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L169 OR L171
 L173 122 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RABCOA/DCN OR RABCO3/DCN
 OR RABCO8/DCN OR RABCO9/DCN OR RABNDP/DCN OR RABNDQ/DCN OR
 RAGHZJ/DCN OR RAGHZM/DCN OR RAHO0Q/DCN OR RAI7ME/DCN OR
 RAKQX2/DCN OR RALH0H/DCN OR RAL3SN/DCN OR RAL3SO/DCN OR
 RAL3SP/DCN OR RAL3SQ/DCN OR RAL3SR/DCN OR RAL3ST/DCN OR
 RANFVN/DCN OR RAN401/DCN OR RAN403/DCN OR RAPVAI/DCN OR
 RAPVAJ/DCN OR RAPVAK/DCN OR RAQW9I/DCN OR RAQW9P/DCN OR
 RAQW9R/DCN OR RAR1ZL/DCN OR RASW2T/DCN OR RASW2U/DCN OR
 RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW2Y/DCN OR
 RASW2Z/DCN OR RASW3A/DCN OR RASW3B/DCN OR RASW3C/DCN OR
 RASW3D/DCN OR RASW3E/DCN OR RASW3F/DCN OR RASW3G/DCN OR
 RASW3H/DCN OR RASW30/DCN OR RASW38/DCN OR RASW39/DCN OR
 RASW4A/DCN OR RASW50/DCN OR RASXL7/DCN OR RAUHHH/DCN OR
 RAUHHH/DCN OR RAUHHH/DCN OR RAUHHF/DCN OR RAUHHG/DCN OR
 RAUHHH/DCN OR RAUHH9/DCN OR RAUVSQ/DCN OR RAUVSR/DCN OR
 RAWFMV/DCN OR RAWUPX/DCN OR RAW47P/DCN OR RAW47Q/DCN OR
 RAW47R/DCN OR RAW47S/DCN OR RAW47T/DCN OR RAW47U/DCN OR
 RAXSIA/DCN OR RA0MNZ/DCN OR RA002O/DCN OR RA007X/DCN OR
 RA0083/DCN OR RA2NB0/DCN OR RA2Y7A/DCN OR RA3MBV/DCN OR
 RA4GNI/DCN OR RA4GOC/DCN OR RA4GOL/DCN OR RA4KMT/DCN OR
 RA4KMZ/DCN OR RA4KN3/DCN OR RA4KN4/DCN OR RA4NBT/DCN OR
 RA4NBW/DCN OR RA6Q5K/DCN OR RA63TX/DCN OR RA660M/DCN OR
 RA8AOM/DCN OR RA9JSH/DCN OR RA9JSI/DCN OR RA9XSQ/DCN OR
 RB0D0S/DCN OR RB0D0T/DCN OR RB0D0U/DCN OR RB0D0V/DCN OR
 R11693/DCN OR R11694/DCN OR R20556/DCN OR R21482/DCN) OR
 L172/DCR
 L174 10 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L173 AND (L58 OR L74 OR
 (L55 OR L56))
 L175 7 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L174 AND (L21 OR L22 OR
 L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
 L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR
 L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR
 L50 OR L51)

=> d que nos 1189

L3 (5) SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
 L4 SEL PLU=ON L3 1- RN : 82 TERMS
 L5 82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L4
 L21 QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
 L22 QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
 L23 QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
 L24 QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
 L25 QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
 L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
 L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
 L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
 L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
 L30 QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
 U, AUTH
 L31 QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
 L32 QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
 L33 QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
 L34 QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH

```

L35      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37      QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38      QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41      QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42      QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44      QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45      QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46      QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49      QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50      QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51      QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS, SO,
        PA
L55      QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56      QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L126     STR
L128     SCR 1812 OR 1758
L130     1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131     1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI
L141     STR
L143     173 SEA FILE=REGISTRY SSS FUL L141
L144     170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
L145     146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES
L146     STR
L148     160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149     133 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L145 AND L148
L150     1427 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L131 OR L149
L179     28 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L5 AND L150
L180     7 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L150 AND MEDLINE/LC
L181     392 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L180
L182     SEL PLU=ON L179 1- NAME : 13 TERMS
L183     17 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L182
L184     399 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L181 OR L183
L185     QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L186     QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMPOIESIS
L187     QUE  SPE=ON  ABB=ON  PLU=ON  "SKIN DISEASES, PAPULOSQUAMO
        US"+PFT,OLD,NEW,NT/CT
L188     1 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L184 AND ((L55 OR
        L56) OR L185 OR (L186 OR L187))
L189     1 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L188 AND (L21 OR L22
        OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
        OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
        OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
        OR L50 OR L51)

=> d que nos 1198
L3      (      5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L4      SEL PLU=ON L3 1- RN : 82 TERMS
L5      82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L4
L21     QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22     QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23     QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24     QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25     QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH

```

L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
 L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
 L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
 L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
 L30 QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
 U, AUTH
 L31 QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
 L32 QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
 L33 QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
 L34 QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH
 L35 QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU,AUTH
 L36 QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU,AUTH
 L37 QUE SPE=ON ABB=ON PLU=ON ANGULO, J?/AU,AUTH
 L38 QUE SPE=ON ABB=ON PLU=ON FRUTOS, J?/AU,AUTH
 L39 QUE SPE=ON ABB=ON PLU=ON VALVERDE LOPEZ, S?/AU,AUTH
 L40 QUE SPE=ON ABB=ON PLU=ON VALVERDELOPEZ, S?/AU,AUTH
 L41 QUE SPE=ON ABB=ON PLU=ON VALVERDE, S?/AU,AUTH
 L42 QUE SPE=ON ABB=ON PLU=ON LOPEZ, S?/AU,AUTH
 L43 QUE SPE=ON ABB=ON PLU=ON ROMERO GARRIDO, A?/AU,AUTH
 L44 QUE SPE=ON ABB=ON PLU=ON ROMEROGARRIDO, A?/AU,AUTH
 L45 QUE SPE=ON ABB=ON PLU=ON ROMERO, A?/AU,AUTH
 L46 QUE SPE=ON ABB=ON PLU=ON GARRIDO, A?/AU,AUTH
 L47 QUE SPE=ON ABB=ON PLU=ON LOZANO PUERTO, R?/AU,AUTH
 L48 QUE SPE=ON ABB=ON PLU=ON LOZANOPUERTO, R?/AU,AUTH
 L49 QUE SPE=ON ABB=ON PLU=ON LOZANO, R?/AU,AUTH
 L50 QUE SPE=ON ABB=ON PLU=ON PUERTO, R?/AU,AUTH
 L51 QUE SPE=ON ABB=ON PLU=ON (ACTION(1W)MEDICINE#)/CS, SO,
 PA
 L55 QUE SPE=ON ABB=ON PLU=ON ?PSORIA?
 L56 QUE SPE=ON ABB=ON PLU=ON ANTIPSORIA?
 L126 STR
 L128 SCR 1812 OR 1758
 L130 1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
 L131 1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI
 L141 STR
 L143 173 SEA FILE=REGISTRY SSS FUL L141
 L144 170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
 L145 146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES
 L146 STR
 L148 160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
 L149 133 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L145 AND L148
 L150 1427 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L131 OR L149
 L179 28 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L5 AND L150
 L182 SEL PLU=ON L179 1- NAME : 13 TERMS
 L186 QUE SPE=ON ABB=ON PLU=ON EPIDERMPOIESIS
 L191 4 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L150 AND EMBASE/LC
 L192 794 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L191
 L193 69 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L182
 L194 838 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON (L192 OR L193)
 L195 QUE SPE=ON ABB=ON PLU=ON PSORIASIS+PFT,OLD,NEW,NT/CT
 L196 QUE SPE=ON ABB=ON PLU=ON "ERYTHEMATOSQUAMOUS SKIN DIS
 EASE"+PFT,OLD,NEW,NT/CT
 L197 2 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L194 AND ((L55 OR L56)
 OR L186 OR (L195 OR L196))
 L198 1 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L197 AND (L21 OR L22
 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
 OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
 OR L50 OR L51)

=> d his 1208

(FILE 'BIOSIS, BIOTECHNO, CABA, DRUGU, VETU' ENTERED AT 11:16:26 ON 25 SEP 2009)

L208 0 S L207 AND L21-L51

=> d que nos 1208

```

L3  ( 5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L4      SEL PLU=ON L3 1- RN : 82 TERMS
L5      82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L4
L21     QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
L22     QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
L23     QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
L24     QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
L25     QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
L26     QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
L27     QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
L28     QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
L29     QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
L30     QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
      U,AUTH
L31     QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
L32     QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
L33     QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
L34     QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH
L35     QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU,AUTH
L36     QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU,AUTH
L37     QUE SPE=ON ABB=ON PLU=ON ANGULO, J?/AU,AUTH
L38     QUE SPE=ON ABB=ON PLU=ON FRUTOS, J?/AU,AUTH
L39     QUE SPE=ON ABB=ON PLU=ON VALVERDE LOPEZ, S?/AU,AUTH
L40     QUE SPE=ON ABB=ON PLU=ON VALVERDELOPEZ, S?/AU,AUTH
L41     QUE SPE=ON ABB=ON PLU=ON VALVERDE, S?/AU,AUTH
L42     QUE SPE=ON ABB=ON PLU=ON LOPEZ, S?/AU,AUTH
L43     QUE SPE=ON ABB=ON PLU=ON ROMERO GARRIDO, A?/AU,AUTH
L44     QUE SPE=ON ABB=ON PLU=ON ROMEROGARRIDO, A?/AU,AUTH
L45     QUE SPE=ON ABB=ON PLU=ON ROMERO, A?/AU,AUTH
L46     QUE SPE=ON ABB=ON PLU=ON GARRIDO, A?/AU,AUTH
L47     QUE SPE=ON ABB=ON PLU=ON LOZANO PUERTO, R?/AU,AUTH
L48     QUE SPE=ON ABB=ON PLU=ON LOZANOPUERTO, R?/AU,AUTH
L49     QUE SPE=ON ABB=ON PLU=ON LOZANO, R?/AU,AUTH
L50     QUE SPE=ON ABB=ON PLU=ON PUERTO, R?/AU,AUTH
L51     QUE SPE=ON ABB=ON PLU=ON (ACTION(1W)MEDICINE#)/CS, SO,
      PA
L53     QUE SPE=ON ABB=ON PLU=ON SKIN
L54     QUE SPE=ON ABB=ON PLU=ON ?DERM?
L126    STR
L128    SCR 1812 OR 1758
L130    1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131    1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI
L141    STR
L143    173 SEA FILE=REGISTRY SSS FUL L141
L144    170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
L145    146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES
L146    STR
L148    160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149    133 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L145 AND L148
L150    1427 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L131 OR L149
L160    QUE SPE=ON ABB=ON PLU=ON DISEAS? OR DISORDER? OR SYND
      ROM? OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB

```

11/839,520

```
? OR DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)
L179      28 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L5 AND L150
L182      SEL PLU=ON L179 1- NAME :      13 TERMS
L200      11 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L150 AND (BIOSIS OR
          BIOTECHNO OR CABA OR DRUGU OR VETU)/LC
L201      437 SEA L200
L202      45 SEA L182
L203      469 SEA (L201 OR L202)
L207      2 SEA L203 AND ((L53 OR L54) (5A) L160)
L208      0 SEA L207 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
          L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
          L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
          L46 OR L47 OR L48 OR L49 OR L50 OR L51)
```

=> d his 1217

(FILE 'HCAPLUS, WPIX, PASCAL, JAPIO, MEDLINE, BIOSIS, EMBASE, CABA,
CEABA-VTB, LIFESCI, KOSMET, BIOENG, BIOTECHNO, BIOTECHDS, DRUGU, DRUGB,
VETU, VETB, SCISEARCH, CONFSCI, DISSABS, RDISCLOSURE' ENTERED AT 11:29:03
ON 25 SEP 2009)

L217 12 S L216 AND L21-L51

=> d que nos 1217

```
L3 (      5)SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L4      SEL PLU=ON L3 1- RN :      82 TERMS
L5      82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L4
L21      QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
L22      QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
L23      QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
L24      QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
L25      QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
L26      QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
L27      QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
L28      QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
L29      QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
L30      QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/A
          U,AUTH
L31      QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
L32      QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
L33      QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
L34      QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH
L35      QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU,AUTH
L36      QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU,AUTH
L37      QUE SPE=ON ABB=ON PLU=ON ANGULO, J?/AU,AUTH
L38      QUE SPE=ON ABB=ON PLU=ON FRUTOS, J?/AU,AUTH
L39      QUE SPE=ON ABB=ON PLU=ON VALVERDE LOPEZ, S?/AU,AUTH
L40      QUE SPE=ON ABB=ON PLU=ON VALVERDELOPEZ, S?/AU,AUTH
L41      QUE SPE=ON ABB=ON PLU=ON VALVERDE, S?/AU,AUTH
L42      QUE SPE=ON ABB=ON PLU=ON LOPEZ, S?/AU,AUTH
L43      QUE SPE=ON ABB=ON PLU=ON ROMERO GARRIDO, A?/AU,AUTH
L44      QUE SPE=ON ABB=ON PLU=ON ROMEROGARRIDO, A?/AU,AUTH
L45      QUE SPE=ON ABB=ON PLU=ON ROMERO, A?/AU,AUTH
L46      QUE SPE=ON ABB=ON PLU=ON GARRIDO, A?/AU,AUTH
L47      QUE SPE=ON ABB=ON PLU=ON LOZANO PUERTO, R?/AU,AUTH
L48      QUE SPE=ON ABB=ON PLU=ON LOZANOPUERTO, R?/AU,AUTH
L49      QUE SPE=ON ABB=ON PLU=ON LOZANO, R?/AU,AUTH
L50      QUE SPE=ON ABB=ON PLU=ON PUERTO, R?/AU,AUTH
L51      QUE SPE=ON ABB=ON PLU=ON (ACTION(1W)MEDICINE#)/CS, SO,
          PA
```


11/839,520

L55 QUE SPE=ON ABB=ON PLU=ON ?PSORIA?
L56 QUE SPE=ON ABB=ON PLU=ON ANTIPSORIA?
L58 QUE SPE=ON ABB=ON PLU=ON A61P0017-06/IPC
L126 STR
L128 SCR 1812 OR 1758
L130 1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131 1294 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L130 NOT PMS/CI
L141 STR
L143 173 SEA FILE=REGISTRY SSS FUL L141
L144 170 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
L145 146 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES
L146 STR
L148 160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149 133 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L145 AND L148
L150 1427 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L131 OR L149
L179 28 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L5 AND L150
L182 SEL PLU=ON L179 1- NAME : 13 TERMS
L186 QUE SPE=ON ABB=ON PLU=ON EPIDERMOPOLYSIS
L204 QUE SPE=ON ABB=ON PLU=ON WILLAN (1A) LEPRO
L205 QUE SPE=ON ABB=ON PLU=ON PARAPSORIA?
L215 425 SEA L182
L216 13 SEA L215 AND ((L55 OR L56) OR L186 OR (L204 OR L205) OR L58)
L217 12 SEA L216 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
L46 OR L47 OR L48 OR L49 OR L50 OR L51)

=> dup rem 170 1122 1165 1213 1175 1189 1198 1208 1217

L208 HAS NO ANSWERS

DUPLICATE IS NOT AVAILABLE IN 'KOSMET, RDISCLOSURE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

FILE 'HCAPLUS' ENTERED AT 11:50:56 ON 25 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 11:50:56 ON 25 SEP 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 11:50:56 ON 25 SEP 2009

CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:50:56 ON 25 SEP 2009

FILE 'EMBASE' ENTERED AT 11:50:56 ON 25 SEP 2009

Copyright (c) 2009 Elsevier B.V. All rights reserved.

PROCESSING COMPLETED FOR L70

PROCESSING COMPLETED FOR L122

PROCESSING COMPLETED FOR L165

PROCESSING COMPLETED FOR L213

PROCESSING COMPLETED FOR L175

PROCESSING COMPLETED FOR L189

PROCESSING COMPLETED FOR L198

PROCESSING COMPLETED FOR L208

PROCESSING COMPLETED FOR L217

L220 22 DUP REM L70 L122 L165 L213 L175 L189 L198 L208 L217 (43 DUPLICATES
REMOVED)

ANSWERS '1-15' FROM FILE HCAPLUS

ANSWERS '16-19' FROM FILE WPIX

11/839,520

ANSWERS '20-21' FROM FILE USPATFULL
ANSWER '22' FROM FILE MEDLINE

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 11:51:10 ON 25 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 18, 2009 (20090918/UP).

=> d ibib ed abs hitind hitstr 1-15

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' - CONTINUE?
(Y)/N:y

L220 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2009:1018664 HCAPLUS Full-text

DOCUMENT NUMBER: 151:272952

TITLE: Skin penetration enhancing systems for polar drugs

INVENTOR(S): Osborne, David W.; Sarpotdar, Pramod P.; Angel, Arturo J.; Saenz De Tejada Gorman, Inigo; Cuevas Sanchez, Pedro

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 51pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009103069	A1	20090820	WO 2009-US34304	20090217
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2008-29231P P 20080215

ED Entered STN: 21 Aug 2009

AB The invention relates to pharmaceutical compns. and related methods for the topical administration of polar drugs. In a particular embodiment, the invention relates to a pharmaceutical composition comprising an active pharmaceutical agent that is a polar drug, such as potassium 2,5-dihydroxybenzenesulfonate (I), at least one occlusive agent, and at least one stabilizer. A formulation contains about 10 % I, about 20 % white petrolatum, about 20 % mineral oil, about 2.5 % stearyl alc., about 0.5 % cetyl alc., about 1.0 % steareth-2, about 4.0 % steareth-21, about 0.5 % benzyl alc., about 0.1 % sodium thiosulfate pentahydrate, about 0.05 % acetic acid, about 0.02 % sodium acetate, and water to 100 %.

CC 63-6 (Pharmaceuticals)

ST skin penetration enhancing system topical polar drug; topical potassium dobesilate occlusive agent stabilizer

IT pH
(adjuster for, penetration enhancing system further containing; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Hydrocarbon oils
Hydrocarbon waxes

Paraffin oils

Petrolatum

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as occlusive agent; occlusive agents and stabilizers in skin
penetration enhancing systems for polar drugs)

IT Emulsifying agents

Solubilizers

(as stabilizing agents; occlusive agents and stabilizers in
skin penetration enhancing systems for polar drugs)

IT Foams

(boosters of, as stabilizing agents; occlusive agents and stabilizers
in skin penetration enhancing systems for polar drugs)

IT Salts

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drugs in form of; occlusive agents and stabilizers in skin
penetration enhancing systems for polar drugs)

IT Polar molecules

(drugs; occlusive agents and stabilizers in skin penetration
enhancing systems for polar drugs)

IT Solubilizers

(hydrotopes, as stabilizing agents; occlusive agents and stabilizers in
skin penetration enhancing systems for polar drugs)

IT Ions

(mol., drugs in form of; occlusive agents and stabilizers in
skin penetration enhancing systems for polar drugs)

IT Permeation enhancers

Skin

Stabilizing agents

Topical drug delivery systems

(occlusive agents and stabilizers in skin penetration
enhancing systems for polar drugs)

IT Polyoxyalkylenes

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(occlusive agents and stabilizers in skin penetration
enhancing systems for polar drugs)

IT Antioxidants

Preservatives

Solvents

Surfactants

Thickening agents

(penetration enhancing system further containing; occlusive agents and
stabilizers in skin penetration enhancing systems for polar
drugs)

IT Biological transport

(permeation; occlusive agents and stabilizers in skin
penetration enhancing systems for polar drugs)

IT Drugs

(polar; occlusive agents and stabilizers in skin penetration
enhancing systems for polar drugs)

IT Suspensions

(suspending agents, as stabilizing agents; occlusive agents and
stabilizers in skin penetration enhancing systems for polar
drugs)

IT Skin, disease

(treatment of, with topical potassium dobesilate; occlusive agents and
stabilizers in skin penetration enhancing systems for polar
drugs)

IT 123-31-9D, 1,4-Benzenediol, derivs., salts, solvates, isomers, prodrugs,
biological studies 2624-44-4, Ethamsylate 20123-80-2
, Calcium dobesilate 97225-83-7

11/839,520

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as drug; occlusive agents and stabilizers in skin
penetration enhancing systems for polar drugs)

IT 9005-00-9, Steareth 12441-09-7, Sorbitan 12441-09-7D, Sorbitan, fatty acid esters, PEG derivs. 25322-68-3D, Polyethylene glycol, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as emulsifying agent for stabilizer; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as polar drug; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT 57-55-6, Propylene glycol, biological studies 64-19-7, Acetic acid, biological studies 100-51-6, Benzyl alcohol, biological studies 112-92-5, Stearyl alcohol 127-09-3, Sodium acetate 1338-41-6, Span 60 7732-18-5, Water, biological studies 9005-67-8, Tween 60 10102-17-7, Sodium thiosulfate pentahydrate 36653-82-4, Cetyl alcohol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT 2624-44-4, Ethamsylate 20123-80-2, Calcium dobesilate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as drug; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

RN 2624-44-4 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)
(CA INDEX NAME)

CM 1

CRN 109-89-7


CMF C4 H11 N



CM 2


CRN 88-46-0

CMF C6 H6 O5 S




RN 20123-80-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

IT 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as polar drug; occlusive agents and stabilizers in skin
 penetration enhancing systems for polar drugs)
 RN 21799-87-1 HCAPLUS
 CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX
 NAME)



● K

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2009:521020 HCAPLUS Full-text

DOCUMENT NUMBER: 150:487712

TITLE: Methods of use 2,5-dihydroxybenzene sulfonic acid
 compounds for the treatment of cancer, rosacea and
psoriasis

INVENTOR(S): Cuevas Sanchez, Pedro; Romero Garrido,
Antonio; Gimenez Gallego, Guillermo;
Valverde Lopez, Serafin; Lozano Puerto,
Rosa Maria

PATENT ASSIGNEE(S): Action Medicines, S.L., Spain

SOURCE: U.S. Pat. Appl. Publ., 32pp., Cont.-in-part of U.S.
 Ser. No. 588,166.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20090111779	A1	20090430	US 2008-257854	20081024

11/839,520

ES 2238924	A1	20050901	ES 2004-371	20040217 <--
ES 2238924	B1	20061201		
WO 2005077352	A1	20050825	WO 2005-ES70017	20050216 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070149618	A1	20070628	US 2006-506469	20060816
US 20080293816	A1	20081127	US 2008-588166	20080807 <--
PRIORITY APPLN. INFO.:			ES 2004-371	A 20040217
			WO 2005-ES70017	W 20050216
			US 2006-506469	A3 20060816
			US 2008-588166	A2 20080807
			US 2006-588166	A2 20060802

OTHER SOURCE(S): MARPAT 150:487712
ED Entered STN: 30 Apr 2009
GI



AB Methods of use 2,5-dihydroxybenzene sulfonic acid compds. of formula I, where X is a hydrogen, an organic cation or an inorg. cation; n is an integer from 1 to 2; and m is an integer from 1 to 2, for the treatment of cancer, rosacea and psoriasis are disclosed. The invention describes compns. and methods of use for 2,5-dihydroxybenzene sulfonic acid compds. and pharmaceutically acceptable salts thereof. The invention provides methods for the treatment of skin cancer, organ cancer and leukemia. Method also involves in improving the efficacy of chemotherapy, radiation therapy and cancer immunotherapy. The invention also provides methods for the treatment of rosacea and psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one other therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compds. or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate.

INCL 514167000; 514576000; 514568000; 514171000

CC 1-6 (Pharmacology)
Section cross-reference(s): 2, 63

ST dihydroxybenzene sulfonate compd steroid combination therapy cancer rosacea psoriasis; antitumor antiinflammatory antioxidant combination chemotherapy potentiation dihydroxybenzene sulfonate compd

IT Animal cell line
(C-6; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for

- treatment of cancer, rosacea and psoriasis)
- IT Skin, neoplasm
(basal cell carcinoma; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
- IT Carcinoma
(basal cell; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
- IT Anti-inflammatory agents
Antimicrobial agents
Antioxidants
(codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
- IT Retinoids
Steroids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
- IT Antiproliferative agents
Antitumor agents
Brain, neoplasm
Combination chemotherapy
Erythema
Human
Leukemia
Melanoma
Neoplasm
Neuroglia, neoplasm
Pharmaceutical carriers
Pharmaceutical creams
Psoriasis
Skin, neoplasm
Telangiectasia
Topical drug delivery systems
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
- IT Hydrocarbon oils
Petrolatum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
- IT Drug interactions
(potentiation; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
- IT Skin, disease
(rosacea, characterized by papules and pustules; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
- IT Skin, disease
(rosacea; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
- IT Neuroglia, neoplasm
(s.c.; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
- IT 69-72-7, Salicylic acid, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
- IT 1406-16-2D, Vitamin D, analogs

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for
treatment of cancer, rosacea and psoriasis)

IT 51-21-8, 5-FU 57-22-7, Vincristine 88-46-0,
2,5-Dihydroxybenzene sulfonic acid 2624-44-4, Diethylamine
2,5-dihydroxybenzenesulfonate 15663-27-1, Cisplatin 20123-80-2
, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium
2,5-dihydroxybenzenesulfonate 33069-62-4, Paclitaxel 97225-83-7,
Magnesium 2,5-dihydroxybenzenesulfonate 97682-44-5, Irinotecan

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for
treatment of cancer, rosacea and psoriasis)

IT 112-92-5, Stearyl alcohol 36653-82-4, Cetyl alcohol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for
treatment of cancer, rosacea and psoriasis)


IT 88-46-0, 2,5-Dihydroxybenzene sulfonic acid 2624-44-4
, Diethylamine 2,5-dihydroxybenzenesulfonate 20123-80-2,
Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium
2,5-dihydroxybenzenesulfonate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for
treatment of cancer, rosacea and psoriasis)

RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 2624-44-4 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)
(CA INDEX NAME)

CM 1

CRN 109-89-7


CMF C4 H11 N




CM 2

CRN 88-46-0

CMF C6 H6 O5 S




RN 20123-80-2 HCAPLUS
 CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

RN 21799-87-1 HCAPLUS
 CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

L220 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3
 ACCESSION NUMBER: 2008:1162068 HCAPLUS Full-text
 DOCUMENT NUMBER: 149:402057
 TITLE: Nitrosated derivatives of 2,5-dihydroxybenzene compounds and their preparation and use in the treatment of diseases
 INVENTOR(S): Gimenez Gallego, Guillermo; Saenz De Tejada Gorman, Inigo; Cuevas Sanchez, Pedro; Angulo Frutos, Javier; Valverde Lopez, Serafin
 PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
 SOURCE: PCT Int. Appl., 147pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008113863	A2	20080925	WO 2008-EP53455	20080324 <--
WO 2008113863	A3	20081211		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW


RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: ES 2007-764 A 20070322
 ES 2007-2037 A 20070720

OTHER SOURCE(S): CASREACT 149:402057; MARPAT 149:402057


ED Entered STN: 26 Sep 2008

GI



AB The invention relates to nitrosated derivs. of 2,5-dihydroxybenzene compds. of formula I that are useful in the preparation of medicinal products for the treatment of different diseases. The diseases in question are, in particular: cancer, rosacea, psoriasis, fibrosis, hemangiomas, ocular diseases, skin pigmentation and skin hyperpigmentation, diseases associated with amyloidosis, dermatitis, actinic and seborrheic keratosis, erectile dysfunction, female sexual dysfunction, arterial hypertension, atherosclerosis, inflammatory diseases in particular, arthritis, glomerulonephritis and asthma, intestinal inflammatory diseases in particular, ulcerative colitis and Crohn's disease, benign prostatic hyperplasia, Leishmaniasis, angiogenesis associated to chronic temporal lobe epilepsy, pain, hyperlipidemia and thrombosis. Compds. of formula I wherein R¹ is (CH₂)₀-6SO₃H and derivs., (CH₂)₀-6PO₃H and derivs., (CH₂)₀-6CO₂H and derivs., CH=CH(CH₂)₀-6SO₃H and derivs., CH=CH(CH₂)₀-6PO₃H and derivs., and CH=CH(CH₂)₀-6CO₂H and derivs.; R⁹ and R^{9'} are independently OH and derivs. and O-acyl, with the proviso that at least one of R⁹ and R^{9'} is OH derivative; and their salts, isomers, prodrugs and solvates thereof, are claimed. Example compound II was prepared by esterification of 5-bromovaleric acid with 4-nitrophenol; the resulting 5-bromovaleric acid 4-nitrophenyl ester underwent nitrosation with silver nitrate to give 5-nitrooxyvaleric acid 4-nitrophenyl ester, which underwent sulfonylation and substitution to give

- compound II. All the invention compds. were evaluated for their FGF-1 inhibitory activity (data given).
- CC 25-13 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
- IT Skin, disease
(hyperpigmentation, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)
- IT Skin, disease
(rosacea, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)
- IT Arthritis
Asthma
Atherosclerosis
Crohn disease
Dermatitis
Eye, disease
Fibrosis
Glomerulonephritis
Hemangioma
Hyperlipidemia
Hypertension
Inflammation
Neuroglia, neoplasm
Pain
Pigmentation disorders
Psoriasis
Thrombosis
Ulcerative colitis
(treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)
- IT 100-02-7, 4-Nitrophenol, reactions 2067-33-6, 5-Bromovaleric acid
20123-80-2, Calcium dobesilate 21799-87-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)
- IT 20123-80-2, Calcium dobesilate 21799-87-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)
- RN 20123-80-2 HCAPLUS
- CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)




● 1/2 Ca

RN 21799-87-1 HCAPLUS

11/839,520

CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

L220 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 4
 ACCESSION NUMBER: 2008:223860 HCAPLUS Full-text
 DOCUMENT NUMBER: 148:276752
 TITLE: Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of fibrosis
 INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Lozano Puerto, Rosa Maria; Romero Garrido, Antonio; Valverde Lopez, Serafin
 PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020040	A2	20080221	WO 2007-EP58454	20070815
WO 2008020040	A3	20080410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
ES 2315118	A1	20090316	ES 2006-2218	20060816 <--
US 20080113947	A1	20080515	US 2007-839515	20070815
US 20080113948	A1	20080515	US 2007-839520	20070815
US 20080114060	A1	20080515	US 2007-839522	20070815
US 20080125486	A1	20080529	US 2007-839525	20070815
PRIORITY APPLN. INFO.:			ES 2006-2218	A 20060816
			ES 2007-1856	A 20070702
OTHER SOURCE(S):		MARPAT 148:276752		

ED Entered STN: 22 Feb 2008

AB The invention relates to the use of a 2,5-dihydroxybenzene derivative or a pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in preparing a medicinal product for the treatment and/or prophylaxis of fibrosis.

CC 1-9 (Pharmacology)

IT Epidermal growth factor receptors
 Fibroblast growth factor receptors
 Vascular endothelial growth factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; use of hydroxybenzene compds. and derivs. for treatment of fibrosis)

IT Angiogenesis inhibitors
 Anti-inflammatory agents
 Antifibrotic agents
 Antimicrobial agents
 Antioxidants
 Antitumor agents
 Apoptosis
 Buccal drug delivery systems
 Burn
 Chronic obstructive pulmonary disease
 Emphysema
 Endothelin receptor antagonists
 Human
 Immunomodulators
 Inhalation drug delivery systems
 Keloid
 Lung, neoplasm
 NMDA receptor antagonists
 Neuroglia, neoplasm
 Ophthalmic drug delivery systems
 Oral drug delivery systems
 Otic drug delivery systems
 Parenteral drug delivery systems
 Prodrugs
 Prophylaxis
 Prostate gland, neoplasm
 Pulmonary fibrosis
 Rectal drug delivery systems
Scleroderma
 Topical drug delivery systems
Transdermal drug delivery systems
 Vaginal drug delivery systems
 (use of hydroxybenzene compds. and derivs. for treatment of fibrosis)

IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 80449-02-1 127464-60-2, Vascular endothelial growth factor 141436-78-4, Protein kinase C
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; use of hydroxybenzene compds. and derivs. for treatment of fibrosis)

IT 69-72-7, Salicylic acid, biological studies 88-46-0D, ester derivs. 123-31-9D, 1,4-Dihydroxybenzene, derivs. 490-79-9, Gentisic acid 636-01-1, 2,5-Dihydroxycinnamic acid 1084-96-4
 5330-25-6 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
51579-69-2 57775-26-5 59687-22-8
 59687-73-9 60630-38-8 71761-06-3D, Vitamin D5, analogs
79122-68-2 79365-88-1 90447-15-7 159252-66-1
159252-66-1D, ester derivs. 748106-93-6
1007839-71-5 1007839-72-6 1007839-72-6D,

11/839,520

ester derivs.	<u>1007839-87-3</u>	<u>1007839-89-5</u>	
<u>1007839-91-9</u>	<u>1007839-93-1</u>	<u>1007839-94-2</u>	
<u>1007839-96-4</u>	<u>1007840-02-9</u>	<u>1007840-05-2</u>	<u>1007840-08-5</u>
<u>1007840-09-6</u>	<u>1007840-11-0</u>	<u>1007840-12-1</u>	<u>1007840-13-2</u>
<u>1007840-16-5</u>	<u>1007840-17-6</u>	<u>1007840-18-7</u>	
<u>1007840-19-8</u>	<u>1007840-20-1</u>	<u>1007840-21-2</u>	
<u>1007849-27-5</u>			

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(use of hydroxybenzene compds. and derivs. for treatment of fibrosis)


IT 88-46-0D, ester derivs. 636-01-1,
2,5-Dihydroxycinnamic acid 21799-87-1, Potassium
2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5
59687-22-8 60630-38-8 79122-68-2
159252-66-1 159252-66-1D, ester derivs.
748106-93-6 1007839-71-5 1007839-72-6
1007839-72-6D, ester derivs. 1007839-87-3
1007839-89-5 1007839-91-9 1007839-93-1
1007839-94-2 1007839-96-4 1007840-16-5
1007840-17-6 1007840-18-7 1007840-19-8
1007840-20-1 1007840-21-2 1007849-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(use of hydroxybenzene compds. and derivs. for treatment of fibrosis)


RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 636-01-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)




RN 21799-87-1 HCAPLUS


CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 51579-69-2 HCAPLUS
 CN Benzenesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
 CN Benzenesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 59687-22-8 HCAPLUS
 CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 60630-38-8 HCAPLUS
 CN Benzenesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)

11/839,520



RN 79122-68-2 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 159252-66-1 HCAPLUS


CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 159252-66-1 HCAPLUS


CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K


RN 748106-93-6 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-71-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS


CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 1007839-72-6 HCAPLUS


CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K


RN 1007839-87-3 HCAPLUS

CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl) sulfonyl]oxy]- (CA INDEX NAME)




RN 1007839-89-5 HCAPLUS

CN Benzenemethanesulfonic acid, 2-hydroxy-5-[(4-methylphenyl)sulfonyl]oxy- (CA INDEX NAME)




RN 1007839-91-9 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis[(4-methylphenyl)sulfonyl]oxy- (CA INDEX NAME)




RN 1007839-93-1 HCAPLUS

CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-94-2 HCAPLUS

CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-96-4 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 1007840-16-5 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-17-6 HCAPLUS


CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-18-7 HCAPLUS


CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA
INDEX NAME)

11/839,520




RN 1007840-19-8 HCAPLUS

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-21-2 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

L220 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 5
 ACCESSION NUMBER: 2008:221345 HCAPLUS Full-text
 DOCUMENT NUMBER: 148:276712
 TITLE: Use of 2,5-dihydroxybenzene compounds and derivatives
 for the treatment of hematological dyscrasias and
 cancer of an organ
 INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego,
Guillermo; Saenz de Tejada Gorman, Inigo;
Angulo Frutos, Javier; Lozano Puerto,
Rosa Maria; Romero Garrido, Antonio;
Valverde Lopez, Serafin
 PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
 SOURCE: PCT Int. Appl., 92 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020039	A2	20080221	WO 2007-EP58453	20070815
WO 2008020039	A3	20080918		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
ES 2315118	A1	20090316	ES 2006-2218	20060816 <--
US 20080113947	A1	20080515	US 2007-839515	20070815
US 20080113948	A1	20080515	US 2007-839520	20070815
US 20080114060	A1	20080515	US 2007-839522	20070815
US 20080125486	A1	20080529	US 2007-839525	20070815
EP 2061453	A2	20090527	EP 2007-802619	20070815
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRIORITY APPLN. INFO.:			ES 2006-2218	A 20060816
			ES 2007-1856	A 20070702
			WO 2007-EP58453	W 20070815

OTHER SOURCE(S): MARPAT 148:276712

ED Entered STN: 21 Feb 2008

AB The present invention refers to the use of a 2,5-dihydroxybenzene derivative or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of hematol. dyscrasias, including myelodysplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a 2,5-dihydroxybenzene derivative in the manufacturing of a medicament for the treatment and/or prophylaxis of cancer of an organ.

CC 1-6 (Pharmacology)

IT Angiogenesis inhibitors

Anti-inflammatory agents

Antimicrobial agents

Antioxidants

Antitumor agents

Apoptosis

Bladder, neoplasm

Brain, neoplasm

Buccal drug delivery systems

Cervix, neoplasm

Colon neoplasm

Endothelin receptor antagonists

Fibrosis

Human

Immunomodulators

Immunotherapy

Inhalation drug delivery systems

Kidney, neoplasm

Leukemia

Lung, neoplasm

Mammary gland, neoplasm

Metastasis

Myelodysplastic syndromes

NMDA receptor antagonists

Neoplasm

Neuroglia, neoplasm

Ophthalmic drug delivery systems

Oral drug delivery systems

Otic drug delivery systems

Ovary, neoplasm

Pancreas, neoplasm

Parenteral drug delivery systems

Prodrugs

Prophylaxis

Prostate gland, neoplasm

Radiotherapy

Rectal drug delivery systems

Rectal neoplasm

Sarcoma

Testis, neoplasm

Thyroid gland, neoplasm

Topical drug delivery systems

Transdermal drug delivery systems

Vaginal drug delivery systems

(use of hydroxybenzene compds. and derivs. for treatment of hematol. dyscrasias and cancer)

IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 127464-60-2, Vascular endothelial growth factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(antagonists; use of hydroxybenzene compds. and derivs. for treatment of hematomol. dyscrasias and cancer)

IT 69-72-7, Salicylic acid, biological studies 88-46-0,
2,5-Dihydroxybenzenesulfonic acid 88-46-0D, ester derivs.
123-31-9D, 1,4-Dihydroxybenzene, derivs. 451-13-8, Homogentisic acid
490-79-9, Gentisic acid 636-01-1, 2,5-Dihydroxycinnamic acid
1084-96-4 1406-16-2D, Vitamin D, analogs 5330-25-6 16094-44-3
21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
51579-69-2 57775-26-5 59687-22-8
59687-73-9 60630-38-8 67127-91-7 79122-68-2
79365-88-1 79755-47-8 90447-15-7 159252-66-1
159252-66-1D, ester derivs. 748106-93-6 814262-90-3
1007839-71-5 1007839-72-6D, ester derivs.
1007839-87-3 1007839-89-5 1007839-91-9
1007839-93-1 1007839-94-2 1007839-96-4
1007840-02-9 1007840-05-2 1007840-08-5 1007840-09-6 1007840-11-0
1007840-12-1 1007840-13-2 1007840-14-3 1007840-15-4
1007840-16-5 1007840-17-6 1007840-18-7
1007840-19-8 1007840-20-1 1007840-21-2
1007840-22-3 1007840-23-4 1007840-24-5
1007849-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(use of hydroxybenzene compds. and derivs. for treatment of hematomol.
dyscrasias and cancer)


IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D,
ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid
21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
51579-69-2 57775-26-5 59687-22-8
60630-38-8 79122-68-2 159252-66-1
159252-66-1D, ester derivs. 748106-93-6
1007839-71-5 1007839-72-6D, ester derivs.
1007839-87-3 1007839-89-5 1007839-91-9
1007839-93-1 1007839-94-2 1007839-96-4
1007840-16-5 1007840-17-6 1007840-18-7
1007840-19-8 1007840-20-1 1007840-21-2
1007840-22-3 1007840-23-4 1007840-24-5
1007849-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(use of hydroxybenzene compds. and derivs. for treatment of hematomol.
dyscrasias and cancer)


RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 636-01-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 21799-87-1 HCAPLUS


CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 51579-69-2 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis[[4-(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS


CN Benzenesulfonic acid, 2-hydroxy-5-[[4-(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)

11/839,520




RN 59687-22-8 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 60630-38-8 HCAPLUS

CN Benzenesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)




● K

RN 159252-66-1 HCAPLUS


CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)

11/839,520




RN 159252-66-1 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 748106-93-6 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-71-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-72-6 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 1007839-87-3 HCAPLUS

CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)




RN 1007839-89-5 HCAPLUS

CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)




RN 1007839-91-9 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA
INDEX NAME)




RN 1007839-93-1 HCAPLUS

CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-94-2 HCAPLUS

CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-96-4 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS


CN 2-Propenoic acid, 3-[5-hydroxy-2-[[[(4-methylphenyl)sulfonyl]oxy]phenyl]]- (CA INDEX NAME)



RN 1007840-17-6 HCAPLUS


CN 2-Propenoic acid, 3-[2-hydroxy-5-[[[(4-methylphenyl)sulfonyl]oxy]phenyl]]- (CA INDEX NAME)

11/839,520




RN 1007840-18-7 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis[[4-methylphenyl]sulfonyl]oxy]phenyl]- (CA INDEX NAME)




RN 1007840-19-8 HCAPLUS

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-21-2 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)




RN 1007840-22-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-23-4 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-24-5 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

L220 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 6
 ACCESSION NUMBER: 2008:221788 HCAPLUS Full-text
 DOCUMENT NUMBER: 148:276732
 TITLE: Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain
 INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Lozano Puerto, Rosa Maria; Romero Garrido, Antonio; Valverde Lopez, Serafin
 PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
 SOURCE: PCT Int. Appl., 134pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020033	A1	20080221	WO 2007-EP58446	20070815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2315117	A1	20090316	ES 2006-2217	20060816
US 20080114063	A1	20080515	US 2007-839529	20070815
EP 2054045	A1	20090506	EP 2007-788431	20070815
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRIORITY APPLN. INFO.:			ES 2006-2217	A 20060816
			ES 2007-1855	A 20070702
			WO 2007-EP58446	W 20070815

OTHER SOURCE(S): MARPAT 148:276732

ED Entered STN: 21 Feb 2008

AB The present invention relates to the use of 2,5-dihydroxybenzene derivs. or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the

- manufacturing of a medicament for the treatment and/or prophylaxis of arthritis and pain.
- CC 1-7 (Pharmacology)
Section cross-reference(s): 63
- IT Arthritis
(lupus-related, psoriasis-related, infectious, viral, parasitic, bacterial; use of hydroxybenzene derivs. for treatment of arthritis and pain)
- IT Analgesics
Anesthetics
Angiogenesis inhibitors
Anti-inflammatory agents
Antiandrogens
Antiarthritics
Antiasthmatics
Antibiotics
Antioxidants
Antirheumatic agents
Antitumor agents
Asthma
Buccal drug delivery systems
Cholinergic antagonists
Crohn disease
Endometriosis
Gastroenteritis
Gout
Hemangioma
Human
Immunomodulators
Immunosuppressants
Inhalation drug delivery systems
Leishmaniasis
Neuroglia, neoplasm
Nonsteroidal anti-inflammatory drugs
Ophthalmic drug delivery systems
Oral drug delivery systems
Osteoarthritis
Otic drug delivery systems
Pain
Parasiticides
Parenteral drug delivery systems
Pharmaceutical creams
Pharmaceutical gels
Pharmaceutical solids
Pharmaceutical solutions
Prodrugs
Prophylaxis
Rectal drug delivery systems
Rheumatoid arthritis
Topical drug delivery systems
Transdermal drug delivery systems
Ulcerative colitis
Vaginal drug delivery systems
 α -Adrenoceptor antagonists
 β -Adrenoceptor agonists
(use of hydroxybenzene derivs. for treatment of arthritis and pain)
- IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; use of hydroxybenzene derivs. for treatment of arthritis)

and pain)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D,
 2,5-Dihydroxybenzenesulfonic acid, ester derivs. 636-01-1,
 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium
 2,5-dihydroxybenzenesulfonate 28088-64-4D, Aminosalicylic acid, derivs.
51579-69-2 57775-26-5 59687-22-8
60630-38-8 63177-57-1 79122-68-2
159252-66-1 159252-66-1D, ester derivs.
748106-93-6 1007839-71-5 1007839-72-6D,
 ester derivs. 1007839-87-3 1007839-89-5
1007839-91-9 1007839-93-1 1007839-94-2
1007839-96-4 1007840-16-5 1007840-17-6
1007840-18-7 1007840-19-8 1007840-20-1
1007840-21-2 1007840-22-3 1007840-23-4
1007840-24-5 1007849-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(use of hydroxybenzene derivs. for treatment of arthritis and pain)


IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D,
 2,5-Dihydroxybenzenesulfonic acid, ester derivs. 636-01-1,
 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium
 2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5
59687-22-8 60630-38-8 79122-68-2
159252-66-1 159252-66-1D, ester derivs.
748106-93-6 1007839-71-5 1007839-72-6D,
 ester derivs. 1007839-87-3 1007839-89-5
1007839-91-9 1007839-93-1 1007839-94-2
1007839-96-4 1007840-16-5 1007840-17-6
1007840-18-7 1007840-19-8 1007840-20-1
1007840-21-2 1007840-22-3 1007840-23-4
1007840-24-5 1007849-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(use of hydroxybenzene derivs. for treatment of arthritis and pain)


RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 88-46-0 HCAPLUS


CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



11/839,520


RN 636-01-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)




RN 21799-87-1 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 51579-69-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS


CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



11/839,520


RN 59687-22-8 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 60630-38-8 HCAPLUS

CN Benzenesulfonic acid, 5-hydroxy-2-[[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 159252-66-1 HCAPLUS


CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




● K

11/839,520


RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-72-6 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]-


(CA INDEX NAME)



RN 1007839-89-5 HCAPLUS


CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)

RN 1007839-91-9 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA
INDEX NAME)


RN 1007839-93-1 HCAPLUS

CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-94-2 HCAPLUS

CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-96-4 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 1007840-16-5 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-17-6 HCAPLUS


CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-18-7 HCAPLUS


CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA
INDEX NAME)

11/839,520




RN 1007840-19-8 HCAPLUS

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-21-2 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)




RN 1007840-22-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-23-4 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-24-5 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 2008:223400 HCAPLUS Full-text

DOCUMENT NUMBER: 148:276783

TITLE: 2,5-Dihydroxybenzene for the treatment of psoriasis

INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo;

Angulo Frutos, Javier; Valverde Lopez,

Serafin; Romero Garrido, Antonio;

Lozano Puerto, Rosa Maria

PATENT ASSIGNEE(S): Action Medicines, S.L., Spain

SOURCE: PCT Int. Appl., 66pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020030	A1	20080221	WO 2007-EP58443	20070815 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM ES 2315118 A1 20090316 ES 2006-2218 20060816 <-- US 20080113947 A1 20080515 US 2007-839515 20070815 US 20080113948 A1 20080515 US 2007-839520 20070815 US 20080114060 A1 20080515 US 2007-839522 20070815 US 20080125486 A1 20080529 US 2007-839525 20070815 EP 2056814 A1 20090513 EP 2007-788429 20070815 <-- R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS PRIORITY APPLN. INFO.: ES 2006-2218 A 20060816 ES 2007-1856 A 20070702 WO 2007-EP58443 W 20070815				

OTHER SOURCE(S): MARPAT 148:276783

ED Entered STN: 22 Feb 2008

AB The invention relates to the use of a 2,5-dihydroxybenzene derivative or a pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in preparing a medicinal product for the treatment and/or prophylaxis of psoriasis.

CC 1-12 (Pharmacology)

ST hydroxybenzene deriv psoriasis therapy

IT Epidermal growth factor receptors

Fibroblast growth factor receptors

Hepatocyte growth factor

Hepatocyte growth factor receptors

Vascular endothelial growth factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antagonists; hydroxybenzene derivs. for treatment of psoriasis)

IT Therapy

(coadjuvant; hydroxybenzene derivs. for treatment of psoriasis)

IT Angiogenesis inhibitors

Anti-inflammatory agents

Antimicrobial agents

Antioxidants

Antitumor agents

Apoptosis

Buccal drug delivery systems

Endothelin receptor antagonists
 Fibrosis
 Human
 Immunomodulators
 Lung, neoplasm
 Neuroglia, neoplasm
 Oral drug delivery systems
 Otic drug delivery systems
 Parenteral drug delivery systems
 Photodynamic therapy
 Phototherapy
 Prodrugs
 Prophylaxis
 Prostate gland, neoplasm

Psoriasis

Rectal drug delivery systems
 Topical drug delivery systems
Transdermal drug delivery systems
 (hydroxybenzene derivs. for treatment of psoriasis)

IT Corticosteroids, biological studies
 Retinoids

Steroids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (hydroxybenzene derivs. for treatment of psoriasis)

IT Fibroblast

(mitogenesis; hydroxybenzene derivs. for treatment of psoriasis
)

IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal
 growth factor 127464-60-2, Vascular endothelial growth factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antagonists; hydroxybenzene derivs. for treatment of psoriasis
)

IT 106096-92-8, FGF-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (hydroxybenzene derivs. for treatment of psoriasis)

IT 59-05-2, Methotrexate 69-72-7, Salicylic acid, biological studies
~~88-46-0~~, 2,5-Dihydroxybenzenesulfonic acid 110-17-8D,
 2-Butenedioic acid (2E)-, derivs. 123-31-9D, 1,4-Dihydroxybenzene,
 derivs. 490-79-9, Gentisic acid ~~636-01-1~~,
 2,5-Dihydroxycinnamic acid 1406-16-2D, Vitamin D, analogs
~~21799-87-1~~, Potassium 2,5-Dihydroxybenzenesulfonate
~~21799-87-1D~~, ester derivs. ~~51579-69-2~~
~~57775-26-5~~ ~~59687-22-8~~ 59865-13-3, Cyclosporin
~~60630-38-8~~ ~~79122-68-2~~ ~~159252-66-1~~
~~159252-66-1D~~, ester derivs. 170277-31-3, Infliximab
 185243-69-0, Etanercept 214745-43-4, Efalizumab 222535-22-0, Alefacept
 331731-18-1, Adalimumab ~~748106-93-6~~ ~~1007839-71-5~~
~~1007839-72-6D~~, ester derivs. ~~1007839-87-3~~
~~1007839-89-5~~ ~~1007839-91-9~~ ~~1007839-93-1~~
~~1007839-94-2~~ ~~1007839-96-4~~ ~~1007840-16-5~~
~~1007840-17-6~~ ~~1007840-18-7~~ ~~1007840-19-8~~
~~1007840-20-1~~ ~~1007840-21-2~~ ~~1007840-22-3~~
~~1007840-23-4~~ ~~1007840-24-5~~ ~~1007849-27-5~~

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(hydroxybenzene derivs. for treatment of psoriasis)


IT 80449-02-1, Protein tyrosine kinase 141436-78-4, Protein kinase C
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; hydroxybenzene derivs. for treatment of psoriasis)

)
 IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 636-01-1,
 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium
 2,5-Dihydroxybenzenesulfonate 21799-87-1D, ester derivs.
51579-69-2 57775-26-5 59687-22-8
60630-38-8 79122-68-2 159252-66-1
159252-66-1D, ester derivs. 748106-93-6
1007839-71-5 1007839-72-6D, ester derivs.
1007839-87-3 1007839-89-5 1007839-91-9
1007839-93-1 1007839-94-2 1007839-96-4
1007840-16-5 1007840-17-6 1007840-18-7
1007840-19-8 1007840-20-1 1007840-21-2
1007840-22-3 1007840-23-4 1007840-24-5
1007849-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (hydroxybenzene derivs. for treatment of psoriasis)


RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 636-01-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 21799-87-1 HCAPLUS


CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K


RN 21799-87-1 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 51579-69-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 57775-26-5 HCAPLUS

CN Benzenesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



11/839,520


RN 60630-38-8 HCAPLUS

CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 159252-66-1 HCAPLUS


CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 159252-66-1 HCAPLUS


CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K


RN 748106-93-6 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-71-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-72-6 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 1007839-87-3 HCAPLUS

CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 1007839-89-5 HCAPLUS

CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 1007839-91-9 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 1007839-93-1 HCAPLUS

CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-94-2 HCAPLUS

CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-96-4 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 1007840-16-5 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)




RN 1007840-17-6 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)




RN 1007840-18-7 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis[[4-methylphenyl)sulfonyl]oxy]phenyl]- (CA
INDEX NAME)




RN 1007840-19-8 HCAPLUS

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-21-2 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)




RN 1007840-22-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-23-4 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-24-5 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 8

ACCESSION NUMBER: 2008:223941 HCAPLUS Full-text

DOCUMENT NUMBER: 148:276785

TITLE: 2,5-Dihydroxybenzene compounds for the treatment of Rosacea

INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria

PATENT ASSIGNEE(S): Action Medicines, S.L., Spain

SOURCE: PCT Int. Appl., 67pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020028	A1	20080221	WO 2007-EP58441	20070815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,				

KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

ES 2315118	A1	20090316	ES 2006-2218	20060816 <--
US 20080113947	A1	20080515	US 2007-839515	20070815
US 20080113948	A1	20080515	US 2007-839520	20070815
US 20080114060	A1	20080515	US 2007-839522	20070815
US 20080125486	A1	20080529	US 2007-839525	20070815
EP 2056813	A1	20090513	EP 2007-788428	20070815

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
 AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.:

ES 2006-2218	A	20060816
ES 2007-1856	A	20070702
WO 2007-EP58441	W	20070815

OTHER SOURCE(S): MARPAT 148:276785

ED Entered STN: 22 Feb 2008

AB The invention relates to the use of a 2,5-dihydroxybenzene derivative or a
 pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in
 preparing a medicinal product for the treatment and/or prophylaxis of rosacea.


CC 1-12 (Pharmacology)

IT Epidermal growth factor receptors
 Fibroblast growth factor receptors
 Hepatocyte growth factor
 Hepatocyte growth factor receptors
 Vascular endothelial growth factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antagonists; hydroxybenzene compds. for treatment of Rosacea)


IT Angiogenesis inhibitors
 Anti-inflammatory agents
 Antimicrobial agents
 Antioxidants
 Antitumor agents
 Apoptosis
 Buccal drug delivery systems
 Endothelin receptor antagonists
 Fibrosis
 Human
 Immunomodulators
 Inhalation drug delivery systems
 Lung, neoplasm
 Neuroglia, neoplasm
 Ophthalmic drug delivery systems
 Oral drug delivery systems
 Otic drug delivery systems
 Parenteral drug delivery systems
 Prodrugs
 Prophylaxis
 Prostate gland, neoplasm
 Rectal drug delivery systems
 Topical drug delivery systems
Transdermal drug delivery systems
 Vasoconstrictors
 (hydroxybenzene compds. for treatment of Rosacea)

- IT Skin, disease
(rosacea, erythematotelangiectatic, papulopustular, phymatous, ocular;
hydroxybenzene compds. for treatment of Rosacea)
- IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal
growth factor 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; hydroxybenzene compds. for treatment of Rosacea)
- IT 69-72-7, Salicylic acid, biological studies 80-08-0, Dapsone
88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D,
ester derivs. 123-31-9D, 1,4-Dihydroxybenzene, derivs. 443-48-1,
Metronidazole 490-79-9, Gentisic acid 636-01-1,
2,5-Dihydroxycinnamic acid 1406-16-2D, Vitamin D, analogs
21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
51579-69-2 57775-26-5 59687-22-8
60630-38-8 79122-68-2 159252-66-1
159252-66-1D, ester derivs. 748106-93-6
1007839-71-5 1007839-72-6D, ester derivs.
1007839-87-3 1007839-89-5 1007839-91-9
1007839-93-1 1007839-94-2 1007839-96-4
1007840-16-5 1007840-17-6 1007840-18-7
1007840-19-8 1007840-20-1 1007840-21-2
1007840-22-3 1007840-23-4 1007840-24-5
1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(hydroxybenzene compds. for treatment of Rosacea)
- IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D,
ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid
21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
51579-69-2 57775-26-5 59687-22-8
60630-38-8 79122-68-2 159252-66-1
159252-66-1D, ester derivs. 748106-93-6
1007839-71-5 1007839-72-6D, ester derivs.
1007839-87-3 1007839-89-5 1007839-91-9
1007839-93-1 1007839-94-2 1007839-96-4
1007840-16-5 1007840-17-6 1007840-18-7
1007840-19-8 1007840-20-1 1007840-21-2
1007840-22-3 1007840-23-4 1007840-24-5
1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(hydroxybenzene compds. for treatment of Rosacea)
- RN 88-46-0 HCAPLUS
- CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




- RN 88-46-0 HCAPLUS
- CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)

11/839,520




RN 636-01-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 21799-87-1 HCAPLUS


CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 51579-69-2 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS


CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)

11/839,520




RN 59687-22-8 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 60630-38-8 HCAPLUS

CN Benzenesulfonic acid, 5-hydroxy-2-[(4-methylphenyl)sulfonyl]oxy)- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



● K


RN 159252-66-1 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 159252-66-1 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 748106-93-6 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-71-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-72-6 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 1007839-87-3 HCAPLUS

CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)




RN 1007839-89-5 HCAPLUS

CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)




RN 1007839-91-9 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA
INDEX NAME)




RN 1007839-93-1 HCAPLUS

CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-94-2 HCAPLUS

CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-96-4 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS


CN 2-Propenoic acid, 3-[5-hydroxy-2-[[4-(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-17-6 HCAPLUS


CN 2-Propenoic acid, 3-[2-hydroxy-5-[[4-(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)

11/839,520




RN 1007840-18-7 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis[[4-methylphenyl]sulfonyl]oxy]phenyl]- (CA INDEX NAME)




RN 1007840-19-8 HCAPLUS

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-21-2 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)




RN 1007840-22-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-23-4 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-24-5 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 9

ACCESSION NUMBER: 2008:223605 HCAPLUS Full-text

DOCUMENT NUMBER: 148:276717

TITLE: Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer

INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria

PATENT ASSIGNEE(S): Action Medicines, S.L., Spain

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020027	A2	20080221	WO 2007-EP58440	20070815
WO 2008020027	A3	20080410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
ES 2315118	A1	20090316	ES 2006-2218	20060816 <--
US 20080113947	A1	20080515	US 2007-839515	20070815
US 20080113948	A1	20080515	US 2007-839520	20070815
US 20080114060	A1	20080515	US 2007-839522	20070815
US 20080125486	A1	20080529	US 2007-839525	20070815
PRIORITY APPLN. INFO.:			ES 2006-2218	A 20060816
			ES 2007-1856	A 20070702

OTHER SOURCE(S): MARPAT 148:276717

ED Entered STN: 22 Feb 2008

AB The invention relates to the use of a 2,5-dihydroxybenzene derivative or pharmaceutically acceptable salts or solvates, isomers or prodrugs thereof in

the manufacture of a medicament for the therapeutic and/or prophylactic treatment of skin cancer.

CC 1-6 (Pharmacology)

ST antitumor hydroxybenzene deriv skin cancer therapy

IT Carcinoma
 (Merkel cell, sweat gland, sebaceous gland; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Epidermal growth factor receptors
 Fibroblast growth factor receptors
 Hepatocyte growth factor
 Hepatocyte growth factor receptors
 Vascular endothelial growth factor receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antagonists; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Skin, neoplasm
 (basal cell carcinoma; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Carcinoma
 (basal cell; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Sebaceous gland
 (carcinoma; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Therapy
 (cryotherapy, curettage and coadjuvant; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Tyrosine kinase receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Skin, neoplasm
 (keratoacanthoma; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Disease, animal
 (lentigo maligna; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Fibroblast
 (mitogenesis; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Leukotrienes
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (modifiers; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Interleukin receptors
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (solubilized; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Carcinoma
 (squamous cell; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Analgesics
 Anesthetics
 Angiogenesis inhibitors
 Antibiotics
 Antitumor agents
 Apoptosis
 Buccal drug delivery systems
 Cutaneous T-cell lymphoma

Fibrosis
Hemangiosarcoma
Human
Immunomodulators
Inhalation drug delivery systems
Lung, neoplasm
Melanoma
Neuroglia, neoplasm
Nonsteroidal anti-inflammatory drugs
Ophthalmic drug delivery systems
Oral drug delivery systems
Otic drug delivery systems
Parenteral drug delivery systems
Photodynamic therapy
Prodrugs
Prophylaxis
Prostate gland, neoplasm
Rectal drug delivery systems
Sarcoma
Skin, neoplasm
Surgery

Topical drug delivery systems

Transdermal drug delivery systems

Vaginal drug delivery systems

(use of hydroxybenzene compds. and derivs. for treatment of
skin cancer)

IT Corticosteroids

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(use of hydroxybenzene compds. and derivs. for treatment of
skin cancer)

IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal
growth factor 127464-60-2, Vascular endothelial growth factor

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(antagonists; use of hydroxybenzene compds. and derivs. for treatment
of skin cancer)

IT 141436-78-4, Protein kinase C

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; use of hydroxybenzene compds. and derivs. for treatment of
skin cancer)

IT 51-21-8, 5-Fluorouracil 64-86-8, Colchicine 76-03-9, Trichloroacetic
acid, biological studies ~~88-46-0~~, 2,5-Dihydroxybenzenesulfonic

acid ~~88-46-0D~~, ester derivs. 106-60-5, 5-Aminolevulinic acid

123-31-9D, 1,4-Dihydroxybenzene, derivs. 490-79-9, Gentisic acid

503-11-7, Glycidic acid 548-04-9, Hypericin ~~636-01-1~~,

2,5-Dihydroxycinnamic acid 4759-48-2, Isotretinoin 15307-86-5,

Diclofenac ~~21799-87-1~~, Potassium 2,5-dihydroxybenzenesulfonate

28088-64-4D, Aminosalicyclic acid, derivs. 33320-16-0, Methyl

aminolevulinate ~~51579-69-2~~ 52227-85-7, T4 Endonuclease V

55079-83-9, Acitretin ~~57775-26-5~~ ~~59687-22-8~~

~~60630-38-8~~ ~~79122-68-2~~ 99011-02-6, Imiquimod

113852-37-2, Cidofovir ~~159252-66-1~~ ~~159252-66-1D~~,

ester derivs. ~~748106-93-6~~ ~~1007839-71-5~~

~~1007839-72-6D~~, ester derivs. ~~1007839-87-3~~

~~1007839-89-5~~ ~~1007839-91-9~~ ~~1007839-93-1~~

~~1007839-94-2~~ ~~1007839-96-4~~ ~~1007840-16-5~~

~~1007840-17-6~~ ~~1007840-18-7~~ ~~1007840-19-8~~

~~1007840-20-1~~ ~~1007840-21-2~~ ~~1007840-22-3~~

~~1007840-23-4~~ ~~1007840-24-5~~ ~~1007849-27-5~~

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(use of hydroxybenzene compds. and derivs. for treatment of
skin cancer)


IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D,
 ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid
 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
 51579-69-2 57775-26-5 59687-22-8
 60630-38-8 79122-68-2 159252-66-1
 159252-66-1D, ester derivs. 748106-93-6
 1007839-71-5 1007839-72-6D, ester derivs.
 1007839-87-3 1007839-89-5 1007839-91-9
 1007839-93-1 1007839-94-2 1007839-96-4
 1007840-16-5 1007840-17-6 1007840-18-7
 1007840-19-8 1007840-20-1 1007840-21-2
 1007840-22-3 1007840-23-4 1007840-24-5
 1007849-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(use of hydroxybenzene compds. and derivs. for treatment of
skin cancer)


RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS


CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



11/839,520


RN 21799-87-1 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 51579-69-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 57775-26-5 HCAPLUS

CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS


11/839,520

CN Benzenesulfonic acid, 5-hydroxy-2-[[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 159252-66-1 HCAPLUS


CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K


RN 159252-66-1 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




● K


RN 748106-93-6 HCAPLUS
 CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-71-5 HCAPLUS
 CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-72-6 HCAPLUS
 CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
 CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl) sulfonyl]oxy]- (CA INDEX NAME)




RN 1007839-89-5 HCAPLUS
 CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl) sulfonyl]oxy]- (CA INDEX NAME)




RN 1007839-91-9 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 1007839-93-1 HCAPLUS

CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-94-2 HCAPLUS

CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-96-4 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 1007840-16-5 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)




RN 1007840-17-6 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)




RN 1007840-18-7 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis[[4-methylphenyl)sulfonyl]oxy]phenyl]- (CA
INDEX NAME)




RN 1007840-19-8 HCAPLUS

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-21-2 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)




RN 1007840-22-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-23-4 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-24-5 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

L220 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 10

ACCESSION NUMBER: 2008:221418 HCAPLUS Full-text

DOCUMENT NUMBER: 148:276779

TITLE: Use of 2,5-dihydroxybenzene derivatives for treating dermatitis

 INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain

SOURCE: PCT Int. Appl., 59pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020026	A1	20080221	WO 2007-EP58439	20070815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,				

11/839,520

PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

ES 2315119 A1 20090316 ES 2006-2219 20060816
US 20080114075 A1 20080515 US 2007-839512 20070815
EP 2056815 A1 20090513 EP 2007-788426 20070815

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.: ES 2006-2219 A 20060816
ES 2007-1857 A 20070702
WO 2007-EP58439 W 20070815

OTHER SOURCE(S): MARPAT 148:276779

ED Entered STN: 21 Feb 2008

AB The present invention relates to the use of a 2,5-dihydroxybenzene derivative
or a pharmaceutically acceptable salt or solvate thereof, isomer or prodrug
thereof to prepare a medicament for the therapeutic and/or prophylactic
treatment of dermatitis.

CC 1-12 (Pharmacology)

ST antiinflammatory hydroxybenzene deriv treating dermatitis
therapy

IT Dermatitis

(actinic, carcinomatous, diaper, stasis, radiation-induced; use of
hydroxybenzene derivs. for treating dermatitis)

IT Allergy

(allergic contact dermatitis; use of hydroxybenzene derivs.
for treating dermatitis)

IT Dermatitis

(allergic contact; use of hydroxybenzene derivs. for treating
dermatitis)

IT Epidermal growth factor receptors

Fibroblast growth factor receptors

Hepatocyte growth factor receptors

Tyrosine kinase receptors

Vascular endothelial growth factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(antagonists; use of hydroxybenzene derivs. for treating
dermatitis)

IT Dermatitis

(atopic; use of hydroxybenzene derivs. for treating dermatitis
)

IT Dermatitis

(contact; use of hydroxybenzene derivs. for treating dermatitis
)

IT Leukotrienes

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(modifiers; use of hydroxybenzene derivs. for treating
dermatitis)

IT Immunomodulators

(oral and topical; use of hydroxybenzene derivs. for treating
dermatitis)

IT Interleukin receptors


RL: BSU (Biological study, unclassified); BIOL (Biological study)

(solubilized; use of hydroxybenzene derivs. for treating
dermatitis)

IT Analgesics


Anesthetics
 Angiogenesis inhibitors
 Anti-inflammatory agents
 Antibiotics
 Buccal drug delivery systems
 Cell infiltration
Dermatomyositis
 Edema
 Immunosuppressants
 Inhalation drug delivery systems
 Leukocyte
Neurodermatitis
 Nonsteroidal anti-inflammatory drugs
 Oral drug delivery systems
 Otic drug delivery systems
 Parenteral drug delivery systems
 Prodrugs
 Prophylaxis
 Topical drug delivery systems
Transdermal drug delivery systems
 (use of hydroxybenzene derivs. for treating dermatitis)

- IT Corticosteroids
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of hydroxybenzene derivs. for treating dermatitis)
- IT 141436-78-4, Protein kinase C
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; use of hydroxybenzene derivs. for treating dermatitis)
- IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 636-01-1,
 2,5-Dihydroxycinnamic acid 4759-48-2, Isotretinoin 15307-86-5,
 Diclofenac 28088-64-4D, Aminosalicyclic acid, derivs.
51579-69-2 52227-85-7, T4 Endonuclease V 55079-83-9, Acitretin
57775-26-5 59687-22-8 60630-38-8
 104987-11-3, Tacrolimus 113852-37-2, Cidofovir 137071-32-0,
 Pimecrolimus 159252-66-1 748106-93-6
1007839-71-5 1007839-87-3 1007839-89-5
1007839-91-9 1007839-93-1 1007839-94-2
1007839-96-4 1007840-16-5 1007840-17-6
1007840-18-7 1007840-19-8 1007840-20-1
1007840-21-2 1007840-22-3 1007840-23-4
1007840-24-5 1007849-27-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of hydroxybenzene derivs. for treating dermatitis)
- IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 636-01-1,
 2,5-Dihydroxycinnamic acid 51579-69-2 57775-26-5
59687-22-8 60630-38-8 159252-66-1
748106-93-6 1007839-71-5 1007839-87-3
1007839-89-5 1007839-91-9 1007839-93-1
1007839-94-2 1007839-96-4 1007840-16-5
1007840-17-6 1007840-18-7 1007840-19-8
1007840-20-1 1007840-21-2 1007840-22-3
1007840-23-4 1007840-24-5 1007849-27-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of hydroxybenzene derivs. for treating dermatitis)
- RN 88-46-0 HCAPLUS
- CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 636-01-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)




RN 51579-69-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 57775-26-5 HCAPLUS

CN Benzenesulfonic acid, 2-hydroxy-5-[[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 59687-22-8 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 60630-38-8 HCAPLUS

CN Benzenesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 159252-66-1 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 748106-93-6 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-71-5 HCAPLUS


CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-87-3 HCAPLUS

CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)

RN 1007839-89-5 HCAPLUS


CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)

RN 1007839-91-9 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA
INDEX NAME)


RN 1007839-93-1 HCAPLUS

CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-94-2 HCAPLUS

CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-96-4 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 1007840-16-5 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-17-6 HCAPLUS


CN 2-Propenoic acid, 3-[2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-18-7 HCAPLUS


CN 2-Propenoic acid, 3-[2,5-bis[[4-methylphenyl)sulfonyl]oxy]phenyl]- (CA
INDEX NAME)

11/839,520




RN 1007840-19-8 HCAPLUS

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-21-2 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)




RN 1007840-22-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-23-4 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-24-5 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 11

ACCESSION NUMBER: 2008:223283 HCAPLUS Full-text

DOCUMENT NUMBER: 148:276782

TITLE: Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis

INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo;

Angulo Frutos, Javier; Valverde Lopez,

Serafin; Romero Garrido, Antonio;

Lozano Puerto, Rosa Maria

PATENT ASSIGNEE(S): Action Medicines, S.L., Spain

SOURCE: PCT Int. Appl., 79pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020025	A1	20080221	WO 2007-EP58438	20070815
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW	
RW:			AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
ES 2315119	A1	20090316	ES 2006-2219	20060816
US 20080114075	A1	20080515	US 2007-839512	20070815
EP 2054051	A1	20090506	EP 2007-788425	20070815
R:			AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS	

PRIORITY APPLN. INFO.: ES 2006-2219 A 20060816
 ES 2007-1857 A 20070702
 WO 2007-EP58438 W 20070815

OTHER SOURCE(S): MARPAT 148:276782

ED Entered STN: 22 Feb 2008

AB The present invention relates to the use of a 2,5-dihydroxybenzene derivative or a pharmaceutically acceptable salt or solvate thereof, isomer or prodrug thereof to prepare a medicament for the therapeutic and/or prophylactic treatment of actinic keratosis.

CC 1-12 (Pharmacology)

Section cross-reference(s): 63

IT Skin, disease

(photoaging; use of hydroxybenzene derivs. for treating actinic keratosis)

IT Skin, disease

(solar lentigos; use of hydroxybenzene derivs. for treating actinic keratosis)

IT Adipogenesis

Analgesics

Anesthetics

Antibiotics

Antitumor agents

Buccal drug delivery systems

Dermatological agents

Hair growth inhibitors

Human

Immunomodulators

Immunosuppressants

Inhalation drug delivery systems

Neuroglia, neoplasm

Nonsteroidal anti-inflammatory drugs

Obesity

Parenteral drug delivery systems

Pharmaceutical creams

Pharmaceutical emulsions

Photodynamic therapy

Prodrugs

Prophylaxis

Rectal drug delivery systems

Surgery

Topical drug delivery systems

Transdermal drug delivery systems

(use of hydroxybenzene derivs. for treating actinic keratosis)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(Dobesilate; use of hydroxybenzene derivs. for treating actinic keratosis)

IT 51-21-8, 5-Fluorouracil 64-86-8, Colchicine 76-03-9, Trichloroacetic acid, biological studies 88-46-0D,
2,5-Dihydroxybenzenesulfonic acid, monoesters 106-60-5, 5-Aminolevulinic acid 123-31-9D, 1,4-Dihydroxybenzene, derivs. 451-13-8, Homogentisic acid 490-79-9, Gentisic acid 503-11-7, Glycidic acid 548-04-9, Hypericin 636-01-1, 2,5-Dihydroxycinnamic acid 1084-96-4 2624-44-4, Ethamsylate 4759-48-2, Isotretinoin 5330-25-6 15307-86-5, Diclofenac 16094-44-3 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 28088-64-4D, Aminosalicyclic acid, derivs. 33320-16-0, Methyl aminolevulinate 51579-69-2 52227-85-7, T4 Endonuclease V 55079-83-9, Acitretin 57775-26-5 59687-22-8 59687-73-9 60630-38-8 67127-91-7 79122-68-2, Potassium 2,5-diacetoxybenzenesulfonate 79365-88-1 79755-47-8 90447-15-7 97225-83-7, Magnesium 2,5-dihydroxybenzenesulfonate 99011-02-6, Imiquimod 113852-37-2, Cidofovir 159252-66-1 159252-66-1D, monoesters 748106-93-6 814262-90-3 1007839-71-5 1007839-72-6D, monoesters 1007839-80-6 1007839-81-7 1007839-83-9 1007839-85-1 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007839-97-5 1007839-99-7 1007840-01-8 1007840-02-9 1007840-05-2 1007840-08-5 1007840-09-6 1007840-11-0 1007840-12-1 1007840-13-2 1007840-14-3 1007840-15-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(use of hydroxybenzene derivs. for treating actinic keratosis)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)


(Dobesilate; use of hydroxybenzene derivs. for treating actinic keratosis)

RN 88-46-0 HCAPLUS


CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



IT 88-46-0D, 2,5-Dihydroxybenzenesulfonic acid, monoesters
636-01-1, 2,5-Dihydroxycinnamic acid 2624-44-4,
 Ethamsylate 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate
21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
51579-69-2 57775-26-5 59687-22-8
60630-38-8 79122-68-2, Potassium
 2,5-diacetoxybenzenesulfonate 159252-66-1
159252-66-1D, monoesters 748106-93-6
1007839-71-5 1007839-72-6D, monoesters
1007839-87-3 1007839-89-5 1007839-91-9
1007839-93-1 1007839-94-2 1007839-96-4
1007840-16-5 1007840-17-6 1007840-18-7
1007840-19-8 1007840-20-1 1007840-21-2
1007840-22-3 1007840-23-4 1007840-24-5
1007849-27-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (use of hydroxybenzene derivs. for treating actinic keratosis)
 RN 88-46-0 HCAPLUS
 CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
 CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)




RN 2624-44-4 HCAPLUS
 CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)
 (CA INDEX NAME)

CM 1


11/839,520

CRN 109-89-7
CMF C4 H11 N




CM 2

CRN 88-46-0
CMF C6 H6 O5 S




RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)




● K

11/839,520


RN 51579-69-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 57775-26-5 HCAPLUS

CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 59687-22-8 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS


CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 79122-68-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)


11/839,520




RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-72-6 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 1007839-87-3 HCAPLUS

CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 HCAPLUS


CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 HCAPLUS


CN Benzenemethanesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)

11/839,520




RN 1007839-93-1 HCAPLUS

CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-94-2 HCAPLUS

CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS


CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS


CN 2-Propenoic acid, 3-[5-hydroxy-2-[[4-(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)

11/839,520




RN 1007840-17-6 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)




RN 1007840-18-7 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA
INDEX NAME)




RN 1007840-19-8 HCAPLUS

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-21-2 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)




RN 1007840-22-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-23-4 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-24-5 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS
 CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA
 INDEX NAME)



● 1/2 Ca

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L220 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 12
 ACCESSION NUMBER: 2008:646739 HCAPLUS Full-text
 DOCUMENT NUMBER: 149:1511
 TITLE: 2,5-dihydroxybenzene derivatives for treating actinic
 keratosis
 INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego,
Guillermo; Saenz De Tejada Morgan, Inigo
; Angulo Frutos, Javier; Valverde
Lopez, Serafin; Romero Garrido, Antonio
; Lozano Puerto, Rosa Maria
 PATENT ASSIGNEE(S): Action Medicines, Spain
 SOURCE: U.S. Pat. Appl. Publ., 43pp., Cont.-in-part of U.S.
 Ser. No. 506,469.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080125485	A1	20080529	US 2007-839508	20070815
ES 2238924	A1	20050901	ES 2004-371	20040217 <--
ES 2238924	B1	20061201		
WO 2005077352	A1	20050825	WO 2005-ES70017	20050216 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070149618	A1	20070628	US 2006-506469	20060816

11/839,520

ES 2315119 A1 20090316 ES 2006-2219 20060816
PRIORITY APPLN. INFO.: ES 2004-371 A 20040217
WO 2005-ES70017 W 20050216
US 2006-588166 A2 20060802
ES 2006-2219 A 20060816
US 2006-506469 A2 20060816
ES 2007-1857 A 20070702

OTHER SOURCE(S): MARPAT 149:1511
ED Entered STN: 30 May 2008
GI



AB The invention relates to the use of a 2,5-dihydroxybenzene derivative (I) [R1 = (CH2)aY, CH=CH(CH2)pY; a, p = 0-6; Y = SO3H, CO2H, etc.; R9, R9' = (un)substituted OH], or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof, for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.

INCL 514546000; 514553000; 514568000; 514548000

CC 1-12 (Pharmacology)
Section cross-reference(s): 63

IT Adipogenesis
Analgesics
Anesthetics
Angiogenesis inhibitors
Antiaging cosmetics
Antibiotics
Antiobesity agents
Antitumor agents
Buccal drug delivery systems
Combination chemotherapy
Cosmetic creams
Cytotoxic agents
Dermatological agents
Hair
Hair growth inhibitors
Immunomodulators
Immunosuppressants
Inhalation drug delivery systems
Neuroglia, neoplasm
Nonsteroidal anti-inflammatory drugs
Obesity
Ophthalmic drug delivery systems
Oral drug delivery systems
Pharmaceutical creams
Pharmaceutical emulsions
Photodynamic therapy
Prodrugs
Prophylaxis
Rectal drug delivery systems
Skin-lightening cosmetics
Surgery

Topical drug delivery systems

Transdermal drug delivery systems

Vaginal drug delivery systems

Wrinkle-preventing cosmetics

(2,5-dihydroxybenzene derivs. for treating actinic keratosis)

IT Skin, disease

(photoaging; 2,5-dihydroxybenzene derivs. for treating actinic keratosis)

IT Skin, disease

(solar lentigos; 2,5-dihydroxybenzene derivs. for treating actinic keratosis)

IT 21799-37-1

RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(2,5-dihydroxybenzene derivs. for treating actinic keratosis)

IT 51-21-8, 5-Fluorouracil 64-86-8, Colchicine 69-72-7D, Salicylic acid, derivs 76-03-9, Trichloroacetic acid, biological studies 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, magnesium complexes 106-60-5, 5-Aminolevulinic acid 123-31-9D, 1,4-Benzenediol, derivs., derivs., salts, or solvates, biological studies 451-13-8 451-13-8D, salts or solvates 490-79-9, 2,5-Dihydroxybenzoic acid 490-79-9D, salts or solvates 503-11-7, Glycidic acid 548-04-9, Hypericin 636-01-1 636-01-1D, salts or solvates 1084-96-4 1084-96-4D, salts or solvates 2624-44-4 4759-48-2, Isotretinoin 5330-25-6 5330-25-6D, salts or solvates 15307-86-5, Diclofenac 16094-44-3 16094-44-3D, salts or solvates 33320-16-0, Methyl aminolevulinate 37217-32-6, Bacteriophage T4 UV-endonuclease 51579-69-2 51579-69-2D, salts or solvates 55079-83-9, Acitretin 57775-26-5 57775-26-5D, salts or solvates 59687-22-8 59687-22-8D, complexes with FGF-1 59687-22-8D, salts or solvates 59687-73-9 59687-73-9D, salts or solvates 60630-38-8 60630-38-8D, salts or solvates 67127-91-7 67127-91-7D, salts or solvates 68864-98-2, 2,5-Dihydroxybenzenesulfonate 68864-98-2D, 2,5-Dihydroxybenzenesulfonate, esters; complexes with FGF-1 70790-72-6 79365-88-1 79365-88-1D, salts or solvates 79755-47-8 79755-47-8D, salts or solvates 90447-15-7 90447-15-7D, salts or solvates 99011-02-6, Imiquimod 106096-92-8D, Fibroblast growth factor-1, complexes with 2,5-dihydroxybenzenesulfonate esters 113852-37-2, Cidofovir 159252-66-1 748106-93-6 748106-93-6D, complexes with FGF-1 748106-93-6D, salts or solvates 814262-90-3 814262-90-3D, salts or solvates 1007839-71-5 1007839-71-5D, complexes with FGF-1 1007839-71-5D, salts or solvates 1007839-72-6 1007839-80-6 1007839-80-6D, salts or solvates 1007839-81-7 1007839-81-7D, salts or solvates 1007839-83-9 1007839-83-9D, salts or solvates 1007839-85-1 1007839-85-1D, salts or solvates 1007839-87-3 1007839-87-3D, salts or solvates 1007839-89-5 1007839-89-5D, salts or solvates 1007839-91-9 1007839-91-9D, salts or solvates 1007839-93-1 1007839-93-1D, salts or solvates 1007839-94-2 1007839-94-2D, salts or solvates 1007839-96-4 1007839-96-4D, salts or solvates 1007839-97-5 1007839-97-5D, salts or solvates 1007839-99-7 1007839-99-7D, salts or solvates 1007840-01-8 1007840-01-8D, salts or solvates 1007840-02-9 1007840-02-9D, salts or solvates 1007840-05-2 1007840-05-2D, salts or solvates 1007840-08-5 1007840-08-5D, salts or solvates 1007840-09-6 1007840-09-6D, salts or solvates 1007840-11-0 1007840-11-0D, salts or solvates 1007840-12-1 1007840-12-1D, salts or solvates 1007840-13-2 1007840-13-2D, salts or solvates 1007840-14-3

1007840-14-3D, salts or solvates 1007840-15-4 1007840-15-4D, salts or
solvates 1007840-16-5 1007840-16-5D, salts or
solvates 1007840-17-6 1007840-17-6D, salts or
solvates 1007840-18-7 1007840-18-7D, salts or
solvates 1007840-19-8 1007840-19-8D, salts or
solvates 1007840-20-1 1007840-20-1D, salts or
solvates 1007840-21-2 1007840-21-2D, salts or
solvates 1007840-22-3 1007840-22-3D, salts or
solvates 1007840-23-4 1007840-23-4D, salts or
solvates 1007840-24-5 1007840-24-5D, salts or
solvates

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(2,5-dihydroxybenzene derivs. for treating actinic keratosis)


IT 21799-87-1

RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)

(2,5-dihydroxybenzene derivs. for treating actinic keratosis)

RN 21799-87-1 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX
NAME)



● K

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D,
magnesium complexes 636-01-1 636-01-1D, salts or
solvates 2624-44-4 51579-69-2
51579-69-2D, salts or solvates 57775-26-5
57775-26-5D, salts or solvates 59687-22-8
59687-22-8D, complexes with FGF-1 60630-38-8
60630-38-8D, salts or solvates 70790-72-6
159252-66-1 748106-93-6 748106-93-6D,
complexes with FGF-1 1007839-71-5 1007839-71-5D,
complexes with FGF-1 1007839-72-6 1007839-87-3
1007839-87-3D, salts or solvates 1007839-89-5
1007839-89-5D, salts or solvates 1007839-91-9
1007839-91-9D, salts or solvates 1007839-93-1
1007839-93-1D, salts or solvates 1007839-94-2
1007839-94-2D, salts or solvates 1007839-96-4
1007839-96-4D, salts or solvates 1007840-16-5
1007840-16-5D, salts or solvates 1007840-17-6
1007840-17-6D, salts or solvates 1007840-18-7
1007840-18-7D, salts or solvates 1007840-19-8
1007840-19-8D, salts or solvates 1007840-20-1
1007840-20-1D, salts or solvates 1007840-21-2
1007840-21-2D, salts or solvates 1007840-22-3
1007840-22-3D, salts or solvates 1007840-23-4
1007840-23-4D, salts or solvates 1007840-24-5

11/839,520


1007840-24-5D, salts or solvates

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(2,5-dihydroxybenzene derivs. for treating actinic keratosis)


RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 636-01-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 636-01-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 2624-44-4 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)

11/839,520

(CA INDEX NAME)

CM 1

CRN 109-89-7


CMF C4 H11 N



CM 2


CRN 88-46-0

CMF C6 H6 O5 S




RN 51579-69-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 51579-69-2 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS


CN Benzenesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]- (CA

INDEX NAME)




RN 57775-26-5 HCAPLUS

CN Benzenesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 59687-22-8 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS


CN Benzenesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)

11/839,520




RN 60630-38-8 HCAPLUS

CN Benzenesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 70790-72-6 HCAPLUS


CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (1:?) (CA INDEX NAME)



●x Ca

RN 159252-66-1 HCAPLUS


CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K


RN 748106-93-6 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 748106-93-6 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-71-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-71-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-72-6 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




● K


RN 1007839-87-3 HCAPLUS

CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)


RN 1007839-87-3 HCAPLUS

CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)

RN 1007839-89-5 HCAPLUS


CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)

RN 1007839-89-5 HCAPLUS

CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)


RN 1007839-91-9 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA
INDEX NAME)




RN 1007839-91-9 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 1007839-93-1 HCAPLUS

CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS


CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS


CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)

11/839,520




RN 1007839-94-2 HCAPLUS

CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-96-4 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 1007839-96-4 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 1007840-16-5 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-[[[4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)




RN 1007840-16-5 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)




RN 1007840-17-6 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-17-6 HCAPLUS


CN 2-Propenoic acid, 3-[2-hydroxy-5-[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-18-7 HCAPLUS


CN 2-Propenoic acid, 3-[2,5-bis[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA
INDEX NAME)

11/839,520




RN 1007840-18-7 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis[[4-methylphenyl]sulfonyl]oxy]phenyl]- (CA INDEX NAME)




RN 1007840-19-8 HCAPLUS

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-19-8 HCAPLUS

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-21-2 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)




RN 1007840-21-2 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)




RN 1007840-22-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-22-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-23-4 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-23-4 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-24-5 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



L220 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 13
 ACCESSION NUMBER: 2008:221722 HCAPLUS Full-text
 DOCUMENT NUMBER: 148:276759
 TITLE: Use of 2,5-dihydroxybenzene derivatives for treating obesity, hirsutism, hypertrichosis and viral warts
 INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo;
Angulo Frutos, Javier; Lozano Puerto, Rosa Maria; Romero Garrido, Antonio; Valverde Lopez, Serafin; Garcia Gomez, Ignacio
 PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
 SOURCE: PCT Int. Appl., 77pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020037	A1	20080221	WO 2007-EP58451	20070815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2315119	A1	20090316	ES 2006-2219	20060816
US 20080114075	A1	20080515	US 2007-839512	20070815
PRIORITY APPLN. INFO.:			ES 2006-2219	A 20060816
			ES 2007-1857	A 20070702

OTHER SOURCE(S): MARPAT 148:276759

ED Entered STN: 21 Feb 2008

AB The present invention relates to the use of a 2,5-dihydroxybenzene derivative or a pharmaceutically acceptable salt or solvate thereof, isomer or prodrug thereof to prepare a medicament for the therapeutic and/or prophylactic treatment of a disease selected from obesity, hirsutism, hypertrichosis and viral warts.

CC 1-10 (Pharmacology)

IT Keratosis

(actinic; use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertrichosis and viral warts)

IT Wart


- (acuminate; use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertrichosis and viral warts)
- IT Skin, disease
(photoaging; use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertrichosis and viral warts)
- IT Keratosis
(seborrhic; use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertrichosis and viral warts)
- IT Adipogenesis
Antiobesity agents
Antitumor agents
Buccal drug delivery systems
Hair growth inhibitors
Hirsutism
Human
Hypolipemic agents
Inhalation drug delivery systems
Neuroglia, neoplasm
Obesity
Oral drug delivery systems
Parenteral drug delivery systems
Pharmaceutical creams
Pharmaceutical emulsions
Prophylaxis
Rectal drug delivery systems
Topical drug delivery systems
Transdermal drug delivery systems
(use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertrichosis and viral warts)
- IT 51-21-8, 5-Fluorouracil 64-86-8, Colchicine 76-03-9, Trichloroacetic acid, biological studies 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, ester derivs. 123-31-9D, 1,4-Dihydroxybenzene, derivs. 451-13-8, Homogentisic acid 490-79-9, Gentisic acid 503-11-7, Glycidic acid 636-01-1, 2,5-Dihydroxycinnamic acid 1084-96-4 2624-44-4, Ethamsylate 4759-48-2, Isotretinoin 5330-25-6 15307-86-5, Diclofenac 16094-44-3 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 52227-85-7, T4 Endonuclease V 55079-83-9, Acitretin 57775-26-5 59687-22-3 59687-73-9 60630-38-8 67127-91-7 79122-68-2 79365-88-1 79755-47-8 90447-15-7 97225-83-7, Magnesium 2,5-dihydroxybenzenesulfonate 99011-02-6, Imiquimod 113852-37-2, Cidofovir 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 814262-90-3 1007839-71-5 1007839-72-6D, ester derivs. 1007839-80-6 1007839-81-7 1007839-83-9 1007839-85-1 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007839-97-5 1007839-99-7 1007840-01-8 1007840-02-9 1007840-05-2 1007840-08-5 1007840-09-6 1007840-11-0 1007840-12-1 1007840-13-2 1007840-14-3 1007840-15-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
- RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertrichosis and viral warts)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D,
ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid
2624-44-4, Ethamsylate 20123-80-2, Calcium
2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium
2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5
59687-22-8 60630-38-8 79122-68-2
159252-66-1 159252-66-1D, ester derivs.
748106-93-6 1007839-71-5 1007839-72-6D,
ester derivs. 1007839-80-6 1007839-81-7
1007839-83-9 1007839-85-1 1007839-87-3
1007839-89-5 1007839-91-9 1007839-93-1
1007839-94-2 1007839-96-4 1007839-97-5
1007839-99-7 1007840-01-8 1007840-16-5
1007840-17-6 1007840-18-7 1007840-19-8
1007840-20-1 1007840-21-2 1007840-22-3
1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)

(use of hydroxybenzene derivs. for treating obesity, hirsutism,
hypertrichosis and viral warts)


RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)




11/839,520

RN 2624-44-4 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)
(CA INDEX NAME)


CM 1

CRN 109-89-7
CMF C4 H11 N




CM 2

CRN 88-46-0
CMF C6 H6 O5 S




RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)




●1/2 Ca


RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 51579-69-2 HCAPLUS
 CN Benzenesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
 CN Benzenesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 59687-22-8 HCAPLUS
 CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 60630-38-8 HCAPLUS
 CN Benzenesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)

11/839,520



RN 79122-68-2 HCAPLUS


CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 159252-66-1 HCAPLUS


CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 159252-66-1 HCAPLUS


CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K


RN 748106-93-6 HCAPLUS

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-71-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS


CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 1007839-80-6 HCAPLUS


CN Benzenesulfonic acid, 5-hydroxy-2-(phenylmethoxy)- (CA INDEX NAME)



RN 1007839-81-7 HCAPLUS


CN Benzenesulfonic acid, 2-hydroxy-5-(phenylmethoxy)- (CA INDEX NAME)

11/839,520




RN 1007839-83-9 HCAPLUS

CN Benzenesulfonic acid, 2,5-bis(phenylmethoxy)- (CA INDEX NAME)




RN 1007839-85-1 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 1007839-87-3 HCAPLUS

CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 1007839-89-5 HCAPLUS

CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 1007839-91-9 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis[[4-(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 1007839-93-1 HCAPLUS

CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-94-2 HCAPLUS

CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-96-4 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)




RN 1007839-97-5 HCAPLUS

CN Benzenemethanesulfonic acid, 5-hydroxy-2-(phenylmethoxy)- (CA INDEX NAME)




RN 1007839-99-7 HCAPLUS

CN Benzenemethanesulfonic acid, 2-hydroxy-5-(phenylmethoxy)- (CA INDEX NAME)




RN 1007840-01-8 HCAPLUS

CN Benzenemethanesulfonic acid, 2,5-bis(phenylmethoxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS


CN 2-Propenoic acid, 3-[5-hydroxy-2-[[4-(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-17-6 HCAPLUS


CN 2-Propenoic acid, 3-[2-hydroxy-5-[[4-(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)

11/839,520




RN 1007840-18-7 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis[[4-methylphenyl]sulfonyl]oxy]phenyl]- (CA INDEX NAME)




RN 1007840-19-8 HCAPLUS

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-21-2 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)




RN 1007840-22-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-23-4 HCAPLUS

CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-24-5 HCAPLUS

CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 14

ACCESSION NUMBER: 2007:705929 HCAPLUS Full-text

DOCUMENT NUMBER: 147:87646

TITLE: 2,5-Dihydroxybenzene sulfonate compounds for treatment of cancer, rosacea, and psoriasis

INVENTOR(S): Cuevas Sanchez, Pedro; Romero Garrido, Antonio; Gimenez Gallego, Guillermo; Valverde Lopez, Serafin; Lozano Puerto, Rosa Maria

PATENT ASSIGNEE(S): Action Medicines, S.L., Spain

SOURCE: U.S. Pat. Appl. Publ., 33pp., Cont.-in-part of U.S. Ser. No. 588,166.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070149618	A1	20070628	US 2006-506469	20060816
ES 2238924	A1	20050901	ES 2004-371	20040217 <--
ES 2238924	B1	20061201		
WO 2005077352	A1	20050825	WO 2005-ES70017	20050216 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20080125485	A1	20080529	US 2007-839508	20070815
US 20090111779	A1	20090430	US 2008-257854	20081024
PRIORITY APPLN. INFO.:			ES 2004-371	A 20040217
			WO 2005-ES70017	W 20050216
			US 2006-588166	A2 20060802
			ES 2006-2219	A 20060816
			US 2006-506469	A2 20060816
			ES 2007-1857	A 20070702
			US 2008-588166	A2 20080807

ED Entered STN: 29 Jun 2007

- AB The invention describes compns. and methods of use for 2,5-dihydroxybenzene sulfonic acid compds. and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compns. comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compds. or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate. Administration of 2,5-dihydroxybenzene sulfonate combined with irinotecan reduced the tumor progression of gliomas in rats to a greater degree than treatment of either agent alone.
- INCL 514553000; 514171000; 514559000; 514167000; 514159000
- CC 1-6 (Pharmacology)
- ST dihydroxybenzene sulfonate cancer rosacea psoriasis therapy;
glioma irinotecan dihydroxybenzene sulfonate antitumor combination
- IT Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Buccal drug delivery systems
Chemosensitizers, pharmaceutical
Chemotherapy
Combination chemotherapy
Cytotoxic agents
Dermatological agents
Immunomodulators
Inhalation drug delivery systems
Leukemia
Melanoma
NMDA receptor antagonists
Neuroglia, neoplasm
Oral drug delivery systems
Parenteral drug delivery systems
Pharmaceutical carriers
Pharmaceutical creams
Proliferation inhibition
Psoriasis
Rectal drug delivery systems
Skin, neoplasm
Topical drug delivery systems
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer,
rosacea and psoriasis)
- IT Retinoids
Steroids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer,
rosacea and psoriasis)
- IT Petrolatum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer,
rosacea and psoriasis)
- IT Carcinoma
Skin, neoplasm

- (Bowen's disease, verrucae; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Keratosis
(actinic; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Apoptosis
(basal cell carcinoma cells; 2,5-dihydroxybenzenesulfonate-induced; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Skin, neoplasm
(basal cell carcinoma; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Carcinoma
(basal cell; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Carcinoma
(cutaneous squamous cell; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Antitumor agents
Immunotherapy
Radiotherapy
(efficacy; agents improving; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Skin, neoplasm
(keratoacanthoma; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Sarcoma
(orangiosarcoma; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Drug interactions
(pharmacodynamic, potentiation; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Skin, disease
(rosacea; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Neoplasm
(solid; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Skin, neoplasm
(squamous cell carcinoma; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT Paraffin waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(white soft; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT 51-21-8, 5-Fluorouracil 57-22-7, Vincristine 69-72-7, Salicylic acid, biological studies 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 1406-16-2D, Vitamin D, analog 2624-44-4, Diethylamine 2,5-dihydroxybenzenesulfonate 15663-27-1, Cisplatin 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 33069-62-4, Paclitaxel 68864-98-2, 2,5-Dihydroxybenzenesulfonate 97225-83-7, Magnesium 2,5-dihydroxybenzenesulfonate 97682-44-5, Irinotecan 100286-90-6, Campto
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)
- IT 112-92-5, Stearic alcohol 7732-18-5, Water, biological studies 36653-82-4, Cetyl alcohol 942134-54-5, Sorbate deato

11/839,520

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer,
rosacea and psoriasis)

IT 116243-73-3, Endothelin


RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonist; 2,5-dihydroxybenzene sulfonate compds. for treatment of
cancer, rosacea and psoriasis)

IT ~~88-46-0~~, 2,5-Dihydroxybenzenesulfonic acid ~~2624-44-4~~
, Diethylamine 2,5-dihydroxybenzenesulfonate ~~20123-80-2~~,
Calcium 2,5-dihydroxybenzenesulfonate ~~21799-87-1~~, Potassium
2,5-dihydroxybenzenesulfonate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer,
rosacea and psoriasis)

RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 2624-44-4 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)
(CA INDEX NAME)

CM 1

CRN 109-89-7


CMF C4 H11 N



CM 2


CRN 88-46-0

CMF C6 H6 O5 S




11/839,520

RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

L220 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 15
ACCESSION NUMBER: 2005:888919 HCAPLUS Full-text
DOCUMENT NUMBER: 143:216719
TITLE: Use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases such as cancer and psoriasis
INVENTOR(S): Cuevas, Sanchez Pedro
PATENT ASSIGNEE(S): Investread Europa, S.L., Spain
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077352	A1	20050825	WO 2005-ES70017	20050216 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

11/839,520

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

ES 2238924	A1	20050901	ES 2004-371	20040217 <--
ES 2238924	B1	20061201		
AU 2005211956	A1	20050825	AU 2005-211956	20050216 <--
CA 2555248	A1	20050825	CA 2005-2555248	20050216 <--
EP 1719509	A1	20061108	EP 2005-708114	20050216 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, IS, YU				
CN 101014330	A	20070808	CN 2005-80005187	20050216 <--
JP 2007522256	T	20070809	JP 2006-553602	20050216 <--
IN 2006DN04546	A	20070810	IN 2006-DN4546	20060807
KR 2007007783	A	20070116	KR 2006-716184	20060811
MX 2006009295	A	20070323	MX 2006-9295	20060816 <--
US 20070149618	A1	20070628	US 2006-506469	20060816
US 20080125485	A1	20080529	US 2007-839508	20070815
US 20080293816	A1	20081127	US 2008-588166	20080807 <--
US 20090111779	A1	20090430	US 2008-257854	20081024

PRIORITY APPLN. INFO.:

ES 2004-371	A	20040217
WO 2005-ES70017	W	20050216
US 2006-588166	A2	20060802
ES 2006-2219	A	20060816
US 2006-506469	A2	20060816
ES 2007-1857	A	20070702
US 2008-588166	A2	20080807

ED Entered STN: 25 Aug 2005

AB The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforementioned compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases which present a reduction in apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compds. in non-quiescent cells. In addition, the invention details the potentiating effect of said compds. on known cytostatic medicines in the treatment of tumors and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compds., based on the combined antiproliferative, antiangiogenic and proapoptotic capacities thereof, in the treatment of chronic psoriatic plaques.

IC ICM A61K031-185

ICS A61P035-00; A61P017-06

CC 63-6 (Pharmaceuticals)

IT Neoplasm

Psoriasis

(use of dihydroxybenzenesulfonic acid in drugs for treatment of angiodependent diseases)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 20123-80-2
, 2,5-Dihydroxybenzenesulfonic acid calcium salt 862162-74-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of dihydroxybenzenesulfonic acid in drugs for treatment of angiodependent diseases)


IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 20123-80-2
, 2,5-Dihydroxybenzenesulfonic acid calcium salt 862162-74-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of dihydroxybenzenesulfonic acid in drugs for treatment of angiodependent diseases)

11/839,520


RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 20123-80-2 HCAPLUS


CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 862162-74-1 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:?) (CA INDEX NAME)



●x K

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d iall abeq tech abex hitstr 16-19

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' - CONTINUE?
(Y)/N:y

L220 ANSWER 16 OF 22 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
 ACCESSION NUMBER: 2008-L13777 [65] WPIX
 CROSS REFERENCE: 2008-D99595; 2008-E49165; 2008-E61270; 2008-G33820
 DOC. NO. CPI: C2008-323605 [65]
 TITLE: Use of dihydroxybenzene compound to treat e.g. benign
 prostatic hyperplasia, Barrett's disease, asthma,
 skeletal muscle and tendon repair, Crohn's disease,
 ulcerative colitis, leishmaniasis, hemangiomas and
 hemangioblastomas
 DERWENT CLASS: B05
 INVENTOR: ANGULO FRUTOS J; CUEVAS SANCHEZ P;
FERNANDEZ JAEN T F; GIMENEZ GALLEGO G;
LOZANO FUERTO R M; MORENO NUNCIO F J; RIVAS LOPEZ
L I; ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN
I; VALVERDE LOPEZ S
 PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL
 COUNTRY COUNT: 121

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020042	A1	20080221	(200865)*	EN	103	[22]
EP 2056805	A1	20090513	(200933)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020042	A1	WO 2007-EP58456	20070815
EP 2056805	A1	EP 2007-788436	20070815
EP 2056805	A1	PCT Application	WO 2007-EP58456 20070815

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 2056805	A1 Based on	WO 2008020042 A

PRIORITY APPLN. INFO: ES 2007-1855 20070702
 ES 2006-2217 20060816

INT. PATENT CLASSIF.:

IPC ORIGINAL: A61K0031-095 [I,C]; A61K0031-095 [I,C]; A61K0031-10 [I,A]
 ; A61K0031-185 [I,C]; A61K0031-185 [I,C]; A61K0031-192
 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]; A61K0031-60
 [I,C]; A61K0031-618 [I,A]; A61P0011-00 [I,C]; A61P0011-00
 [I,C]; A61P0011-06 [I,A]

ECLA: A61K0031-10; A61K0031-192; A61K0031-60; A61K0031-618

BASIC ABSTRACT:

WO 2008020042 A1 UPAB: 20090527

NOVELTY - Use of a dihydroxybenzene compound (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of diseases of benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis and leishmaniasis, is claimed.

DETAILED DESCRIPTION - Use of a dihydroxybenzene compound of formula (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of diseases of benign

prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis and leishmaniasis, is claimed.

R1 = -(CH₂)_aY1 or -CH=CH-(CH₂)_pY1;

Y1 = -SO₃H, -SO₃-.X⁺, -SO₃R₃, -PO₃H, -PO₃-.X⁺, -PO₃R₃, -CO₂H, -CO₂-.X⁺ or -CO₂R₃;

X⁺ = organic cation or inorganic cation such that the general charge of (I) is neutral;

R₉, R_{9a} = -OH or -OR₂;

R₂ = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl;

R₃ = alkyl or aryl; and

a, p = 0-6.

Provided that when R₉, R_{9a} are both -OR₂, then R₉ and R_{9a} can be the same or different.

ACTIVITY - Cytostatic; Gastrointestinal-Gen; Antiinflammatory; Antiasthmatic; Muscular-Gen; Osteopathic; Protozoacide; Antiulcer. Gastrointestinal-Gen.

MECHANISM OF ACTION - None given.

USE - (I) is useful for treating/preventing benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, leishmaniasis, ulcerative colitis (claimed) (proctitis, proctosigmoiditis, pancolitis), hemangiomas and hemangioblastomas. The ability of (I) to treat muscle lesion was tested in a patient. The result showed that the patient (taken 500 mg of 2,5-dihydroxybenzenesulfonic acid for two weeks) recovered from the lesion in the quadriceps and the hematoma was not observed.

ADVANTAGE - (I) is safe and effective for treating leishmaniasis. (I) exhibits pharmacological properties. MANUAL CODE: CPI: B05-B01F; B10-A09B; B10-B02A; B10-C04B; B10-C04C;

B14-A03F; B14-E08; B14-E10C1; B14-H01B; B14-H05; B14-J05; B14-K01A; B14-N07; B14-S14

TECH

PHARMACEUTICALS - Preferred Components: The medicament comprises at least one additional therapeutic agent such as a chemotherapeutic agent, corticosteroid, antibiotic, analgesic, alpha-adrenergic blocker, beta-adrenergic agonist, anticholinergic, inhibitor of 5-alpha-reductase, antiandrogen, oral contraceptive, immunomodulator, immunosuppressant, anti-angiogenic, bronchodilator, leukotriene modifier, aminosalicylate, anesthetic, non-steroidal anti-inflammatory, antiparasitic, proton pump inhibitor, hydrogen-receptor antagonist, therapy of the solubilized interleukin receptor, intramuscular gold, cytotoxic and/or antioxidant. (I) is in the form of esters at position 1, preferably methyl and ethyl esters.

ABEX DEFINITIONS - Preferred Definitions: - Y1 = -SO₃H, -SO₃-.X⁺, -SO₃R₃, -CO₂H, -CO₂-.X⁺ or -CO₂R₃; - R₉ and R_{9a} = alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted); and - R₂ = methylcarbonyl, phenylsulfonyl, 4-methylphenylsulfonyl, benzylsulfonyl, benzyl or phenyl.

ADMINISTRATION - Administration of (I) is topical, oral, buccal, transdermal, parenteral or rectal (claimed). Dosage of (I) is 0.05-50 (preferably 1-1.5) g/day.


SPECIFIC COMPOUNDS - The use of 53 compounds (I) is specifically claimed e.g. 5-hydroxy-2-(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2-hydroxy-5-(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2,5-bis(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2-(acetyloxy)-5-hydroxybenzenesulfonic acid and 2,5-dihydroxybenzenesulfonic acid (dobesilate) of formula (Ia).

AN.S DCR-1595300

CN.S Acetic acid 4-acetoxy-3-sulfo-phenyl ester

SDCN RASW2X


11/839,520



AN.S DCR-1669099

CN.S Toluene-4-sulfonic acid 4-hydroxy-2-sulfomethyl-phenyl ester


SDCN RAUHHH



AN.S DCR-1669100

CN.S Toluene-4-sulfonic acid 4-hydroxy-3-sulfomethyl-phenyl ester


SDCN RAUHHD



AN.S DCR-1669101

SDCN RAUHHE


11/839,520



AN.S DCR-1669102

CN.S Acetic acid 4-hydroxy-2-sulfomethyl-phenyl ester


SDCN RAUHHF



AN.S DCR-1669103

CN.S Acetic acid 4-hydroxy-3-sulfomethyl-phenyl ester


SDCN RAUHHG



AN.S DCR-1669104


11/839,520

CN.S Acetic acid 4-acetoxy-3-sulfomethyl-phenyl ester
SDCN RAUHHH




AN.S DCR-1595313

CN.S (E)-3-[2-Hydroxy-5-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid
SDCN RASW3A



AN.S DCR-1595315


CN.S (E)-3-(2-Acetoxy-5-hydroxy-phenyl)-acrylic acid
SDCN RASW3C



AN.S DCR-1595316

CN.S (E)-3-(5-Acetoxy-2-hydroxy-phenyl)-acrylic acid


SDCN RASW3D



AN.S DCR-1595317

CN.S (E)-3-(2,5-Diacetoxy-phenyl)-acrylic acid


SDCN RASW3E



AN.S DCR-1595318

CN.S (E)-3-(2-Benzyloxy-5-hydroxy-phenyl)-acrylic acid


SDCN RASW3F




AN.S DCR-1595319

CN.S (E)-3-(5-Benzyloxy-2-hydroxy-phenyl)-acrylic acid


SDCN RASW3G



AN.S DCR-1595320
 CN.S (E)-3-(2,5-Bis-benzyloxy-phenyl)-acrylic acid
 SDCN RASW3H




AN.S DCR-1595296
 CN.S 5-Hydroxy-2-(toluene-4-sulfonyloxy)-benzenesulfonic acid
 SDCN RASW2T



AN.S DCR-108109
 CN.P SULTOSILATE
 SDCN RA2Y7A


11/839,520



AN.S DCR-1595297

CN.S 2,5-Bis-(toluene-4-sulfonyloxy)-benzenesulfonic acid


SDCN RASW2U




AN.S DCR-1595298

CN.S Acetic acid 4-hydroxy-2-sulfo-phenyl ester

SDCN RASW2V



AN.S DCR-1595299
 CN.S Acetic acid 4-hydroxy-3-sulfo-phenyl ester
 SDCN RASW2W



L220 ANSWER 17 OF 22 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
 ACCESSION NUMBER: 2008-D99595 [28] WPIX
 CROSS REFERENCE: 2008-E49165; 2008-E61270; 2008-G33820; 2008-L13777
 DOC. NO. CPI: C2008-131560 [28]
 TITLE: Use of dihydroxybenzene compound to treat e.g. hemangiomas, hemangioblastomas, benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis and leishmaniasis
 DERWENT CLASS: B05
 INVENTOR: ANGULO FRUTOS J; CUEVAS SANCHEZ P; GIMENEZ GALLEGO G; LOZANO PUERTO R M; ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN I; VALVERDE LOPEZ S; LOPEZ S V; FERNANDEZ JAEN T F; FRUTOS J A; MORENO NUNCIO F J; RIVAS LOPEZ L I; SANCHEZ P C
 PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL
 COUNTRY COUNT: 120

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020034	A1	20080221	(200828)*	EN	101	[22]
US 20080114063	A1	20080515	(200835)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020034	A1	WO 2007-EP58447	20070815
US 20080114063	A1	US 2007-839529	20070815

PRIORITY APPLN. INFO: ES 2007-1855 20070702
 ES 2006-2217 20060816

INT. PATENT CLASSIF.:

IPC ORIGINAL: A61K0031-095 [I,C]; A61K0031-10 [I,A]; A61K0031-185 [I,C]
 ; A61K0031-185 [I,A]; A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-21 [I,C]; A61K0031-22 [I,A]; A61K0031-225 [I,A]; A61K0031-60 [I,A]; A61K0031-60 [I,C];
 A61K0031-618 [I,A]; A61P0035-00 [I,A]; A61P0035-00 [I,C]
 ECLA: A61K0031-10; A61K0031-192; A61K0031-60; A61K0031-618

USCLASS NCLM: 514/546.000
 NCLS: 514/548.000; 514/553.000
 BASIC ABSTRACT:

WO 2008020034 A1 UPAB: 20080501

NOVELTY - Use of a 2,5-dihydroxybenzene compound (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of a disease of hemangiomas and hemangioblastomas, is claimed.

DETAILED DESCRIPTION - Use of a 2,5-dihydroxybenzene compound of formula (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of a disease of hemangiomas and hemangioblastomas, is claimed.

R1 = -(CH₂)_aY1 or -CH=CH-(CH₂)_pY1;

Y1 = -SO₃H, -SO₃-.X⁺, -SO₃R₃, -PO₃H, -PO₃-.X⁺, -PO₃R₃, -CO₂H, -CO₂-.X⁺ or -CO₂R₃;

X⁺ = organic cation or inorganic cation such that general charge of (I) is neutral;

R₉, R_{9a} = -OH or -OR₂;

R₂ = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl (all optionally substituted);

R₃ = alkyl or aryl (both optionally substituted); and

a, p = 0-6.

ACTIVITY - Cytostatic; Gastrointestinal-Gen; Antiinflammatory; Antiasthmatic; Muscular-Gen; Osteopathic; Antiulcer; Protozoacide; Analgesic; Antiarthritic.

MECHANISM OF ACTION - None given.

USE - (I) is useful for treating/preventing a disease of hemangiomas and hemangioblastomas (claimed), benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis (proctitis, proctosigmoiditis and pancolitis), leishmaniasis, pain and arthritis. The ability of (I) to treat muscle lesion was tested in a patient. The result showed that the patient (taken 500 mg of 2,5-dihydroxybenzene sulfonic acid for two weeks) recovered from the lesion in the quadriceps and the hematoma was not observed.

ADVANTAGE - (I) is safe and effective for treating leishmaniasis. (I) exhibits pharmacological properties. MANUAL CODE: CPI: B02-Z; B05-A01B; B05-B01N; B10-A09B; B10-C03;

B10-E02; B10-G02; B14-A03F; B14-C01; B14-C03; B14-C07; B14-C09; B14-D06C; B14-E08; B14-E10A; B14-E10C1; B14-F02F2; B14-G02; B14-G03; B14-H01; B14-H01E2; B14-H05; B14-J05; B14-K01A; B14-L06; B14-N01; B14-S08; B14-S16

TECH

PHARMACEUTICALS - Preferred Components: The medicament comprises at least one additional therapeutic agent (such as chemotherapeutic agent, corticosteroid, antibiotic, analgesic, antiandrogen, immunomodulator, anti-angiogenic including anti-vascular endothelial growth factor, anti-fibroblast growth factor, anti-epidermal growth factor and anti-hepatocyte growth factor), inhibitors of tyrosin-kinase receptors, protein kinase C inhibitors, non-steroidal anti-inflammatory, a therapy of the solubilized interleukin receptor, a cytotoxic and/or antioxidant. (I) is in the form of esters at position 1, preferably methyl and ethyl esters.

ABEX DEFINITIONS - Preferred Definitions: - Y1 = -SO₃H, -SO₃-X⁺, -SO₃R₃, -CO₂H, -CO₂-.X⁺ or -CO₂R₃; - R₉, R_{9a} = alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted); and - R₂ = methylcarbonyl, phenylsulfonyl, 4-methylphenylsulfonyl, benzylsulfonyl, benzyl or phenyl.

ADMINISTRATION - Administration of (I) is oral, buccal, parenteral, rectal, intravaginal, intraocular, transdermal, topical or via inhalation (claimed). Dosage of (I) is 0.05-50 (preferably 1-1.5) g/day.


11/839,520

SPECIFIC COMPOUNDS - The use of 54 compounds (I) is specifically claimed e.g. 5-hydroxy-2-(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2-hydroxy-5-(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2,5-bis(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2-(acetyloxy)-5-hydroxybenzenesulfonic acid and 2,5-dihydroxybenzenesulfonic acid (dobesilate) of formula (Ia).

AN.S DCR-1595296

CN.S 5-Hydroxy-2-(toluene-4-sulfonyloxy)-benzenesulfonic acid


SDCN RASW2T



AN.S DCR-108109

CN.P SULTOSILATE

SDCN RA2Y7A




AN.S DCR-1595297

CN.S 2,5-Bis-(toluene-4-sulfonyloxy)-benzenesulfonic acid

SDCN RASW2U


11/839,520



AN.S DCR-1595298

CN.S Acetic acid 4-hydroxy-2-sulfo-phenyl ester


SDCN RASW2V



AN.S DCR-1595299

CN.S Acetic acid 4-hydroxy-3-sulfo-phenyl ester

SDCN RASW2W




AN.S DCR-1595300

CN.S Acetic acid 4-acetoxy-3-sulfo-phenyl ester

SDCN RASW2X


11/839,520



AN.S DCR-1595312

CN.S (E)-3-[5-Hydroxy-2-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid


SDCN RASW39



AN.S DCR-1595313

CN.S (E)-3-[2-Hydroxy-5-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid


SDCN RASW3A



AN.S DCR-1595314

CN.S (E)-3-[2,5-Bis-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid


SDCN RASW3B



AN.S DCR-1595315

CN.S (E)-3-(2-Acetoxy-5-hydroxy-phenyl)-acrylic acid

SDCN RASW3C




AN.S DCR-1595316


CN.S (E)-3-(5-Acetoxy-2-hydroxy-phenyl)-acrylic acid

SDCN RASW3D


11/839,520




AN.S DCR-1595317
CN.S (E)-3-(2,5-Diacetoxy-phenyl)-acrylic acid
SDCN RASW3E



AN.S DCR-1595318
CN.S (E)-3-(2-Benzyloxy-5-hydroxy-phenyl)-acrylic acid
SDCN RASW3F



AN.S DCR-1595319
CN.S (E)-3-(5-Benzyloxy-2-hydroxy-phenyl)-acrylic acid
SDCN RASW3G



L220 ANSWER 18 OF 22 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
 ACCESSION NUMBER: 2008-E61270 [31] WPIX
 CROSS REFERENCE: 2008-D99595; 2008-E49165; 2008-G33820; 2008-L13777
 DOC. NO. CPI: C2008-153460 [31]
 TITLE: Use of substituted phenyl compounds in the manufacturing of a medicament for the treatment and/or prophylaxis of e.g. macular degeneration, corneal neovascularization or angiogenesis and diabetic proliferative retinopathy
 DERWENT CLASS: B05
 INVENTOR: ANGULO FRUTOS J; CUEVAS SANCHEZ F; GIMENEZ GALLEGO G; LOZANO PUERTO R M; ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN I; VALVERDE LOPEZ S
 PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL
 COUNTRY COUNT: 121

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020032	A1	20080221	(200831)*	EN	133	[29]
WO 2008020032	A8	20080417	(200831)	EN		
EP 2056804	A1	20090513	(200933)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020032	A1	WO 2007-EP58445	20070815
EP 2056804	A1	EP 2007-802616	20070815
EP 2056804	A1	PCT Application	WO 2007-EP58445 20070815

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 2056804	A1 Based on	WO 2008020032 A

PRIORITY APPLN. INFO: ES 2007-1855 20070702
 ES 2006-2217 20060816

INT. PATENT CLASSIF.:

IPC ORIGINAL: A61K0031-095 [I,C]; A61K0031-095 [I,C]; A61K0031-10 [I,A]
 ; A61K0031-185 [I,C]; A61K0031-185 [I,C]; A61K0031-192
 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]; A61K0031-60
 [I,C]; A61K0031-618 [I,A]; A61P0027-00 [I,C]; A61P0027-00
 [I,C]; A61P0027-02 [I,A]

ECLA: A61K0031-10; A61K0031-192; A61K0031-60; A61K0031-618

BASIC ABSTRACT:

WO 2008020032 A1 UPAB: 20090527

NOVELTY - Use of substituted phenyl compounds (I) or their salts, solvates, isomers or prodrugs in the manufacturing of a medicament for the treatment and/or prophylaxis of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy, is claimed

DETAILED DESCRIPTION - Use of substituted phenyl compounds of formula (I) or their salts, solvates, isomers or prodrugs in the manufacturing of a medicament for the treatment and/or prophylaxis of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy, is claimed.

R1 = $-(CH_2)_aY_1$ or $-CH=CH-(CH_2)_pY_1$;

Y1 = $-SO_3H$, $-SO_3-X^+$, $-SO_3R_3$, $-PO_3H$, $-PO_3-X^+$, $-PO_3R_3$, $-CO_2H$, $-CO_2-X^+$ or $-CO_2R_3$;

X+ = an organic cation or an inorganic cation, such that the general charge of (I) is neutral;

R9, R9a = $-OH$ or $-OR_2$;

R2 = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl (all optionally substituted);

R3 = alkyl or aryl (both optionally substituted); and

a, p = 0-6.

When R9 and R9a are both $-OR_2$, then the R9 and R9a can be the same or different; when Y1 is $-SO_3H$, $-SO_3-X^+$ or $-SO_3R_3$, then R9 and R9a are $-OH$ and $-OR_2$; and at least one of R9 and R9a is alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted).

ACTIVITY - Antibacterial; Ophthalmological; Gynecological; Nephrotropic; Cytostatic; Gastrointestinal-Gen.; Antiinflammatory; Antiasthmatic; Antiulcer; Protozoacide; Analgesic; Antiarthritic; Angiogenesis inhibitor.

MECHANISM OF ACTION - Fibroblast mitogenesis inhibitor.

USE - (I) are useful for the treatment and/or prophylaxis of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy (claimed). (I) are useful for the treatment and/or prophylaxis of hemangiomas, hemangioblastomas, benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Barrett's disease, Crohn's disease, ulcerative colitis (proctitis, proctosigmoiditis, pancolitis), leishmaniasis, Helicobacter pylori infection, pterygium, endometriosis, ovarian hyperstimulation syndrome, polycystic kidney disease, pain, arthritis. (I) were tested for their ability to reduce the proliferation capacity of human retinal endothelial cells (HREC). The results showed that 2,5-dihydroxycinnamic acid methyl ester significantly inhibited HREC proliferation at 50-100 μM .

ADVANTAGE - (I) are effective for the treatment of e.g. hemangiomas, leishmaniasis, polycystic kidney disease, ovarian hyperstimulation syndrome, endometriosis and benign prostatic hyperplasia. MANUAL CODE: CPI: B05-A01B; B05-B01N; B10-A09B; B10-C03; B10-E02;

B10-G02; B14-A01A; B14-A03F; B14-B02; B14-C01; B14-C03;
B14-C07; B14-C09; B14-E08; B14-E10A; B14-E10C1;
B14-F02F2; B14-G02; B14-G03; B14-H01E2; B14-H05;
B14-J02C1; B14-J02D1; B14-J05; B14-K01A; B14-L06;
B14-N03; B14-N07; B14-N10; B14-P01; B14-S08; B14-S16

TECH

PHARMACEUTICALS - Preferred Components: (I) are in the form of esters at

position 1, particularly methyl or ethyl esters. The medicament comprises an additional therapeutic agent such as a chemotherapeutic agent, corticosteroid, antibiotic, analgesic, alpha-adrenergic blocker, beta-adrenergic agonist, anticholinergic, inhibitor of 5-alpha-reductase, antiandrogen, oral contraceptive, immunomodulator, immunosuppressant, anti-angiogenic, bronchodilator, leukotriene modifier, aminosalicylate, anesthetic, non-steroidal anti-inflammatory, antiparasitic, proton pump inhibitor, hydrogen-receptor antagonist, therapy of the solubilized interleukin receptor, intramuscular gold, cytotoxic and/or an antioxidant.

ABEX DEFINITIONS - Preferred Definitions: - Y1 = -SO₃H, -SO₃-X⁺, -SO₃R₃, -CO₂H, -CO₂-X⁺ or -CO₂R₃; and - R₂ = methylcarbonyl, phenylsulfonyl, 4-methylphenylsulfonyl, benzylsulfonyl, benzyl or phenyl. - At least one of R₉ and R_{9a} are alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted).


ADMINISTRATION - Administration of (I) is topical, transdermal, oral, buccal, parenteral, intradermal, rectal, intravaginal, intraocular or by inhalation (claimed). Dosage of (I) is 0.05-50 (preferably 0.1, 0.25, 0.5, 0.75, 1, 5, 10, 25 or 50) g/day.

SPECIFIC COMPOUNDS - The use of 42 compounds (I) is specifically claimed e.g. 5-hydroxy-2-(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid (Ia), 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, 5-(acetyloxy)-2-hydroxybenzenesulfonic acid, 2,5-bis(acetyloxy)benzenesulfonic acid and 2,5-bis(benzyloxy)benzoic acid.

AN.S DCR-1595312

CN.S (E)-3-[5-Hydroxy-2-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid

SDCN RASW39




AN.S DCR-1595313

CN.S (E)-3-[2-Hydroxy-5-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid

SDCN RASW3A


11/839,520



AN.S DCR-1595314

CN.S (E)-3-[2,5-Bis-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid

SDCN RASW3B




AN.S DCR-1595315

CN.S (E)-3-(2-Acetoxy-5-hydroxy-phenyl)-acrylic acid

SDCN RASW3C


11/839,520



AN.S DCR-1595316

CN.S (E)-3-(5-Acetoxy-2-hydroxy-phenyl)-acrylic acid


SDCN RASW3D



AN.S DCR-1595317

CN.S (E)-3-(2,5-Diacetoxy-phenyl)-acrylic acid

SDCN RASW3E




AN.S DCR-1595318

CN.S (E)-3-(2-Benzyloxy-5-hydroxy-phenyl)-acrylic acid

SDCN RASW3F


11/839,520



AN.S DCR-1595319

CN.S (E)-3-(5-Benzyloxy-2-hydroxy-phenyl)-acrylic acid


SDCN RASW3G



AN.S DCR-1595320

CN.S (E)-3-(2,5-Bis-benzyloxy-phenyl)-acrylic acid

SDCN RASW3H




AN.S DCR-108109

CN.P SULTOSILATE

SDCN RA2Y7A


11/839,520



AN.S DCR-1595297

CN.S 2,5-Bis-(toluene-4-sulfonyloxy)-benzenesulfonic acid


SDCN RASW2U



AN.S DCR-1595298

CN.S Acetic acid 4-hydroxy-2-sulfo-phenyl ester


SDCN RASW2V



AN.S DCR-1595299

CN.S Acetic acid 4-hydroxy-3-sulfo-phenyl ester


SDCN RASW2W



AN.S DCR-1595300

CN.S Acetic acid 4-acetoxy-3-sulfo-phenyl ester


SDCN RASW2X



AN.S DCR-1595296

CN.S 5-Hydroxy-2-(toluene-4-sulfonyloxy)-benzenesulfonic acid

SDCN RASW2T



L220 ANSWER 19 OF 22

WPIX COPYRIGHT 2009

THOMSON REUTERS on STN

ACCESSION NUMBER:

2008-E49165 [30] WPIX

CROSS REFERENCE:

2008-D99595; 2008-E61270; 2008-G33820; 2008-L13777

DOC. NO. CPI:

C2008-149386 [30]

11/839,520

TITLE: Use of substituted phenyl compounds in the manufacturing of a medicament for the treatment and/or prophylaxis of e.g. pterygium, endometriosis, ovarian hyperstimulation syndrome and polycystic kidney disease

DERWENT CLASS: B05

INVENTOR: ANGULO FRUTOS J; CUEVAS SANCHEZ P;
GIMENEZ GALLEGO G; LOZANO PUERTO R M;
ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN I;
VALVERDE LOPEZ S

PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL

COUNTRY COUNT: 120

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020031	A1	20080221	(200830)*	EN	135	[29]
ES 2315117	A1	20090316	(200922)	ES		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020031	A1	WO 2007-EP58444	20070815
ES 2315117	A1	ES 2006-2217	20060816

PRIORITY APPLN. INFO: ES 2007-1855 20070702
ES 2006-2217 20060816

INT. PATENT CLASSIF.:

IPC ORIGINAL: A61K0031-095 [I,C]; A61K0031-10 [I,A]; A61K0031-185 [I,C]
; A61K0031-192 [I,A]; A61K0031-60 [I,A]; A61K0031-60
[I,C]; A61K0031-618 [I,A]; A61P0015-00 [I,A]; A61P0015-00
[I,C]; A61K0031-185 [I,A]; A61K0031-185 [I,C];
A61K0031-192 [I,A]; A61P0011-00 [I,C]; A61P0011-06 [I,A]
ECLA: A61K0031-10; A61K0031-192; A61K0031-60; A61K0031-618

BASIC ABSTRACT:

WO 2008020031 A1 UPAB: 20090407

NOVELTY - Use of substituted phenyl compounds (I) or their salts, solvates, isomers or prodrugs in the manufacturing of a medicament for the treatment and/or prophylaxis of diseases associated to Helicobacter pylori infection, pterygium, endometriosis, ovarian hyperstimulation syndrome and/or polycystic kidney disease, is claimed

DETAILED DESCRIPTION - Use of substituted phenyl compounds of formula (I) or their salts, solvates, isomers or prodrugs in the manufacturing of a medicament for the treatment and/or prophylaxis of diseases associated to Helicobacter pylori infection, pterygium, endometriosis, ovarian hyperstimulation syndrome and/or polycystic kidney disease, is claimed.

R1 = -(CH₂)_aY1 or -CH=CH-(CH₂)_pY1;

Y1 = -SO₃H, -SO₃-X⁺, -SO₃R₃, -PO₃H, -PO₃-X⁺, -PO₃R₃, -CO₂H, -CO₂-X⁺ or -CO₂R₃;

X⁺ = an organic cation or an inorganic cation, such that the general charge of (I) is neutral;

R₉, R_{9a} = -OH or -OR₂;

R₂ = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl (all optionally substituted);

R₃ = alkyl or aryl (both optionally substituted); and

a, p = 0-6.

When R₉ and R_{9a} are both -OR₂, then the R₉ and R_{9a} can be the same or different; when Y1 is -SO₃H, -SO₃-X⁺ or -SO₃R₃, then R₉ and R_{9a} are -OH and -

OR2; and at least one of R9 and R9a is alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted).

ACTIVITY - Antibacterial; Ophthalmological; Gynecological; Nephrotropic; Cytostatic; Gastrointestinal-Gen.; Antiinflammatory; Antiasthmatic; Antiulcer; Protozoacide; Analgesic; Antiarthritic; Angiogenesis inhibitor.

MECHANISM OF ACTION - Fibroblast mitogenesis inhibitor.

USE - (I) are useful for the treatment and/or prophylaxis of diseases associated to *Helicobacter pylori* infection, pterygium, endometriosis, ovarian hyperstimulation syndrome and/or polycystic kidney disease (claimed). (I) are useful for the treatment and/or prophylaxis of hemangiomas, hemangioblastomas, benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis (proctitis, proctosigmoiditis, pancolitis), leishmaniasis, pain, arthritis, macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy. (I) were tested for their ability to reduce the proliferation capacity of human retinal endothelial cells (HREC). The results showed that 2,5-dihydroxycinnamic acid methyl ester significantly inhibited HREC proliferation at 50-100 μ M.

ADVANTAGE - (I) are effective for the treatment of e.g. hemangiomas, leishmaniasis, polycystic kidney disease, ovarian hyperstimulation syndrome, endometriosis and benign prostatic hyperplasia. MANUAL CODE: CPI: B02-Z; B05-A01B; B05-B01N; B10-A09B; B10-C03;

B10-E02; B10-G02; B14-A01A; B14-A03F; B14-B02; B14-C01; B14-C03; B14-C07; B14-C09; B14-E08; B14-E10A; B14-E10C1; B14-F02F2; B14-G02; B14-G03; B14-H05; B14-J02C1; B14-J02D1; B14-J05; B14-K01A; B14-L01; B14-L06; B14-L12; B14-N03; B14-N07; B14-N10; B14-P01; B14-S08

TECH

PHARMACEUTICALS - Preferred Components: (I) are in the form of esters at position 1, particularly methyl or ethyl esters. The medicament comprises an additional therapeutic agent such as a chemotherapeutic agent, corticosteroid, antibiotic, analgesic, alpha-adrenergic blocker, beta-adrenergic agonist, anticholinergic, inhibitor of 5-alpha-reductase, antiandrogen, oral contraceptive, immunomodulator, immunosuppressant, anti-angiogenic, bronchodilator, leukotriene modifier, aminosalicylate, anesthetic, non-steroidal anti-inflammatory, antiparasitic, proton pump inhibitor, hydrogen-receptor antagonist, therapy of the solubilized interleukin receptor, intramuscular gold, cytotoxic and/or an antioxidant.

ABEX DEFINITIONS - Preferred Definitions: - Y1 = -SO₃H, -SO₃-X⁺, -SO₃R₃, -CO₂H, -CO₂-X⁺ or -CO₂R₃; and - R2 = methylcarbonyl, phenylsulfonyl, 4-methylphenylsulfonyl, benzylsulfonyl, benzyl or phenyl. - At least one of R9 and R9a are alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted).

ADMINISTRATION - Administration of (I) is topical, transdermal, oral, buccal, parenteral, intradermal, rectal, intravaginal, intraocular or by inhalation (claimed). Dosage of (I) is 0.05-50 (preferably 0.1, 0.25, 0.5, 0.75, 1, 5, 10, 25 or 50) g/day.


SPECIFIC COMPOUNDS - The use of 42 compounds (I) is specifically claimed e.g. 5-(acetyloxy)-2-hydroxyhomobenzoic acid (Ia), 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, 5-(acetyloxy)-2-hydroxybenzenesulfonic acid, 2,5-bis(acetyloxy)benzenesulfonic acid and 2,5-bis(benzyloxy)homobenzoic acid.

AN.S DCR-1595296


CN.S 5-Hydroxy-2-(toluene-4-sulfonyloxy)-benzenesulfonic acid

SDCN RASW2T


11/839,520



AN.S DCR-108109
CN.P SULTOSILATE
SDCN RA2Y7A




AN.S DCR-1595297
CN.S 2,5-Bis-(toluene-4-sulfonyloxy)-benzenesulfonic acid
SDCN RASW2U



AN.S DCR-1595298

CN.S Acetic acid 4-hydroxy-2-sulfo-phenyl ester


SDCN RASW2V



AN.S DCR-1595299

CN.S Acetic acid 4-hydroxy-3-sulfo-phenyl ester


SDCN RASW2W



AN.S DCR-1595300

CN.S Acetic acid 4-acetoxy-3-sulfo-phenyl ester

SDCN RASW2X




AN.S DCR-1595320

CN.S (E)-3-(2,5-Bis-benzyloxy-phenyl)-acrylic acid

SDCN RASW3H


11/839,520



AN.S DCR-1595316

CN.S (E)-3-(5-Acetoxy-2-hydroxy-phenyl)-acrylic acid


SDCN RASW3D



AN.S DCR-1595317

CN.S (E)-3-(2,5-Diacetoxy-phenyl)-acrylic acid

SDCN RASW3E




AN.S DCR-1595318

CN.S (E)-3-(2-Benzyloxy-5-hydroxy-phenyl)-acrylic acid

SDCN RASW3F


11/839,520



AN.S DCR-1595319

CN.S (E)-3-(5-Benzyloxy-2-hydroxy-phenyl)-acrylic acid


SDCN RASW3G



AN.S DCR-1595312

CN.S (E)-3-[5-Hydroxy-2-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid

SDCN RASW39




AN.S DCR-1595313

CN.S (E)-3-[2-Hydroxy-5-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid

SDCN RASW3A


11/839,520



AN.S DCR-1595314

CN.S (E)-3-[2,5-Bis-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid


SDCN RASW3B



AN.S DCR-1595315

CN.S (E)-3-(2-Acetoxy-5-hydroxy-phenyl)-acrylic acid

SDCN RASW3C



=> d ibib ab hitstr 20-21

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' - CONTINUE?
(Y)/N:y

L220 ANSWER 20 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2008:334640 USPATFULL Full-text

TITLE: Use of 2,5-Dihydroxybenzenesulphonic Acid in the
Production of Medicaments for the Treatment of
Angiodependent Diseases Such as Cancer and Psoriasis

INVENTOR(S): Cuevas Sanchez, Pedro, Madrid, SPAIN
Romero Garrido, Antonio, Madrid, SPAIN
Gimenez Gallego, Guillermo, Madrid, SPAIN
Valverde Lopez, Serafin, Madrid, SPAIN
Lozano Puerto, Rosa Maria, Madrid, SPAIN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080293816	A1	20081127
APPLICATION INFO.:	US 2005-588166	A1	20050216 (10)
	WO 2005-ES70017		20050216
			20080807 PCT 371 date


	NUMBER	DATE
PRIORITY INFORMATION:	ES 2004-371	20040217
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LADAS & PARRY LLP, 26 WEST 61ST STREET, NEW YORK, NY, 10023, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	623	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity

of said family of compounds in non-quiescent cells. In addition, the invention details the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compounds, based on the combined antiproliferative, antiangiogenic and proapoptotic capacities thereof, in the treatment of chronic psoriatic plaques.

IT ~~88-46-0~~, 2,5-Dihydroxybenzenesulfonic acid 20123-80-2,
2,5-Dihydroxybenzenesulfonic acid calcium salt 862162-74-1
(use of dihydroxybenzenesulfonic acid in drugs for treatment of
angiodependent diseases)
RN 88-46-0 USPATFULL
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 20123-80-2 USPATFULL
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



● 1/2 Ca

RN 862162-74-1 USPATFULL
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:?) (CA INDEX NAME)



● x K

L220 ANSWER 21 OF 22 USPATFULL on STN

ACCESSION NUMBER: 2008:130980 USPATFULL Full-textTITLE: Use of 2,5-Dihydroxybenzene Compounds and Derivatives
for the Treatment of PsoriasisINVENTOR(S): Cuevas Sanchez, Pedro, Madrid, SPAIN
Gimenez Gallego, Guillermo, Madrid, SPAIN
Morgan, Inigo Saenz de Tejada, Madrid, SPAIN
Angulo Frutos, Javier, Madrid, SPAIN
Valverde Lopez, Serafin, Madrid, SPAIN
Romero Garrido, Antonio, Madrid, SPAIN
Lozano Puerto, Rosa Maria, Madrid, SPAINPATENT ASSIGNEE(S): Action Medicines, Madrid, SPAIN
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080113948	A1	20080515
APPLICATION INFO.:	US 2007-839520	A1	20070815 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	ES 2006-2218	20060816
	ES 2007-1856	20070702
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FROMMER LAWRENCE & HAUG, 745 FIFTH AVENUE- 10TH FL., NEW YORK, NY, 10151, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	1755	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, psoriasis.

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D,
ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid
21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
51579-69-2 57775-26-5 59687-22-8
60630-38-8 79122-68-2 159252-66-1
159252-66-1D, ester derivs. 748106-93-6
1007839-71-5 1007839-72-6D, ester derivs.
1007839-87-3 1007839-89-5 1007839-91-9
1007839-93-1 1007839-94-2 1007839-96-4
1007840-16-5 1007840-17-6 1007840-18-7
1007840-19-8 1007840-20-1 1007840-21-2
1007840-22-3 1007840-23-4 1007840-24-5
1007849-27-5(use of hydroxybenzene compds. and derivs. for treatment of hematol.
dyscrasias and cancer)

RN 88-46-0 USPATFULL


CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)

11/839,520




RN 88-46-0 USPATFULL

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)




RN 636-01-1 USPATFULL

CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 21799-87-1 USPATFULL


CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 51579-69-2 USPATFULL


CN Benzenesulfonic acid, 2,5-bis[[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)

11/839,520




RN 57775-26-5 USPATFULL

CN Benzenesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)




RN 59687-22-8 USPATFULL

CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 USPATFULL


CN Benzenesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 USPATFULL


CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)

11/839,520




RN 159252-66-1 USPATFULL

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 159252-66-1 USPATFULL

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 748106-93-6 USPATFULL

CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)




RN 1007839-71-5 USPATFULL

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-72-6 USPATFULL

CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)




RN 1007839-87-3 USPATFULL

CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 USPATFULL


CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 USPATFULL


CN Benzenemethanesulfonic acid, 2,5-bis[[4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)

11/839,520




RN 1007839-93-1 USPATFULL

CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)




RN 1007839-94-2 USPATFULL

CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 USPATFULL


CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 USPATFULL


CN 2-Propenoic acid, 3-[5-hydroxy-2-[[4-(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)

11/839,520




RN 1007840-17-6 USPATFULL

CN 2-Propenoic acid, 3-[2-hydroxy-5-[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)




RN 1007840-18-7 USPATFULL

CN 2-Propenoic acid, 3-[2,5-bis[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA
INDEX NAME)




RN 1007840-19-8 USPATFULL

CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-20-1 USPATFULL

CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)




RN 1007840-21-2 USPATFULL

CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)




RN 1007840-22-3 USPATFULL

CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-23-4 USPATFULL

CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 1007840-24-5 USPATFULL

CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 USPATFULL
 CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA
 INDEX NAME)



● 1/2 Ca

=> d ibib ed ab ind 22
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' - CONTINUE?
 (Y)/N:y

L220 ANSWER 22 OF 22 MEDLINE on STN DUPLICATE 16
 ACCESSION NUMBER: 2005510146 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 16183548
 TITLE: Dobesilate in the treatment of plaque psoriasis.
 AUTHOR: Cuevas Pedro; Arrazola Jose M
 CORPORATE SOURCE: Servicio de Histologia, Departamento de Investigacion,
 Hospital Ramon y Cajal, Ctra. de Colmenar, km. 9.100,
 E-28034-Madrid, Spain.. pedro.cuevas@hrc.es
 SOURCE: European journal of medical research, (2005 Sep 12) Vol.
 10, No. 9, pp. 373-6.
 Journal code: 9517857. ISSN: 0949-2321.
 PUB. COUNTRY: Germany: Germany, Federal Republic of
 DOCUMENT TYPE: (CASE REPORTS)
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200511
 ENTRY DATE: Entered STN: 27 Sep 2005
 Last Updated on STN: 9 Nov 2005
 Entered Medline: 8 Nov 2005
 ED Entered STN: 27 Sep 2005
 Last Updated on STN: 9 Nov 2005
 Entered Medline: 8 Nov 2005
 AB Fibroblast growth factor (FGF)-mediated pathways participate in many of the
 cellular events implicated in the pathogenesis of psoriasis. Thus, targeting
 FGF signals may be potentially therapeutic in the treatment of psoriasis. We
 report for the first time on a 43-year-old man with chronic-type plaque
psoriasis with a daily topical treatment of dobessilate, a new FGF inhibitor.
 As early as at day 14, the patient had cleared or achieved excellent
 improvement of psoriatic skin lesions. Topical dobessilate offers the

11/839,520

potential for treatment of plaque psoriasis without atrophy or other local side effects associated with the use of topical corticosteroids.

CT Check Tags: Male

Adult

*Calcium Dobesilate: TU, therapeutic use

*Fibroblast Growth Factors: AI, antagonists & inhibitors

*Hemostatics: TU, therapeutic use

Humans

*Psoriasis: DT, drug therapy

RN 20123-80-2 (Calcium Dobesilate); 62031-54-3 (Fibroblast Growth Factors)

CN 0 (Hemostatics)

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 11:53:31 ON 25 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 18, 2009 (20090918/UP).

11/839,520

=> d his ful

(FILE 'HOME' ENTERED AT 07:58:56 ON 25 SEP 2009)

FILE 'STNGUIDE' ENTERED AT 07:58:59 ON 25 SEP 2009

FILE 'HCAPLUS' ENTERED AT 07:59:16 ON 25 SEP 2009
ACT PAG520HCAAPP/A

L1 5 SEA SPE=ON ABB=ON PLU=ON US2007-839520/APPS

FILE 'WPIX' ENTERED AT 07:59:33 ON 25 SEP 2009
ACT PAG520WPIAPP/A

L2 1 SEA SPE=ON ABB=ON PLU=ON US2007-839520/APPS

FILE 'REGISTRY' ENTERED AT 07:59:47 ON 25 SEP 2009
ACT PAG520REGAPP/A

L3 (5)SEA SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L4 SEL PLU=ON L3 1- RN : 82 TERMS
L5 82 SEA SPE=ON ABB=ON PLU=ON L4

ACT PAG520PSET1/A

L6 (5)SEA SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L7 SEL PLU=ON L6 1- RN : 82 TERMS
L8 (82)SEA SPE=ON ABB=ON PLU=ON L7
L9 STR
L10 28 SEA SUB=L8 SSS FUL L9

ACT PAG520CROSS/A

L11 (5)SEA SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L12 SEL PLU=ON L11 1- RN : 82 TERMS
L13 (82)SEA SPE=ON ABB=ON PLU=ON L12
L14 STR
L15 (28)SEA SUB=L13 SSS FUL L14
L16 (270)SEA SPE=ON ABB=ON PLU=ON (1007839-71-5/CRN OR 1007839-72-6/C
 RN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR 1007839-91-9/CRN
 OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR 1007839-96-4/CRN OR
 1007840-16-5/CRN OR 1007840-17-6/CRN OR 1007840-18-7/CRN OR
 1007840-19-8/CRN OR 1007840-20-1/CRN OR 1007840-21-2/CRN OR
 1007840-22-3/CRN OR 1007840-23-4/CRN OR 1007840-24-5/CRN OR
 1007849-27-5/CRN OR 159252-66-1/CRN OR 21799-87-1/CRN OR
 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-8/CRN OR 60630-38-
 8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR 79122-68-2/CRN OR
 88-46-0/CRN)
L17 293 SEA SPE=ON ABB=ON PLU=ON L15 OR L16

L18 129 SEA SPE=ON ABB=ON PLU=ON L17 NOT PMS/CI
 SAVE TEMP L18 PAG520CROSS2/A

FILE 'STNGUIDE' ENTERED AT 08:03:05 ON 25 SEP 2009
D SAVED

FILE 'WPIX' ENTERED AT 08:03:39 ON 25 SEP 2009

ACT PAG520WPIANS/A

L19 34 SEA SPE=ON ABB=ON PLU=ON (1595296-K/AN.S OR 1595296-M/AN.S
OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K/AN.S OR
1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR 9091-U/AN.S OR
DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/AN.S OR
DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S OR
DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S OR
DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR
DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR
DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR
DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR
DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR
DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/A
N.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR
DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/
AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR
12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.
S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR
1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K
/AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR
1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M
/AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR
1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K
/AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR
1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M
/AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR
1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/
AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR
528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR
86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR
91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S
OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S
)

D CODE L2

L20 1 SEA SPE=ON ABB=ON PLU=ON DCR-1669102/AN.S
D TRI

FILE 'ZCAPLUS' ENTERED AT 08:06:08 ON 25 SEP 2009

L21 QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
L22 QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
L23 QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
L24 QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
L25 QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
L26 QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
L27 QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
L28 QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
L29 QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH
L30 QUE SPE=ON ABB=ON PLU=ON SAENZ DE TEJADA MORGAN, I?/AU,AUTH

L31 QUE SPE=ON ABB=ON PLU=ON SAENZDETEJADA, I?/AU,AUTH
L32 QUE SPE=ON ABB=ON PLU=ON SAENZ, I?/AU,AUTH
L33 QUE SPE=ON ABB=ON PLU=ON DETEJADA, I?/AU,AUTH
L34 QUE SPE=ON ABB=ON PLU=ON DE TEJADA, I?/AU,AUTH
L35 QUE SPE=ON ABB=ON PLU=ON ANGULO FRUTOS, J?/AU,AUTH
L36 QUE SPE=ON ABB=ON PLU=ON ANGULOFRUTOS, J?/AU,AUTH
L37 QUE SPE=ON ABB=ON PLU=ON ANGULO, J?/AU,AUTH
L38 QUE SPE=ON ABB=ON PLU=ON FRUTOS, J?/AU,AUTH
L39 QUE SPE=ON ABB=ON PLU=ON VALVERDE LOPEZ, S?/AU,AUTH

11/839,520

L40 QUE SPE=ON ABB=ON PLU=ON VALVERDELOPEZ, S?/AU,AUTH
 L41 QUE SPE=ON ABB=ON PLU=ON VALVERDE, S?/AU,AUTH
 L42 QUE SPE=ON ABB=ON PLU=ON LOPEZ, S?/AU,AUTH
 L43 QUE SPE=ON ABB=ON PLU=ON ROMERO GARRIDO, A?/AU,AUTH
 L44 QUE SPE=ON ABB=ON PLU=ON ROMEROGARRIDO, A?/AU,AUTH
 L45 QUE SPE=ON ABB=ON PLU=ON ROMERO, A?/AU,AUTH
 L46 QUE SPE=ON ABB=ON PLU=ON GARRIDO, A?/AU,AUTH
 L47 QUE SPE=ON ABB=ON PLU=ON LOZANO PUERTO, R?/AU,AUTH
 L48 QUE SPE=ON ABB=ON PLU=ON LOZANOPUERTO, R?/AU,AUTH
 L49 QUE SPE=ON ABB=ON PLU=ON LOZANO, R?/AU,AUTH
 L50 QUE SPE=ON ABB=ON PLU=ON PUERTO, R?/AU,AUTH
 L51 QUE SPE=ON ABB=ON PLU=ON (ACTION(1W)MEDICINE#)/CS,SO,PA
 L52 QUE SPE=ON ABB=ON PLU=ON AY<2008 OR PY<2008 OR PRY<2008 OR
 MY<2008 OR REVIEW/DT
 L53 QUE SPE=ON ABB=ON PLU=ON SKIN
 L54 QUE SPE=ON ABB=ON PLU=ON ?DERM?
 L55 QUE SPE=ON ABB=ON PLU=ON ?PSORIA?
 L56 QUE SPE=ON ABB=ON PLU=ON ANTIPSORIA?
 E PSORIASIS/CT
 E E3+ALL
 L57 QUE SPE=ON ABB=ON PLU=ON PSORIASIS+PFT,OLD,NEW,NT/CT
 E ANTIPSORIA/CT
 E SKIN TREATMENT/CT
 E E31+ALL
 E E46+ALL
 L58 QUE SPE=ON ABB=ON PLU=ON A61P0017-06/IPC

FILE 'HCAPLUS' ENTERED AT 08:12:17 ON 25 SEP 2009
 D SCAN L1

FILE 'STNGUIDE' ENTERED AT 08:12:27 ON 25 SEP 2009

FILE 'HCAPLUS' ENTERED AT 08:13:18 ON 25 SEP 2009

L59 780 SEA SPE=ON ABB=ON PLU=ON L18
 L60 11 SEA SPE=ON ABB=ON PLU=ON L59 (L) ((L53 OR L54 OR L55 OR
 L56))
 D SCAN TI HIT
 L61 10 SEA SPE=ON ABB=ON PLU=ON L59 AND L58
 L62 6 SEA SPE=ON ABB=ON PLU=ON L59 AND L57
 D SCAN TI HIT

FILE 'ZCAPLUS' ENTERED AT 08:15:45 ON 25 SEP 2009

E DERMATOLOGICAL AGENTS/CT
 E E67+ALL
 L63 QUE SPE=ON ABB=ON PLU=ON "DERMATOLOGICAL AGENTS"+PFT,OLD,NEW
 /CT

FILE 'HCAPLUS' ENTERED AT 08:16:22 ON 25 SEP 2009

L64 3 SEA SPE=ON ABB=ON PLU=ON L59 AND L63
 L65 1 SEA SPE=ON ABB=ON PLU=ON L64 AND (L55 OR L56)
 L66 7 SEA SPE=ON ABB=ON PLU=ON L59 AND (L55 OR L56)
 L67 20 SEA SPE=ON ABB=ON PLU=ON (L60 OR L61 OR L62) OR (L64 OR L65
 OR L66)
 L68 20 SEA SPE=ON ABB=ON PLU=ON L67 AND (L53 OR L54 OR L55 OR L56)
 L69 20 SEA SPE=ON ABB=ON PLU=ON (L67 OR L68)
 L70 14 SEA SPE=ON ABB=ON PLU=ON L69 AND (L21 OR L22 OR L23 OR L24
 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR

11/839,520

```
L51)
  SAVE TEMP L70 PAG520HCAINV/A
L71    6 SEA SPE=ON  ABB=ON  PLU=ON  L69 NOT L70
      D SCAN TI HIT

FILE 'STNGUIDE' ENTERED AT 08:20:34 ON 25 SEP 2009

FILE 'REGISTRY' ENTERED AT 08:20:56 ON 25 SEP 2009
L72    1 SEA SPE=ON  ABB=ON  PLU=ON  57775-26-5/RN
      D SCAN

FILE 'HCAPLUS' ENTERED AT 08:21:14 ON 25 SEP 2009
L73    1 SEA SPE=ON  ABB=ON  PLU=ON  L71 AND CHOLESTEROL/TI
      D BIB

FILE 'STNGUIDE' ENTERED AT 08:21:39 ON 25 SEP 2009

FILE 'WPIX' ENTERED AT 08:24:17 ON 25 SEP 2009
L*** DEL    QUE (B14-N17C OR C14-N17C OR B12-107 OR C12-A07)/MC
L*** DEL    21165 S L58 OR L74
L74      QUE SPE=ON  ABB=ON  PLU=ON  (B14-N17C OR C14-N17C OR B12-A07
      OR C12-A07)/MC
L75      32388 SEA SPE=ON  ABB=ON  PLU=ON  L58 OR L74
L76      16186 SEA SPE=ON  ABB=ON  PLU=ON  L75 AND (L55 OR L56)
L77      5786 SEA SPE=ON  ABB=ON  PLU=ON  L76 AND G015/M0,M1,M2,M3,M4,M5,M6
L78      1752 SEA SPE=ON  ABB=ON  PLU=ON  L76 AND (G015/M0,M1,M2,M3,M4,M5,M6
      (P) T/DCN)

FILE 'STNGUIDE' ENTERED AT 08:28:29 ON 25 SEP 2009

FILE 'WPIX' ENTERED AT 08:29:33 ON 25 SEP 2009
L79      4373 SEA SPE=ON  ABB=ON  PLU=ON  L76 AND (G015/M0,M1,M2,M3,M4,M5,M6
      (P) P420/M0,M1,M2,M3,M4,M5,M6)
L80      1362 SEA SPE=ON  ABB=ON  PLU=ON  L78 AND L79

FILE 'STNGUIDE' ENTERED AT 08:30:15 ON 25 SEP 2009

FILE 'WPIX' ENTERED AT 08:32:58 ON 25 SEP 2009
L81      5336 SEA SPE=ON  ABB=ON  PLU=ON  L76 AND (G015/M0,M1,M2,M3,M4,M5,M6
      (P) P943/M0,M1,M2,M3,M4,M5,M6)
L82      1308 SEA SPE=ON  ABB=ON  PLU=ON  L80 AND L81
      D TRI FRAGHITSTR

FILE 'STNGUIDE' ENTERED AT 08:34:39 ON 25 SEP 2009

FILE 'WPIX' ENTERED AT 08:36:16 ON 25 SEP 2009
L83      QUE SPE=ON  ABB=ON  PLU=ON  (G015/M0,M1,M2,M3,M4,M5,M6 (P) (H4
      OR K4 OR J0 OR B81?)/M0,M1,M2,M3,M4,M5,M6)
L84      1081 SEA SPE=ON  ABB=ON  PLU=ON  L82 AND L83
      D TRI FRAGHITSTR 1-10
L85      QUE SPE=ON  ABB=ON  PLU=ON  (G015/M0,M1,M2,M3,M4,M5,M6 (P) (H4
      OR K4 OR J0 OR B81?)/M0,M1,M2,M3,M4,M5,M6) (NOTP) (D? OR E? OR
      F?)/M0,M1,M2,M3,M4,M5,M6
L*** DEL    0 S L84 AND L85]
L86      353 SEA SPE=ON  ABB=ON  PLU=ON  L84 AND L85
      D TRI FRAGHITSTR 1-4
L87      QUE SPE=ON  ABB=ON  PLU=ON  (G015/M0,M1,M2,M3,M4,M5,M6 (P) (H4
      OR K4)/M0,M1,M2,M3,M4,M5,M6) (NOTP) (D? OR E? OR F?)/M0,M1,M2,M3,
      M4,M5,M6
      D HIS40
```

L88 240 SEA SPE=ON ABB=ON PLU=ON L86 AND L87
 DEL SELECT
 SELECT L88 1- DCR
 DEL SELECT
 L89 QUE SPE=ON ABB=ON PLU=ON (G015/M0,M1,M2,M3,M4,M5,M6 (P) (H4
 OR K4)/M0,M1,M2,M3,M4,M5,M6) (NOTP) (D? OR E? OR F? OR H1)/M0,M1,
 M2,M3,M4,M5,M6
 L90 177 SEA SPE=ON ABB=ON PLU=ON L88 AND L89
 D TRI FRAGHITSTR 1-3
 L91 QUE SPE=ON ABB=ON PLU=ON (G015/M0,M1,M2,M3,M4,M5,M6 (P)
 (H441 OR H442 OR K431)/M0,M1,M2,M3,M4,M5,M6) (NOTP) (D? OR E? OR
 F? OR H1)/M0,M1,M2,M3,M4,M5,M6
 L92 QUE SPE=ON ABB=ON PLU=ON ((G015/M0,M1,M2,M3,M4,M5,M6 (P)
 (H441 OR H442 OR K431)/M0,M1,M2,M3,M4,M5,M6) (NOTP) (D? OR E? OR
 F? OR H1)/M0,M1,M2,M3,M4,M5,M6) (P) T/DCN
 L93 178 SEA SPE=ON ABB=ON PLU=ON L76 AND L92
 D TRI FRAGHITSTR
 L94 QUE SPE=ON ABB=ON PLU=ON ((G015/M0,M1,M2,M3,M4,M5,M6 (P)
 (H441 OR H442 OR K431)/M0,M1,M2,M3,M4,M5,M6) (NOTP) (D? OR E? OR
 F? OR H1? OR H2? OR K6?)/M0,M1,M2,M3,M4,M5,M6) (P) T/DCN
 L95 171 SEA SPE=ON ABB=ON PLU=ON L76 AND L94
 D TRI FRAGHITSTR
 L96 QUE SPE=ON ABB=ON PLU=ON (((G015/M0,M1,M2,M3,M4,M5,M6 (P)
 (H441 OR H442 OR K431)/M0,M1,M2,M3,M4,M5,M6) (NOTP) (D? OR E? OR
 F? OR H1? OR H2? OR K6?)/M0,M1,M2,M3,M4,M5,M6)) (P) T/DCN
 L97 171 SEA SPE=ON ABB=ON PLU=ON L76 AND L96
 L98 56 SEA SPE=ON ABB=ON PLU=ON L97 AND L58 AND L74
 L99 0 SEA SPE=ON ABB=ON PLU=ON L98 AND (B14-N17C/BIX,BIEX,ABEX,TT
 OR C14-N17C/BIX,BIEX,ABEX,TT)
 D HIS50
 L100 152 SEA SPE=ON ABB=ON PLU=ON L96 AND (B14-N17C OR C14-N17C)/MC
 L101 58 SEA SPE=ON ABB=ON PLU=ON L100 AND L58
 D TRI FRAGHITSTR
 L102 113 SEA SPE=ON ABB=ON PLU=ON L100 AND (L55 OR L56)
 L103 115 SEA SPE=ON ABB=ON PLU=ON (L101 OR L102)
 DEL SELECT
 SELECT L102 1- DCN
 DEL SELECT
 L104 56 SEA SPE=ON ABB=ON PLU=ON L101 AND L102
 L105 58 SEA SPE=ON ABB=ON PLU=ON L101 OR L104
 DEL SELECT
 SELECT L105 1-25 DCN
 L106 1009 SEA SPE=ON ABB=ON PLU=ON (R00180/SDCN OR R03057/SDCN OR
 R10974/SDCN OR R18653/SDCN OR R18808/SDCN OR RACANB/SDCN OR
 RACRCN/SDCN OR RACRCO/SDCN OR RACRCQ/SDCN OR RACRCY/SDCN OR
 RACRCZ/SDCN OR RACRDB/SDCN OR RACRDC/SDCN OR RACRDE/SDCN OR
 RACRDF/SDCN OR RACRDG/SDCN OR RACRDH/SDCN OR RACRDN/SDCN OR
 RACRDO/SDCN OR RACRDQ/SDCN OR RACRDR/SDCN OR RACRDS/SDCN OR
 RACRDV/SDCN OR RACRD0/SDCN OR RADRS8/SDCN OR RAF0PZ/SDCN OR
 RA0DJE/SDCN OR RA0HDM/SDCN OR RA00C8/SDCN OR RA00GT/SDCN OR
 RA00H3/SDCN OR RA00TQ/SDCN OR RA0120/SDCN OR RA0120/SDCN OR
 RA02SP/SDCN OR RA04OB/SDCN OR RA088T/SDCN OR RA1HNP/SDCN OR
 RA1YR6/SDCN OR RA6EV7/SDCN OR R00076/SDCN OR R00122/SDCN OR
 R00137/SDCN OR R00291/SDCN OR R00689/SDCN OR R01330/SDCN OR
 R01987/SDCN OR R02044/SDCN OR R02049/SDCN OR R02069/SDCN OR
 R03442/SDCN OR R04259/SDCN OR R06973/SDCN OR R09011/SDCN OR
 R10769/SDCN OR R11063/SDCN OR R12996/SDCN OR R20748/SDCN OR
 R21749/SDCN OR R23692/SDCN OR RAAJSH/SDCN OR RAALE1/SDCN OR
 RAAMCC/SDCN OR RAAMCD/SDCN OR RAAMCE/SDCN OR RAAMCF/SDCN OR
 RAAMCG/SDCN OR RAAMCI/SDCN OR RAAMCK/SDCN OR RAAMCN/SDCN OR

RAAMCO/SDCN OR RAAMCP/SDCN OR RAAMCQ/SDCN OR RAAMCR/SDCN OR
 RAAMCS/SDCN OR RAAMCT/SDCN OR RAAMCW/SDCN OR RAAMCX/SDCN OR
 RAAMCY/SDCN OR RAAMCZ/SDCN OR RAAMDF/SDCN OR RAAMDG/SDCN OR
 RAAMDJ/SDCN OR RAAMD L/SDCN OR RAAMDM/SDCN OR RAAMDN/SDCN OR
 RAAMDO/SDCN OR RAAMDP/SDCN OR RAAMDR/SDCN OR RAAMDS/SDCN OR
 RAAMDT/SDCN OR RAAMDU/SDCN OR RAAMD0/SDCN OR RAAMD1/SDCN OR
 RAAMD2/SDCN OR RAAMD6/SDCN OR RAAM1I/SDCN OR RAAM1J/SDCN OR
 RAAM1K/SDCN OR RAAM1L/SDCN OR RAAM1M/SDCN OR RAAM1N/SDCN OR
 RAAM1O/SDCN OR RAAM1P/SDCN OR RAAM1Q/SDCN OR RAAM1R/SDCN OR
 RAAM1S/SDCN OR RAAM1T/SDCN OR RAAM1U/SDCN OR RAAM1V/SDCN OR
 RAAM1W/SDCN OR RAAM1X/SDCN OR RAAM1Y/SDCN OR RAAM1Z/SDCN OR
 RAAM2A/SDCN OR RAAM2B/SDCN OR RAAM2C/SDCN OR RAAM20/SDCN OR
 RAAM21/SDCN OR RAAM22/SDCN OR RAAM23/SDCN OR RAAM24/SDCN OR
 RAAM26/SDCN OR RAAM27/SDCN OR RAAM28/SDCN OR RAAM29/SDCN OR
 RAANIU/SDCN OR RAAQNG/SDCN OR RABNAH/SDCN OR RABNAI/SDCN OR
 RABNAK/SDCN OR RABNAO/SDCN OR RABNAQ/SDCN OR RABNAR/S

DEL SELECT

SELECT L105 26-40 DCN

L107

418 SEA SPE=ON ABB=ON PLU=ON (RA02SP/SDCN OR R18653/SDCN OR
 R01614/SDCN OR R04292/SDCN OR R13080/SDCN OR R23692/SDCN OR
 RA0DWB/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA01SC/SDCN OR
 RA02JW/SDCN OR RA040B/SDCN OR RA1C7N/SDCN OR RA28R6/SDCN OR
 RA5D1M/SDCN OR R00095/SDCN OR R00298/SDCN OR R03361/SDCN OR
 R04116/SDCN OR R04227/SDCN OR R04654/SDCN OR R09668/SDCN OR
 RA0K9J/SDCN OR RA00C8/SDCN OR RA01E9/SDCN OR RA1HNP/SDCN OR
 RA43CA/SDCN OR RA74YB/SDCN OR RA74YC/SDCN OR RA74YE/SDCN OR
 RA74YZ/SDCN OR RA74Y7/SDCN OR RA74Y8/SDCN OR RA74ZA/SDCN OR
 RA74ZI/SDCN OR RA74ZY/SDCN OR RA74ZZ/SDCN OR RA74Z0/SDCN OR
 RA74Z1/SDCN OR RA74Z2/SDCN OR RA74Z3/SDCN OR RA74Z4/SDCN OR
 RA74Z5/SDCN OR RA74Z7/SDCN OR RA74Z8/SDCN OR RA74Z9/SDCN OR
 RA750A/SDCN OR RA750B/SDCN OR RA7500/SDCN OR RA7501/SDCN OR
 RA7502/SDCN OR RA7503/SDCN OR RA7505/SDCN OR RA7506/SDCN OR
 RA7507/SDCN OR RA7508/SDCN OR R00271/SDCN OR R00991/SDCN OR
 RA0CGV/SDCN OR RA0C4V/SDCN OR RA0HNY/SDCN OR RA0IKS/SDCN OR
 RA0KH3/SDCN OR RA0LMH/SDCN OR RA0MTA/SDCN OR RA0WLX/SDCN OR
 RA006H/SDCN OR RA01BE/SDCN OR RA01Q7/SDCN OR RA01SX/SDCN OR
 RA015V/SDCN OR RA02DZ/SDCN OR RA021Q/SDCN OR RA027G/SDCN OR
 RA027I/SDCN OR RA027J/SDCN OR RA03SR/SDCN OR RA03YX/SDCN OR
 RA03YY/SDCN OR RA05GM/SDCN OR RA05JM/SDCN OR RA05WC/SDCN OR
 RA07GX/SDCN OR RA1HN1/SDCN OR RA1QEQ/SDCN OR RA1Q SX/SDCN OR
 RA1YFH/SDCN OR RA13IL/SDCN OR RA13XQ/SDCN OR RA152R/SDCN OR
 RA18TQ/SDCN OR RA2VNT/SDCN OR RA20DZ/SDCN OR RA3ITX/SDCN OR
 RA3SGW/SDCN OR RA41J1/SDCN OR RA44DH/SDCN OR RA6SD5/SDCN OR
 RA6VEH/SDCN OR RA6VEI/SDCN OR RA6VEJ/SDCN OR RA6VEK/SDCN OR
 RA6VEL/SDCN OR RA6VEM/SDCN OR RA6VEN/SDCN OR RA6VEO/SDCN OR
 RA6VEP/SDCN OR RA6VER/SDCN OR RA6VES/SDCN OR RA6VET/SDCN OR
 RA6VEU/SDCN OR RA6VEV/SDCN OR RA6VEW/SDCN OR RA6VEX/SDCN OR
 RA6VEY/SDCN OR RA6VEZ/SDCN OR RA6VFA/SDCN OR RA6VFB/SDCN OR
 RA6VFC/SDCN OR RA6VFD/SDCN OR RA6VFE/SDCN OR RA6VFF/SDCN OR
 RA6VFG/SDCN OR RA6VFH/SDCN OR RA6VFI/SDCN OR RA6VFJ/SDCN OR
 RA6VFK/SDCN OR RA6VFL

DEL SELECT

SELECT L105 41-58 DCN

L108

324 SEA SPE=ON ABB=ON PLU=ON (RA00C8/SDCN OR RA0ETL/SDCN OR
 RA0ETQ/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA0K9J/SDCN OR
 RA0YL4/SDCN OR RA00GT/SDCN OR RA02JW/SDCN OR RA02SP/SDCN OR
 RA040B/SDCN OR RA1HNP/SDCN OR RA28R6/SDCN OR RA43CA/SDCN OR
 R00477/SDCN OR R00669/SDCN OR R01119/SDCN OR R03562/SDCN OR
 R04115/SDCN OR R04292/SDCN OR R09668/SDCN OR R13080/SDCN OR
 R18653/SDCN OR R23692/SDCN OR RA00H1/SDCN OR RA00NS/SDCN OR

11/839,520

RA01SC/SDCN OR RA012P/SDCN OR RA043B/SDCN OR RA043C/SDCN OR
RA043E/SDCN OR RA043F/SDCN OR RA043G/SDCN OR RA043H/SDCN OR
RA043I/SDCN OR RA043J/SDCN OR RA043K/SDCN OR RA043L/SDCN OR
RA043M/SDCN OR RA043N/SDCN OR RA043O/SDCN OR RA043P/SDCN OR
RA1C7N/SDCN OR RA1ILG/SDCN OR RA1ILH/SDCN OR RA1ILU/SDCN OR
RA1ILW/SDCN OR RA1ILX/SDCN OR RA1ILY/SDCN OR RA1ILZ/SDCN OR
RA1IMB/SDCN OR RA1IMK/SDCN OR RA1IMO/SDCN OR RA1IM0/SDCN OR
RA1IM2/SDCN OR RA1IM4/SDCN OR RA1IM9/SDCN OR RA1INB/SDCN OR
RA1IND/SDCN OR RA1IN0/SDCN OR RA1IN2/SDCN OR RA1IN5/SDCN OR
RA1IN6/SDCN OR RA1IN7/SDCN OR RA100A/SDCN OR RA100C/SDCN OR
RA100D/SDCN OR RA100F/SDCN OR RA1000/SDCN OR RA1002/SDCN OR
RA1003/SDCN OR RA1004/SDCN OR RA1005/SDCN OR RA1006/SDCN OR
RA1007/SDCN OR RA1008/SDCN OR RA1009/SDCN OR RA1WSI/SDCN OR
RA1WSJ/SDCN OR RA1WSQ/SDCN OR RA1WTY/SDCN OR RA17JY/SDCN OR
RA17KF/SDCN OR RA17KG/SDCN OR RA17K3/SDCN OR RA195G/SDCN OR
RA195H/SDCN OR RA195I/SDCN OR RA195J/SDCN OR RA195K/SDCN OR
RA195L/SDCN OR RA195M/SDCN OR RA195N/SDCN OR RA195O/SDCN OR
RA2FSP/SDCN OR RA250K/SDCN OR RA250R/SDCN OR RA250S/SDCN OR
RA250T/SDCN OR RA250V/SDCN OR RA250W/SDCN OR RA250X/SDCN OR
RA250Y/SDCN OR RA2510/SDCN OR RA2511/SDCN OR RA2512/SDCN OR
RA2513/SDCN OR RA2514/SDCN OR RA2515/SDCN OR RA2516/SDCN OR
RA2517/SDCN OR RA2518/SDCN OR RA2519/SDCN OR RA33DB/SDCN OR
RA33DC/SDCN OR RA33DD/SDCN OR RA33DO/SDCN OR RA33DP/SDCN OR
RA33DW/SDCN OR RA33D7/SDCN OR RA33D8/SDCN OR RA33EN/SDCN OR
RA33ER/SDCN OR RA33ES/SDCN OR RA33E1/S
DEL SELECT

L109 1658 SEA SPE=ON ABB=ON PLU=ON (L106 OR L107 OR L108)
D TRI 1-10
D QUE L10
D QUE L9

L110 0 SEA SUB=L109 SSS SAM L9

L111 1 SEA SPE=ON ABB=ON PLU=ON L2 NOT L105

L112 1685 SEA SPE=ON ABB=ON PLU=ON L109 OR L19

L113 1 SEA SUB=L112 SSS SAM L9

D TRI

L114 22 SEA SUB=L112 SSS FUL L9

SAVE TEMP L114 PAG520WPIS/A

L115 0 SEA SPE=ON ABB=ON PLU=ON L114 NOT L19

FILE 'LREGISTRY' ENTERED AT 09:07:43 ON 25 SEP 2009
ACT PAG520PSTR/Q

L116 STR

FILE 'WPIX' ENTERED AT 09:07:58 ON 25 SEP 2009

L117 0 SEA SSS SAM L116

D TRI L114 1-22

SELECT L114 1- SDCN

L118 16 SEA SPE=ON ABB=ON PLU=ON (RASW2T/DCN OR RASW2U/DCN OR
RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW3A/DCN OR
RASW3B/DCN OR RASW3C/DCN OR RASW3D/DCN OR RASW3E/DCN OR
RASW3F/DCN OR RASW3G/DCN OR RASW3H/DCN OR RASW39/DCN OR
RAUHHHC/DCN OR RAUHHD/DCN OR RAUHHH/DCN OR RAUHHF/DCN OR
RAUHHG/DCN OR RAUHHH/DCN OR RAUHH9/DCN OR RA2Y7A/DCN) OR
L114/DCR

L119 6 SEA SPE=ON ABB=ON PLU=ON L118 AND (L58 OR L74 OR (L55 OR
L56))

D TRI 1-6

L120 14 SEA SPE=ON ABB=ON PLU=ON L118 AND (L53 OR L54 OR L55 OR

11/839,520

```

L121      14 SEA SPE=ON  ABB=ON  PLU=ON  (L119 OR L120)
L122      13 SEA SPE=ON  ABB=ON  PLU=ON  L121 AND (L21 OR L22 OR L23 OR L24
OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
L51)
L123      1 SEA SPE=ON  ABB=ON  PLU=ON  L121 NOT L122
D TRI

FILE 'STNGUIDE' ENTERED AT 09:12:36 ON 25 SEP 2009

FILE 'WPIX' ENTERED AT 09:13:10 ON 25 SEP 2009
D HITSTR 1

FILE 'STNGUIDE' ENTERED AT 09:13:11 ON 25 SEP 2009

FILE 'STNGUIDE' ENTERED AT 09:13:28 ON 25 SEP 2009

FILE 'STNGUIDE' ENTERED AT 09:56:56 ON 25 SEP 2009

FILE 'LREGISTRY' ENTERED AT 09:57:08 ON 25 SEP 2009
L124      STR L9

FILE 'REGISTRY' ENTERED AT 09:58:57 ON 25 SEP 2009
L125      0 SEA SSS SAM L124

FILE 'STNGUIDE' ENTERED AT 09:59:08 ON 25 SEP 2009

FILE 'LREGISTRY' ENTERED AT 09:59:47 ON 25 SEP 2009
L126      STR L124

FILE 'REGISTRY' ENTERED AT 10:01:43 ON 25 SEP 2009
L127      0 SEA SSS SAM L126

FILE 'STNGUIDE' ENTERED AT 10:02:03 ON 25 SEP 2009

FILE 'REGISTRY' ENTERED AT 10:04:04 ON 25 SEP 2009
L128      SCREEN 1812 OR 1758
L129      3 SEA SSS SAM (L128 AND L126)
D SCAN

FILE 'STNGUIDE' ENTERED AT 10:04:55 ON 25 SEP 2009
D QUE STAT

FILE 'REGISTRY' ENTERED AT 10:10:33 ON 25 SEP 2009
L130      1799 SEA SSS FUL (L128 AND L126)
SAVE TEMP L130 PAG520PSETC2/A
D SAVED
L131      1294 SEA SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L132      18 SEA SPE=ON  ABB=ON  PLU=ON  L5 AND L131

FILE 'LREGISTRY' ENTERED AT 10:15:12 ON 25 SEP 2009
L133      STR L9

FILE 'REGISTRY' ENTERED AT 10:21:11 ON 25 SEP 2009
L134      0 SEA SSS SAM L133
L135      SCREEN 1838
L136      SCREEN 1840
L137      0 SEA SSS SAM ((L135 NOT L136) AND L133)
```

11/839,520

L138 STR L133
L139 0 SEA SSS SAM L138
L140 0 SEA SSS SAM ((L135 NOT L136) AND L138)

FILE 'LREGISTRY' ENTERED AT 10:26:17 ON 25 SEP 2009
L141 STR L138

FILE 'REGISTRY' ENTERED AT 10:33:14 ON 25 SEP 2009
L142 1 SEA SSS SAM L141
D SCAN
D QUE STAT

FILE 'STNGUIDE' ENTERED AT 10:33:42 ON 25 SEP 2009

FILE 'REGISTRY' ENTERED AT 10:37:52 ON 25 SEP 2009
L143 173 SEA SSS FUL L141
SAVE TEMP L143 PAG520PSETC6/A
L144 170 SEA SPE=ON ABB=ON PLU=ON L143 NOT PMS/CI
L145 146 SEA SPE=ON ABB=ON PLU=ON L144 NOT OC5/ES

FILE 'LREGISTRY' ENTERED AT 10:39:45 ON 25 SEP 2009
L146 STR L141

FILE 'REGISTRY' ENTERED AT 10:40:33 ON 25 SEP 2009
L147 4 SEA SUB=L143 SSS SAM L146
L148 160 SEA SUB=L143 SSS FUL L146
SAVE TEMP L148 PAG520RSETC6/A
L149 133 SEA SPE=ON ABB=ON PLU=ON L145 AND L148
L150 1427 SEA SPE=ON ABB=ON PLU=ON L131 OR L149
SAVE TEMP L150 PAG520CROSSF/A

FILE 'STNGUIDE' ENTERED AT 10:42:22 ON 25 SEP 2009
D SAVED

FILE 'HCAPLUS' ENTERED AT 10:43:03 ON 25 SEP 2009
L151 1760 SEA SPE=ON ABB=ON PLU=ON L150
L152 11 SEA SPE=ON ABB=ON PLU=ON L151 AND L58
L153 8 SEA SPE=ON ABB=ON PLU=ON L151 AND L57
L154 9 SEA SPE=ON ABB=ON PLU=ON L151 AND (L55 OR L56)
L155 14 SEA SPE=ON ABB=ON PLU=ON (L152 OR L153 OR L154)

FILE 'ZCAPLUS' ENTERED AT 10:44:32 ON 25 SEP 2009
E SKIN DISEASES/CT
E E25+ALL
L156 QUE SPE=ON ABB=ON PLU=ON "SKIN, DISEASE"+PFT,OLD,NEW,NT/CT

FILE 'HCAPLUS' ENTERED AT 10:44:55 ON 25 SEP 2009
L157 95 SEA SPE=ON ABB=ON PLU=ON L151 AND (L156 OR L64 OR (L53 OR
L54 OR L55 OR L56 OR L57))
L158 316 SEA SPE=ON ABB=ON PLU=ON L151 (L) (THU OR PKT OR PAC OR DMA
OR BAC) /RL
L*** DEL 4113 S L57 AND L58
L159 63 SEA SPE=ON ABB=ON PLU=ON L157 AND L158

FILE 'STNGUIDE' ENTERED AT 10:49:07 ON 25 SEP 2009

FILE 'ZCAPLUS' ENTERED AT 10:49:56 ON 25 SEP 2009
L160 QUE SPE=ON ABB=ON PLU=ON DISEAS? OR DISORDER? OR SYNDROM?
OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB? OR
DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)

FILE 'HCAPLUS' ENTERED AT 10:50:22 ON 25 SEP 2009

L161 18 SEA SPE=ON ABB=ON PLU=ON L159 AND ((L53 OR L54) (3A) L160)
 L162 27 SEA SPE=ON ABB=ON PLU=ON L155 OR L161
 L163 27 SEA SPE=ON ABB=ON PLU=ON L162 AND ((L53 OR L54 OR L55 OR
 L56 OR L57 OR L58) OR L64)
 L164 27 SEA SPE=ON ABB=ON PLU=ON (L162 OR L163)
 L165 14 SEA SPE=ON ABB=ON PLU=ON L164 AND (L21 OR L22 OR L23 OR L24
 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
 L51)
 L166 13 SEA SPE=ON ABB=ON PLU=ON L164 NOT L165
 D SCAN TI HIT
 L167 3 SEA SPE=ON ABB=ON PLU=ON L166 AND L57
 D BIB 1-3
 D HITSTR 1-3

FILE 'STNGUIDE' ENTERED AT 10:54:46 ON 25 SEP 2009

FILE 'WPIX' ENTERED AT 10:56:03 ON 25 SEP 2009

L168 4 SEA SSS SAM (L128 AND L126)
 D QUE STAT
 L169 82 SEA SSS FUL (L128 AND L126)
 SAVE TEMP L169 PAG520WPIS2/A
 L170 1 SEA SSS SAM L141
 D QUE STAT
 L171 15 SEA SSS FUL L141
 SAVE TEMP L171 PAG520WPIS3/A
 L172 97 SEA SPE=ON ABB=ON PLU=ON L169 OR L171
 SAVE TEMP L172 PAG520WPIF/A
 D SAVED
 SELECT L172 1- SDCN
 L173 122 SEA SPE=ON ABB=ON PLU=ON (RABCOA/DCN OR RABCO3/DCN OR
 RABCO8/DCN OR RABCO9/DCN OR RABNDP/DCN OR RABNDQ/DCN OR
 RAGHZJ/DCN OR RAGHZM/DCN OR RAHO0Q/DCN OR RAI7ME/DCN OR
 RAKQX2/DCN OR RALH0H/DCN OR RAL3SN/DCN OR RAL3SO/DCN OR
 RAL3SP/DCN OR RAL3SQ/DCN OR RAL3SR/DCN OR RAL3ST/DCN OR
 RANFVN/DCN OR RAN401/DCN OR RAN403/DCN OR RAPVAI/DCN OR
 RAPVAJ/DCN OR RAPVAK/DCN OR RAQW9I/DCN OR RAQW9P/DCN OR
 RAQW9R/DCN OR RAR1ZL/DCN OR RASW2T/DCN OR RASW2U/DCN OR
 RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW2Y/DCN OR
 RASW2Z/DCN OR RASW3A/DCN OR RASW3B/DCN OR RASW3C/DCN OR
 RASW3D/DCN OR RASW3E/DCN OR RASW3F/DCN OR RASW3G/DCN OR
 RASW3H/DCN OR RASW30/DCN OR RASW38/DCN OR RASW39/DCN OR
 RASW4A/DCN OR RASW50/DCN OR RASXL7/DCN OR RAUHHHC/DCN OR
 RAUHHD/DCN OR RAUHHE/DCN OR RAUHHF/DCN OR RAUHHG/DCN OR
 RAUHHH/DCN OR RAUHH9/DCN OR RAUVSQ/DCN OR RAUVSR/DCN OR
 RAWFMV/DCN OR RAWUPX/DCN OR RAW47P/DCN OR RAW47Q/DCN OR
 RAW47R/DCN OR RAW47S/DCN OR RAW47T/DCN OR RAW47U/DCN OR
 RAXSIA/DCN OR RA0MNZ/DCN OR RA002O/DCN OR RA007X/DCN OR
 RA0083/DCN OR RA2NB0/DCN OR RA2Y7A/DCN OR RA3MBV/DCN OR
 RA4GNI/DCN OR RA4GOC/DCN OR RA4GOL/DCN OR RA4KMT/DCN OR
 RA4KMZ/DCN OR RA4KN3/DCN OR RA4KN4/DCN OR RA4NBT/DCN OR
 RA4NBW/DCN OR RA6Q5K/DCN OR RA63TX/DCN OR RA660M/DCN OR
 RA8AOM/DCN OR RA9JSH/DCN OR RA9JSI/DCN OR RA9XSQ/DCN OR
 RB0D0S/DCN OR RB0D0T/DCN OR RB0D0U/DCN OR RB0D0V/DCN OR
 R11693/DCN OR R11694/DCN OR R20556/DCN OR R21482/DCN) OR
 L172/DCR
 L174 10 SEA SPE=ON ABB=ON PLU=ON L173 AND (L58 OR L74 OR (L55 OR


```

L175      7 SEA SPE=ON  ABB=ON  PLU=ON  L174 AND (L21 OR L22 OR L23 OR L24
        OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
        OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
        OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
        L51)
L176      3 SEA SPE=ON  ABB=ON  PLU=ON  L174 NOT L175
        D TRI HITSTR 1-3
L177      3 SEA SPE=ON  ABB=ON  PLU=ON  L176 AND ((L53 OR L54 OR L55 OR
        L56) OR L160)
L178      3 SEA SPE=ON  ABB=ON  PLU=ON  (L176 OR L177)

FILE 'REGISTRY' ENTERED AT 11:04:33 ON 25 SEP 2009
L179      28 SEA SPE=ON  ABB=ON  PLU=ON  L5 AND L150

FILE 'STNGUIDE' ENTERED AT 11:04:50 ON 25 SEP 2009

FILE 'REGISTRY' ENTERED AT 11:05:09 ON 25 SEP 2009
L180      7 SEA SPE=ON  ABB=ON  PLU=ON  L150 AND MEDLINE/LC

FILE 'MEDLINE' ENTERED AT 11:05:22 ON 25 SEP 2009
L181      392 SEA SPE=ON  ABB=ON  PLU=ON  L180

FILE 'REGISTRY' ENTERED AT 11:05:33 ON 25 SEP 2009
        SET SMARTSELECT ON
L182      SEL PLU=ON  L179 1- NAME :      13 TERMS
        SET SMARTSELECT OFF

FILE 'MEDLINE' ENTERED AT 11:05:36 ON 25 SEP 2009
L183      17 SEA SPE=ON  ABB=ON  PLU=ON  L182
L184      399 SEA SPE=ON  ABB=ON  PLU=ON  L181 OR L183
        E PSORIASIS/CT
        E E137+ALL
L185      QUE SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT

FILE 'ZCAPLUS' ENTERED AT 11:07:08 ON 25 SEP 2009
L186      QUE SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS

FILE 'MEDLINE' ENTERED AT 11:07:26 ON 25 SEP 2009
L187      QUE SPE=ON  ABB=ON  PLU=ON  "SKIN DISEASES, PAPULOSQUAMOUS"+PFT
        ,OLD,NEW,NT/CT
        D HIS50
L188      1 SEA SPE=ON  ABB=ON  PLU=ON  L184 AND ((L55 OR L56) OR L185 OR
        (L186 OR L187))
        D TRI
        D BIB
L189      1 SEA SPE=ON  ABB=ON  PLU=ON  L188 AND (L21 OR L22 OR L23 OR L24
        OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
        OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
        OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
        L51)
L190      0 SEA SPE=ON  ABB=ON  PLU=ON  L188 NOT L189

FILE 'STNGUIDE' ENTERED AT 11:10:05 ON 25 SEP 2009

FILE 'REGISTRY' ENTERED AT 11:10:59 ON 25 SEP 2009
L191      4 SEA SPE=ON  ABB=ON  PLU=ON  L150 AND EMBASE/LC

FILE 'EMBASE' ENTERED AT 11:11:10 ON 25 SEP 2009
L192      794 SEA SPE=ON  ABB=ON  PLU=ON  L191

```

11/839,520

L193 69 SEA SPE=ON ABB=ON PLU=ON L182
L194 838 SEA SPE=ON ABB=ON PLU=ON (L192 OR L193)
E PSORIASIS/CT
E E161+ALL
L195 QUE SPE=ON ABB=ON PLU=ON PSORIASIS+PFT,OLD,NEW,NT/CT
L196 QUE SPE=ON ABB=ON PLU=ON "ERYTHEMATOSQUAMOUS SKIN DISEASE"+P
FT,OLD,NEW,NT/CT
L197 2 SEA SPE=ON ABB=ON PLU=ON L194 AND ((L55 OR L56) OR L186 OR
(L195 OR L196))
L198 1 SEA SPE=ON ABB=ON PLU=ON L197 AND (L21 OR L22 OR L23 OR L24
OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
L51)
L199 1 SEA SPE=ON ABB=ON PLU=ON L197 NOT L198
D BIB
D TRI

FILE 'REGISTRY' ENTERED AT 11:13:43 ON 25 SEP 2009

L200 11 SEA SPE=ON ABB=ON PLU=ON L150 AND (BIOSIS OR BIOTECHNO OR
CABA OR DRUGU OR VETU)/LC

FILE 'BIOSIS, BIOTECHNO, CABA, DRUGU, VETU' ENTERED AT 11:14:12 ON 25 SEP
2009

L201 437 SEA SPE=ON ABB=ON PLU=ON L200
L202 45 SEA SPE=ON ABB=ON PLU=ON L182
L203 469 SEA SPE=ON ABB=ON PLU=ON (L201 OR L202)

FILE 'ZCAPLUS' ENTERED AT 11:15:20 ON 25 SEP 2009

L204 QUE SPE=ON ABB=ON PLU=ON WILLAN (1A) LEPPA
L205 QUE SPE=ON ABB=ON PLU=ON PARAPSORIA?

FILE 'BIOSIS, BIOTECHNO, CABA, DRUGU, VETU' ENTERED AT 11:16:26 ON 25 SEP
2009

L206 0 SEA SPE=ON ABB=ON PLU=ON L203 AND ((L55 OR L56) OR L186 OR
(L204 OR L205))
L207 2 SEA SPE=ON ABB=ON PLU=ON L203 AND ((L53 OR L54) (5A) L160)
L208 0 SEA SPE=ON ABB=ON PLU=ON L207 AND (L21 OR L22 OR L23 OR L24
OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
L51)
L209 2 SEA SPE=ON ABB=ON PLU=ON L207 NOT L208
D SCAN
D TRI 2
D KWIC 1-2

FILE 'STNGUIDE' ENTERED AT 11:18:53 ON 25 SEP 2009

FILE 'REGISTRY' ENTERED AT 11:20:02 ON 25 SEP 2009

L210 333 SEA SPE=ON ABB=ON PLU=ON L150 AND (USPATFULL OR USPAT2 OR
USPATOLD)/LC

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:20:08 ON 25 SEP 2009

L211 409 SEA SPE=ON ABB=ON PLU=ON L210
L212 5 SEA SPE=ON ABB=ON PLU=ON L211 AND (L55/CLM OR L56/CLM OR
L186/CLM OR L204/CLM OR L205/CLM)
L213 3 SEA SPE=ON ABB=ON PLU=ON L212 AND (L21 OR L22 OR L23 OR L24
OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33

11/839,520

OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
L51)

```
L214          2 SEA SPE=ON  ABB=ON  PLU=ON  L212 NOT L213
               D SCAN
               D KWIC 1
               D KWIC 2
               D SCAN
               D BIB 1
```

FILE 'STNGUIDE' ENTERED AT 11:23:48 ON 25 SEP 2009

D QUE L160
D QUE L186
D QUE L104
D QUE L204
D QUE L205

FILE 'HCAPLUS, WPIX, PASCAL, JAPIO, MEDLINE, BIOSIS, EMBASE, CABA,
CEABA-VTB, LIFESCI, KOSMET, BIOENG, BIOTECHNO, BIOTECHDS, DRUGU, DRUGB,
VETU, VETB, SCISEARCH, CONFSCI, DISSABS, RDISCLOSURE' ENTERED AT 11:29:03
ON 25 SEP 2009

L215	425	SEA SPE=ON	ABB=ON	PLU=ON	L182
L216	13	SEA SPE=ON	ABB=ON	PLU=ON	L215 AND ((L55 OR L56) OR L186 OR (L204 OR L205) OR L58)
L217	12	SEA SPE=ON	ABB=ON	PLU=ON	L216 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR L51)
L218	1	SEA SPE=ON	ABB=ON	PLU=ON	L216 NOT L217 D SCAN

FILE 'STNGUIDE' ENTERED AT 11:33:45 ON 25 SEP 2009

FILE 'REGISTRY' ENTERED AT 11:33:54 ON 25 SEP 2009

FILE 'STNGUIDE' ENTERED AT 11:34:02 ON 25 SEP 2009

D QUE STAT L10
D QUE NOS L17
D QUE NOS L18
D QUE NOS L71
D QUE STAT L114
D QUE L123
D QUE STAT L130
D QUE NOS L131
D QUE STAT L143
D QUE STAT L148
D QUE NOS L150
D QUE NOS L179
D QUE NOS L166
D QUE NOS L214
D QUE STAT L169
D QUE STAT L171
D QUE NOS L172
D QUE NOS L178
D QUE NOS L190
D QUE NOS L199
D QUE NOS L209
D QUE NOS L218

11/839,520

FILE 'HCAPLUS, WPIX, USPATFULL, EMBASE, BIOSIS, DRUGU' ENTERED AT
11:40:01 ON 25 SEP 2009

L219 21 DUP REM L71 L123 L166 L214 L178 L190 L199 L209 L218 (8 DUPLICAT
ANSWERS '1-15' FROM FILE HCAPLUS
ANSWERS '16-17' FROM FILE WPIX
ANSWERS '18-19' FROM FILE USPATFULL
ANSWER '20' FROM FILE EMBASE
ANSWER '21' FROM FILE DRUGU
SAVE TEMP L219 PAG520MAINP/A

FILE 'STNGUIDE' ENTERED AT 11:40:18 ON 25 SEP 2009

FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' ENTERED AT 11:40:52 ON 25
SEP 2009

D IBIB ED ABS HITIND HITSTR 1-15

FILE 'STNGUIDE' ENTERED AT 11:40:57 ON 25 SEP 2009

FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' ENTERED AT 11:43:26 ON 25
SEP 2009

D IALL ABEQ TECH ABEX HITSTR 16-17

FILE 'STNGUIDE' ENTERED AT 11:43:27 ON 25 SEP 2009

FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' ENTERED AT 11:44:54 ON 25
SEP 2009

D IBIB AB KWIC HITSTR 18-19

FILE 'STNGUIDE' ENTERED AT 11:44:56 ON 25 SEP 2009

FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' ENTERED AT 11:48:08 ON 25
SEP 2009

D IBIB ED AB IND 20-21

FILE 'STNGUIDE' ENTERED AT 11:48:09 ON 25 SEP 2009

D QUE NOS L70
D QUE NOS L122
D QUE NOS L165
D QUE NOS L213
D QUE NOS L175
D QUE NOS L189
D QUE NOS L198
D QUE NOS L208
D QUE NOS L217

FILE 'HCAPLUS, WPIX, USPATFULL, MEDLINE, EMBASE' ENTERED AT 11:50:56 ON
25 SEP 2009

L220 22 DUP REM L70 L122 L165 L213 L175 L189 L198 L208 L217 (43 DUPLICA
ANSWERS '1-15' FROM FILE HCAPLUS
ANSWERS '16-19' FROM FILE WPIX
ANSWERS '20-21' FROM FILE USPATFULL
ANSWER '22' FROM FILE MEDLINE
SAVE TEMP L220 PAG520INV/A

FILE 'STNGUIDE' ENTERED AT 11:51:10 ON 25 SEP 2009

FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' ENTERED AT 11:51:49 ON 25 SEP
2009

D IBIB ED ABS HITIND HITSTR 1-15

11/839,520

FILE 'STNGUIDE' ENTERED AT 11:51:59 ON 25 SEP 2009

FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' ENTERED AT 11:52:37 ON 25 SEP 2009

D IALL ABEQ TECH ABEX HITSTR 16-19

FILE 'STNGUIDE' ENTERED AT 11:52:41 ON 25 SEP 2009

FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' ENTERED AT 11:53:04 ON 25 SEP 2009

D IBIB AB HITSTR 20-21

FILE 'STNGUIDE' ENTERED AT 11:53:05 ON 25 SEP 2009

FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' ENTERED AT 11:53:18 ON 25 SEP 2009

D IBIB ED AB IND 22

FILE 'STNGUIDE' ENTERED AT 11:53:19 ON 25 SEP 2009

FILE 'STNGUIDE' ENTERED AT 11:53:31 ON 25 SEP 2009

FILE HOME

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 18, 2009 (20090918/UP).

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Sep 2009 VOL 151 ISS 14

FILE LAST UPDATED: 24 Sep 2009 (20090924/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer

to NEWS 9.

FILE WPIX

FILE LAST UPDATED: 18 SEP 2009 <20090918/UP>
 MOST RECENT UPDATE: 200960 <200960/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
 >>> Now containing more than 1.4 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
 and FI-Terms have been updated with reclassifications to
 mid-June 2009.

No update date (UP) has been created for the reclassified
 documents, but they can be identified by
 specific update codes (see HELP CLA for details)<<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:

http://www.stn-international.com/stn_guide.html

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomsonreuters.com/support/patents/coverage/latestupdate>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:

http://www.stn-international.com/DWPIAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2009 HIGHEST RN 1186290-74-3

DICTIONARY FILE UPDATES: 24 SEP 2009 HIGHEST RN 1186290-74-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

FILE ZCAPLUS

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS is
 strictly prohibited.

11/839,520

FILE COVERS 1907 - 25 Sep 2009 VOL 151 ISS 14
FILE LAST UPDATED: 24 Sep 2009 (20090924/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

ZCplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

FILE LREGISTRY
LREGISTRY IS A STATIC LEARNING FILE

CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE MEDLINE
FILE LAST UPDATED: 24 Sep 2009 (20090924/UP). FILE COVERS 1949 TO DATE.

MEDLINE and LMEDLINE have been updated with the 2009 Medical Subject Headings (MeSH) vocabulary and tree numbers from the U.S. National Library of Medicine (NLM). Additional information is available at

http://www.nlm.nih.gov/pubs/techbull/nd08/nd08_medline_data_changes_2009.

On February 21, 2009, MEDLINE was reloaded. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

FILE EMBASE
FILE COVERS 1974 TO 25 Sep 2009 (20090925/ED)

EMBASE was reloaded on March 30, 2008.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

11/839,520

FILE BIOSIS
FILE COVERS 1926 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 23 September 2009 (20090923/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

FILE BIOTECHNO
FILE LAST UPDATED: 7 JAN 2004 <20040107/UP>
FILE COVERS 1980 TO 2003.
THIS FILE IS A STATIC FILE WITH NO UPDATES

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
/CT AND BASIC INDEX <<<

FILE CABA
FILE COVERS 1973 TO 3 Sep 2009 (20090903/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The CABA file was reloaded 7 December 2003. Enter HELP RLOAD for details.

FILE DRUGU
FILE LAST UPDATED: 22 SEP 2009 <20090922/UP>
>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<
>>> THESAURUS AVAILABLE IN /CT <<<

FILE VETU
FILE LAST UPDATED: 2 JAN 2002 <20020102/UP>
FILE COVERS 1983-2001

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Sep 2009 (20090924/PD)
FILE LAST UPDATED: 24 Sep 2009 (20090924/ED)
HIGHEST GRANTED PATENT NUMBER: US7594277
HIGHEST APPLICATION PUBLICATION NUMBER: US20090241233
CA INDEXING IS CURRENT THROUGH 24 Sep 2009 (20090924/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Sep 2009 (20090924/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

USPATFULL now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

To ensure comprehensive retrieval of US patent information, including US patent application information, search USPATFULL in combination with USPAT2.

FILE USPATOLD

FILE COVERS U.S. PATENTS 1790-1975

Produced using data provided by Univentio.

This database was created using Optical Character Recognition (OCR) technology. For this reason, some characters may be missing or mistranslated. In order to improve searchability and retrieval, CA indexing information has been added to the Title, Inventor, and Patent Assignee fields where possible. Please see HELP CASDATA for more information on the availability of CAS indexing in this database.

USPATOLD now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 24 Sep 2009 (20090924/PD)
 FILE LAST UPDATED: 24 Sep 2009 (20090924/ED)
 HIGHEST GRANTED PATENT NUMBER: US20090202559
 HIGHEST APPLICATION PUBLICATION NUMBER: US20090241217
 CA INDEXING IS CURRENT THROUGH 24 Sep 2009 (20090924/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Sep 2009 (20090924/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

USPAT2 now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

To ensure comprehensive retrieval of US patent information, including US patent application information, search USPAT2 in combination with USPATFULL.

FILE PASCAL

FILE LAST UPDATED: 21 SEP 2009 <20090921/UP>
 FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
 IN THE BASIC INDEX (/BI) FIELD <<<

FILE JAPIO

FILE LAST UPDATED: 28 AUG 2009 <20090828/UP>
 MOST RECENT PUBLICATION DATE: 28 MAY 2009 <20090528/PD>
 >>> GRAPHIC IMAGES AVAILABLE <<<

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION (SLART) IS AVAILABLE
 IN THE BASIC INDEX (/BI) FIELD <<<

FILE CEABA-VTB

FILE LAST UPDATED: 21 SEP 2009 <20090921/UP>
 FILE COVERS 1966 TO DATE

>>> DECHEMA, the producer of CEABA-VTB is using a new classification scheme.

The new classification schemes are available as a PDF file and may be downloaded free-of-charge from:

<http://www.stn-international.com/cc-de.html>

and

<http://www.stn-international.com/cc-en.html><<<

FILE LIFESCI

FILE COVERS 1978 TO 9 Sep 2009 (20090909/ED)

11/839,520

FILE KOSMET

FILE LAST UPDATED: 26 AUG 2009 <20090826/UP>

FILE COVERS 1968 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE BIOENG

FILE LAST UPDATED: 13 AUG 2009 <20090813/UP>

FILE COVERS 1982 TO DATE

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
THE BASIC INDEX <<<

FILE BIOTECHDS

FILE LAST UPDATED: 24 SEP 2009 <20090924/UP>

FILE COVERS 1982 TO DATE

>>> USE OF THIS FILE IS LIMITED TO BIOTECH SUBSCRIBERS <<<

FILE DRUGB

>>> FILE COVERS 1964 TO 1982 - CLOSED FILE <<<

FILE VETB

FILE LAST UPDATED: 25 SEP 94 <940925/UP>

FILE COVERS 1968-1982

FILE SCISEARCH

FILE COVERS 1974 TO 24 Sep 2009 (20090924/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE CONFSCI

FILE COVERS 1973 TO 30 Jun 2009 (20090630/ED)

CSA has resumed updates, see NEWS FILE

FILE DISSABS

FILE COVERS 1861 TO 8 SEP 2009 (20090908/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

FILE RDISCLOSURE

FILE LAST UPDATED: 11 SEP 2009 <20090911/UP>

FILE COVERS 1960 TO DATE

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE IN THE
BASIC INDEX (/BI) AND TITLE (/TI) FIELDS <<<

11/839,520

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=>